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THE GROWING INCIDENCE OF NOSOCOMIAL INTENSIVE CARE INFECTIONS
The advances to be made in critical care are hampered by the increasing incidence of nosoco-
mial Intensive Care (ICU) infections. These infections are acknowledged to be a major grow-
ing clinical problem in hospitals worldwide, and within the ICU in particular.
ICU patients become more prone to develop infections as the severity of their illness in-
creases. Modern intensive care medicine has to deal with more complex critically ill patients 
with a temporarily compromised immunity and a plethora of aggressive invasive diagnostics 
and devices that breach their host defences. These are both intrinsic and extrinsic factors 
that put these patients at risk. Many of these risk factors are unavoidable during ICU stay. For 
example, almost all ICU patients require artifi cial ventilation, which indeed may be a criterion 
for admission to the ICU. Peripheral or central venous infusions are characteristic; and total 
parenteral nutrition may be required. Urinary catheters are almost invariably in situ. In addi-
tion, various invasive procedures may be performed to monitor the critically ill patient. As a 
result, several lines of defence are broken. Thus, although these patients benefi t from close 
monitoring with invasive devices, such care is not without hazard.
In the past few years we have seen: a rapid growth in multi-drug resistancy of ICU patho-
gens to the newest antimicrobial therapy, a growing emphasis on the use of technology and 
instrumentation, a recognition of new organisms causing infection, and an increasing focus 
on cost control. Today, ICU patients are more complex critically ill; they are immune-compro-
mised patients who would previously have died of severe illness. To survive, these patients 
are condemned to the critical care of the ICU, and consequently, they are condemned to stay 
in the “lion’s den of infection”. To this day, we have not been successful in taming this growing 
problem.
THE GROWING IMPACT OF NOSOCOMIAL INTENSIVE CARE INFECTIONS
The costs of nosocomial ICU infections, in terms of added morbidity, mortality, hospital days 
and hospital charges, are overwhelming. However, besides this impact of nosocomial infec-
tions on morbidity, mortality and real costs, another major problem to be mentioned is the 
fact that these infections may continue to limit the potential advances to be made in critical 
care medicine. Some data from literature:
In 1981 the costs of excess hospitalization caused by nosocomial infections in the USA was 
estimated at $2.38 billion per year (1). In 1982 it was estimated that decreasing the nosoco-
mial infection rate by 10-24% in Germany, would result in savings of DM 63 to 800 million per 
year (2). According to the SENIC Project (Study on the Effi  cacy of Nosocomial Infection Con-
trol) in 1974 in US hospitals: nosocomial infections added over 7.5 million extra hospital days 
and over 1 billion dollars to the charges for hospital care per year. Hospitals with eff ective 
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programs reduced their infection rate by 32%. Among hospitals without eff ective programs 
there was an increasing secular trend in the nationwide infection rate of 18% from 1970 to 
1976 (3). The nationwide nosocomial infection rate in the USA was estimated to be 5.7 noso-
comial infections per 100 admissions to acute care hospitals between 1975 and 1976; this is 
more than the number of hospital admissions for either cancer or accidents and at least four 
times greater than admissions for acute myocardial infarction (4). In Australia, the fi rst na-
tional nosocomial prevalence study, prompted by the need to collect data on surgical wound 
infection relevant to the Australian population, estimated that surgical wound infections cost 
about $60 million in 1984 (5). Hospital-acquired infections occur in 5.7% (incidence) and in 
10% (prevalence) of patients admitted to US hospitals. These rates may be 300-400% higher 
in selected critical care areas (6). Data from seven single-day prevalence surveys, conducted 
between 1986-1989 in a hospital in Hong Kong, showed infected patients to have an excess 
mortality rate of 7.4%, an average excess hospital stay of 23 days and an average excess 
antibiotic expenditure of US $190. The annual costs of potentially avoidable nosocomial 
infections were calculated at 130 lives, 42,000 bed days and US $ 0.3 million of antibiotics 
in this hospital (7). Numerous studies have reported high rates of infection in ICU patients 
accounting for >20% of nosocomial infections, with increased morbidity and fi nancial cost 
and a mortality exceeding 40% (8-10). Among surgical patients, surgical site infections (SSI) 
account for 38% of nosocomial infections. It is estimated that SSIs develop in 2-5% of the 16 
million patients undergoing surgical procedures each year, i.e.; one out of every 24 patients 
who have inpatient surgery in the United Sates has a post-operative SSI (11,12). SSIs increase 
the post-operative length of hospital stay by 7 to 10 days, hospital charges increase by $2,000 
to $4,500, and death is directly related to SSI in over 75% of patients with SSI who die in the 
post-opartive period (13,14). Ventilator associated pneumonia is a major cause of morbid-
ity and mortality, there are approximately 250,000 cases and 23,000 deaths related to this 
disease each year in the United States. Crude mortality has been estimated to be as high as 
70%, and attributable mortality as high as 30% (15). Although intensive care units account for 
fewer than 10% of total beds in most hospitals, more than 20% of all nosocomial infections 
are acquired in ICUs (16).
SOME EXAMPLES OF RECENT HIGHLIGHTS IN THE DAY PRESS
- In july 2005, 34 patients in a peripheral hospital in the Netherlands acquired an infec-
tion with the intestinal bacterium ‘Clostridium diffi  cile’ and developed nosocomial diarrhoea. 
Three patients died because of, or with this infection. The origin was probably the abuse 
of one type of antibiotic, which already has been removed from the medication list of the 
hospital.
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- Whereas the occurrence of a MRSA (Methicillin-resistant Staphylococcus aureus) infection 
in a hospital in the Netherlands creates frontpage news; elsewhere in Europe (mainly the 
southern part of Europe) most types of Staphylococcus aureus infections are methicillin-resis-
tant, which is now considered to be undergoing an epidemic increase. Hence the designation 
EMRSA for epidemic MRSA.
- In 1999; almost 250 visitors to the “Floriade” – an indoor fl ower and garden show – in the 
northern part of the Netherlands developed Legionnaire’s disease and eventually 32 people 
died. During the following months; ventilator-associated pneumonia caused by Legionnella 
was observed in several ICUs in the Netherlands, whereas hospital-acquired Legionnaire’s 
isease had not been observed in the decades prior to this outbreak.
- New sources of exogenous infection for nosocomial Intensive Care infections have been 
reported, including bedside computer keyboards from digital data systems in the newer ICUs, 
artifi cial nails of hospital personnel, and piercings (especially through mucous membranes) 
in patients or hospital personnel.
OUTLINE OF THE THESIS
To evaluate the scale of the problem of nosocomial ICU infections, a European-wide study 
was conducted: the ‘European Prevalence of Infection in Intensive Care’ (EPIIC) Study, includ-
ing 10,038 ICU patients in 17 European countries.
Nosocomial ICU infections are divided in the following categories: 1) ICU-acquired infec-
tions, defi ned as infections clinically manifest or under treatment during ICU stay, but not 
clinically manifest or incubating at the moment of admission of the patient to the ICU. 2) 
Hospital-acquired infections, defi ned as infections clinically manifest or incubating at the 
moment of admission to the ICU, and apparently related to the preceding hospital stay. 3) 
Externally-acquired infections, defi ned as infections clinically manifest or incubating at the 
moment of admission to the hospital or ICU, and not related to another preceding hospital 
stay.
The aims of this thesis are 1) to determine the scope and magnitude of nosocomial ICU 
infections in Europe, and to compare this landscape with the situation in the USA (chapter 2), 
2) to determine the scope and magnitude of nosocomial ICU infections in the Netherlands, 
and to compare this landscape with the situation in Europe (chapter 3 and 4), 3) to determine 
the scope and magnitude of nosocomial ICU infections for the surgical ICU patients (chapter 
5), 4) to determine the scope and magnitude of MRSA (Methicillin-Resistant Staphylococcus 
Aureus) ICU infections, compared with MSSA (Methicillin-Sensitive Staphylococcus Aureus) 
infections (chapter 6), and 5) to review the problem of Candida ICU infections, called ‘the 
emerging pathogens’(chapter 7).
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In search for solutions to the candidiasis problem in the ICU setting, we performed a risk 
analysis of Candida peritonitis in the surgical ICU, in order to identify high risk subgroups 
and to target antifungal prophylaxis or early empirical therapy (chapter 8). Furthermore, we 
evaluated a new, rapid identifi cation method of Candida species by Raman spectroscopy, 
in comparison to the relatively time-consuming conventional microbiological identifi cation 
(chapter 9). Finally, we discuss the future challenges of infection control (chapter 10).
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INTRODUCTION
The scope and magnitude of nosocomial (ICU) infections is overwhelming, with a negative 
impact on both the added morbidity and the mortality, and as a consequence on the overall 
hospital charges and economic costs. Many studies come to similar results (1-6). This is not a 
special European, but also acknowledged to be a worldwide problem. It is special for the ICU, 
with considerably higher rates of nosocomial infection than in other hospital wards (2, 7-10). 
Aggressive invasive diagnostics, multiple therapies and a plethora of invasive devices in 
combinati on with a temporarily compromised immunity renders the ICU patient population 
uniquely susceptible to nosocomial infections (11-14). Overall, intrinsic risk together with ex-
trinsic factors make the ICU patient extremely vulnerable to nosocomial infections. As stated 
by Meakins et al. ‘Infection is their Achilles heel’ (15). With the continuous recognition, the 
past few years, of new and more virulent organisms and with a rapid growth in antimicrobial 
resistance, the problem becomes even worse. Towards the year 2000 the medical profession 
will face the challenge of infections against which none of the current antimicrobial agents 
are eff ective; many clinicians unfortunately are not aware of this impending crisis (16).
 The problem of the nosocomial ICU infections will continue to limit the potential ad-
vances to be made in critical care medicine. It is therefore of paramount concern to reduce 
this impact. There is still room for improvement in the control of these ICU infections. Results 
of the study on the Effi  cacy of Nosocomial Infection Control (SENIC) have suggested that up 
to one third of nosocomial infections to which the modern hospital is prone should be pre-
ventable (17). An epidemiological database is needed to make a quantifi cation of the scale 
of the ICU infection problem and to identifi cate the factors, both intrinsic and extrinsic, that 
aff ect it, highlighting the risks to which the ICU patient is exposed. Awareness of the problem 
of these risks has already been shown to be an important factor in successful implementation 
of infection control policies (17,18). Investigation of this entity of infection risk must lead 
to targeted surveillance program mes and the subsequent initiation of appropriate infection 
control measures, better prevention and appropriate therapy, hopefully resulting in lower 
infection rates, morbidity, mortality and substantial savings for the hospital budget.
 There is a remarkable diff erence in the knowledge of the magnitude of the infection prob-
lem between the USA and Europe. In the United States systematized information concerning 
the rates of nosocomial infections, ethiological organisms and risk factors are available due 
to the development of various national formalized systems for ongoing surveillance. In the 
1960s, the Centers for Disease Control (CDC) in Georgia began recommending that hospitals 
conduct surveillance over the occurrence of nosocomial infections to obtain epidemiological 
evidence on which to base rational control measures (19,20). After an international confer-
ence on nosocomial infections in Chicago in 1970 (21) and diverse publications (22) a nation-
wide movement toward the establishment of organized infection surveillance ensued, and 
by the end of the 1970s the majority of US nation’s hospitals had jumped on the ‘surveillance 
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bandwagon’ (23). In January 1974, CDC initiated the SENIC Project (Study on the Effi  cacy 
of Nosocomial Infection Control, 24) to determine whether and, if so, to what extent, this 
control program approach was eff ective in reducing nosocomial infection risks (17). Of more 
recent date the National Nosocomial Infection Surveillance (NNIS) study was generated by 80 
medical centers in the USA from 1980-1992 (25). In Europe, no such formalized systems exist, 
and there has been no large international study to determine the nosocomial infection rates 
throughout the continent, up to 1992. Only a few studies have been undertaken in individual 
countries (Table 1, 26-31). With relatively few hospitals taking part in each country and with 
very low numbers of patients, so examining only hospital-limited rates of infections. Besides, 
the design of the protocol of these studies diff ered widely (prevalence opposite incidence 
studies (32). Consequently it is thus absolutely inappropriate to extrapolate the data from 
these studies to overall, European, epidemiological ICU settings.
THE EPIIC STUDY
It was against this background that in 1992 the European Prevalence of Infection in Intensive 
Care (EPIIC) study was undertaken, - the largest ever study of this type, conducted throughout 
Europe- to deal with the relative lack of information concerning nosocomial ICU infections, 
providing a new perspective on the scale of the problem in Europe.
The aims of the study
The primary aim of the EPIIC study was to determine, during exactly one day, the prevalence 
of ICU-acquired infections in patients on ICUs in 17 European countries. In addition, the study 
Table 1. Studies before 1992 of nosocomial infection rates in Europe
Reference Year Country Type of study Infection 
rate (%)
No. of ICUs 
surveyed
No.of patients
Included
Bernander et al. (26) 1978 Sweden Point 
prevalence
72 3 29
Daschner (27) 1982 Germany,
Switzerland
3-year 
incidence
12,5
7,2
total:3-27
5
4
5374
1578
Moro et al. (28) 1986 Italy Prevalence 6,8-12,4
(hosp-ICU)
130 34577
Constantini et al. (29) 1987 Italy 1-year 
incidence
26,9 4 859
Mertens et al. (30) 1987 Belgium Point 
prevalence
9,3 106 8723
EPINCAT Working Group 
(31)
1990 Spain Prevalence 26,8-46,6
(hosp-ICU)
33 7434
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had a number of subsidiary aims: to diff erentiate the prevalence rates of specifi c types of 
nosocomial infections, to establish the microbiology and thus determining those patho-
gens considered to be causal of these infections, including their patterns of antimicrobial 
susceptibility (or resistance) to particular antibiotics, to assess the pattern of antimicrobial 
prescribing, to identify risk factors for infection and to establish the relative importance of 
these factors by correlating them with the rates and types of infection, to correlate rates of 
infection with the patients clinical status on admission and with their outcome (death or 
survival) at a predefi ned end point in a 6 week follow-up period, and fi nally to compare infec-
tion rates in diff erent types of ICUs and to gauge the variations in infection rates between 
units in the 17 diff erent countries throughout Europe. The overall key aim of the EPIIC Study 
was to raise awareness of the problems of nosocomial infection in the ICU and to stimulate 
discussion, hopefully leading to better prevention, appropriate therapy and improving infec-
tion control programs.
The protocol of the study
This point prevalence study was conducted on a 24-hour period, 29 April 1992. On the study 
day, information was collected for later analysis on 10038 patients in 1417 adult, non-coro-
nary care ICUs in 17 Western European countries, by questionnaire. Nosocomial infections 
in ICU were classifi ed according to standard defi nitions of the Centers for Disease Control, 
CDC (33). Assessment of the patient’s status on admission was made on the basis of his/her 
APACHE II score (Acute Physiology and Chronic Health Evaluation, 34,35). A logistic regres-
sion analysis was done to estimate the eff ects of possible risk factors, measured as odds ratios 
(OR, comparing relative risks), together with their 95% confi dence intervals (CI). In addition 
multiple logistic regression analysis was done to assess which independent factors aff ected 
the overall risks of infection and death, and to investigate the relationship between these dif-
ferent risk factors. The complete methods have been described elsewhere (36,37). The most 
important reservation of the study to be mentioned, is the diffi  culty of identifying pathogens, 
who may have only refl ected possible contamination or colonization in stead of represented 
the cause of the infection.
THE EPIIC RESULTS: EUROPE OVERALL
Participation and demographics of ICUs in Europe
Data from 1417 participating Intensive Care Units, in 17 European countries, were entered 
in to the study database providing a total of 10038 completed case report forms suitable 
for analysis. Half of these ICUs were situated in community-based hospitals (51%), 35% in 
university hospitals, and 14% in university-affi  liated hospitals. Most units (74%) were mixed 
medical/surgical ICUs. The majority of ICUs (57%) were of intermediate size, consisting of 
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6-10 beds, though 25% were large, having 11 or more beds. Most ICUs (74%) admitted up 
to 14 patients per week, although a substantial number (11%) had a high admission rate 
of 22 or more patients per week. There was an average bed occupancy rate on the study 
day of 79%. The great majority of ICUs had a full-time director (67%) and/or 24-hour physi-
cian cover (72%), with consequently up to a quarter having only part-time cover. Other staff  
regularly joining the ICU teams included a microbiologist (overall 43%), an infection control 
nurse (24%), a pharmacist (20%) and an infectious diseases specialist (15%). Half of the ICUs 
(58%) used a written infection control policy (the others having only an informal policy), only 
a quarter (25%) used a written antibiotic policy, and 66% used regular bacteriological surveil-
lance on the ICU.
Patient demographics
The EPIIC Study population was largely male (62%), and overall predominantly aged over 40 
years (83%), 30% was even older than 70 years. Female patients tended to be older than men 
Table 2. Patient demography: prevalence of underlying conditions
Organ failure (all types) 56.5%
Impaired respiratory refl ex 21.5%
Chronic respiratory insuffi  ciency 14.4%
Carcinoma 13.6%
Diabetes mellitus 12.6%
Multiple trauma with head injury  8.1%
Multiple trauma without head injury  4.4%
AIDS  0.8%
0,0
5,0
10,0
15,0
20,0
25,0
30,0
%
 o
f p
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s
0-5  6-10  11-15  16-20  21-25  26-30  31-35  >=36
APACHE II score
Figure 1. APACHE II scores (% of patients)
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(mean age 61 and 51 years respectively). From the scored underlying conditions organ failure 
(of one type or another) was mostly present, in over half of the study population (57%) (Table 
2). Half of the patients had undergone surgery in the month prior to the study.; 32% elective 
surgery and 23% emergency surgery. The site of surgery most frequently performed was ab-
Table 3. Prevalence (% patients) of reported potential risk factors for nosocomial ICU- infection, scored in the week preceding the study day.
Length of ICU stay (days)
 0-1 17.8
 1-3 28.9
 3-5 8.4
 5-6 8.6
 7-13 13.8
 14-20 8.0
 >20 14.5
Diagnostic intervention
Intravenous catheter 78.3
Urinary catheter 75.2
Central venous pressure line 63.9
Mechanical ventilation 63.0
Intubation 62.2
Arterial catheter 44.2
Central iv nutrition 36.5
Wound drain 30.6
Chest drain 14.7
Pulmonary artery catheter 12.8
Tracheostomy 12.6
Peripheral iv nutrition 9.2
Hemodialysis 5.2
Atrial/ventricular pacing 4.8
Intracranial pressure line 2.2
Peritoneal dialysis 0.5
Therapeutic intervention
Sedation 51.2
Stress ulcer prophylaxis
H2 receptor antagonist 39.0
Sucralfate 23.5
Antacids 9.2
Omeprazole & others 9.0
Prophylactic antibiotics 19.4
Longterm/ high dose steroids 12.9
SDD 6.3
Immunosupressive therapy 2.7
Radiotherapy 0.3
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dominal surgery (19%). Organ systems cited as being the most important reason for admis-
sion to the ICU were the respiratory (37%), cardiovascular (30%) and central nervous systems 
(23%). Of the patients 39% were admitted to the ICU for postsurgical control or surveillance. 
The mean APACHE II score calculated on admission was 12.7 (Figure 1). The prevalence of 
potential risk factors for nosocomial infection relating to the length of ICU stay prior to 29-04-
92 and certain procedural or therapeutic interventions (scored in the week prior to the study) 
is shown in Table 3 (SDD = selective digestive decontamination).
Prevalence of nosocomial infection and the key infection types
On the study day a total of 4501 patients (45% of the total patient population) had one or 
more infections. Almost half were ICU acquired infections (21% of the total). Hospital-ac-
quired infections were recorded in 10%, and community-acquired infections in 14%. Of those 
patients reported as having an ICU-acquired infection, the majority had only one such an 
infection, although 25% had two or more infections. Figure 2 gives the prevalence of the 
types of the most frequently reported ICU-acquired infections (incidence > 4.0%).
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Figure 2. Key infection types. prevalence in ICU patients (%)
Lrti = lower respiratory tract infection, Uti = urinary tract infection, Ent = ear, nose and throat, Sst = skin and soft tissue, Gi = 
gastrointestinal
The key types of pathogens, isolated from patients with ICU-acquired infections
Overall, 55% of the ICU-acquired infections were polymicrobial. Staphylococcus aureus was 
the ‘key pathogen’ most frequently isolated (30%). Only the Enterobacteriaceae were re-
ported more often (34%), but as a class. The most commonly reported isolates acquired in 
the ICU infections are shown in Table 4.
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From the Enterobacteriaceae, as a class within the gram-negative organisms, E.coli was the 
most commonly scored pathogen, followed by Klebsiella spp., and Enterobacter spp. The En-
terobacteriaceae were cultured from a substantial proportion of urinary isolates, particularly 
E.coli: the most common cause of urinary tract infection –both symptomatic and asymptom-
atic (colonization?)- cultured in 22% of these urinary isolates. In addition, the Enterobacteria-
ceae were reported in 28% of the lower respiratory tract infections other than pneumonia.
As noted, S. aureus was the most commonly reported bacterial isolate overall. Particularly 
causing skin and soft tissue infections (cultured in 36% of total isolates from this type of 
infection), pneumonia (cultured in 32%), other lower respiratory tract infections (in 31%), 
wound infections (in 27%), and laboratory-confi rmed bloodstream infections (in 22%).
P. aeruginosa was of substantial importance in pulmonary infections: both in pneumonia 
(cultured in 30% of the total pneumoniae-isolates), and in the other lower respiratory tract 
infections (cultured in 35%). Besides, P. aeruginosa was also frequently cultured from skin and 
soft tissue infections (in 33% of total isolates of this infection), wound infections (in 21%), and 
urinary tract infections (in 19%).
Coagulase-negative staphylococci (CNS) were the most frequently documented isolates in 
laboratory–confi rmed bloodstream infections, being reported in 45% of the cultures. Overall, 
gram-positive organisms accounted for about 70% of the cultured isolates responsible for 
bacteremia: besides CNS, S. aureus accounted for 22% of isolates and enterococci for 11%. 
This result confi rmed the results of other studies that have documented an increasing num-
ber of gram-positive infections, particularly CNS and enterococci in bacteremia (38). This is 
most probably due to the selective pressure exerted by the use of broad-spectrum antibiot-
ics, such as the third-generation cephalosporins, which are generally more potent against 
gram-negative than gram-positive bacteria, and to the increasing use of intravascular devices 
(bearing in mind the propensity of particularly CNS to colonise vascular invasive devices). 
However, uncertainty exists always over whether CNS are true pathogens or merely contami-
nants of blood cultures, when taken from an intravascular catheter? In literature, diff erent 
criteria and defi nitions have been used to defi ne true bloodstream infections after isolation 
of CNS (39-41). The EPIIC study used the CDC defi nitions for laboratory-confi rmed primary 
bloodstream infection, and clinical sepsis (33).
Candida spp. are called ‘emerging pathogens’, because over the past decades they es-
tablished themselves as serious causes of infection. Many recent studies reported Candida 
spp. as a signifi cant pathogen (42,43). This growing importance of fungal isolates is related 
presumably to an increasing use of broad-spectrum antibiotics, in an increasingly immuno-
suppressed patientpopulation (due to the primary disease and to treatment with corticoste-
roids). Also the EPIIC results highlighted the growing prevalence of fungal pathogens, with 
a surprisingly high frequency of 17% (despite the low number of AIDS patients). The most 
common site from which fungi were cultured, was the urinary tract (isolated in 18% of urine 
samples, making fungi together with E. coli the most important pathogens in urinary tract 
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infections). In addition, fungi were the third most frequently isolated pathogens in pneu-
monia (isolated in 14% of the cultures). Again here the diff erence between infection and 
colonization remains uncertain, as Candida pneumonia is a rare event. Yet more than 50% of 
patients with a positive fungal isolate were receiving antifungal treatment, indicating that 
these isolates were thought to be of clinical signifi cance (36).
Other so called ‘emerging pathogens’ are the Acinetobacter spp. These isolates have been 
cultured mostly in nosocomial pneumonia (in 10%), and in the other lower respiratory tract 
infections (in 11%).
With respect to the microbiological isolates reported in the EPIIC study, the results are com-
parable with those of the NNIS study in the USA from 1980 through 1992 (25,44). One excep-
tion, being a low prevalence of Enterobacter species in the EPIIC results (6.6%), particularly for 
laboratory-proven bloodstream infections. In the NNIS study the most common pathogens 
were P. aeruginosa (12%), S. aureus (12%), CNS (10%), Candida spp. (10%), Enterobacter spp. 
(9%), and enterococci (9%). The data of the NNIS documented the same increasing number 
of gram-positive infections, particularly CNS (with a frequency of 9% in 1989, increasing to 
30% in 1992). The results of all these epidemiological studies emphasizes the need for broad-
spectrum antibiotics, when starting empirical antimicrobial therapy on the ICU, being equally 
eff ective against gram-positive and gram-negative bacteria, changing to smaller specifi ed 
antibiotics, eff ective for the causal pathogens, when culture results are positive.
Pattern of antibiotic administration
In total, 6250 patients (62%) were receiving antimicrobials on the study day, prescribed 
either for treatment or prophylaxis. Half of these patients (49%) were receiving single anti-
biotic therapy, the others receiving combination therapy with multiple antibiotics. The most 
Table 4. Prevalence of reported isolates in ICU-acquired infections
Isolate %
 Staphylococcus aureus 30.1
 Pseudomonas aeruginosa 28.7
 Coagulase-negative staphylococci 19.1
 Fungi 17.1
 Escherichia coli 12.7
 Enterococci 11.7
 Acinetobacter spp.  9.3
 Klebsiella spp.  8.1
 Streptococci (other than pneumococci)  7.1
 Enterobacter spp.  6.6
 Proteus spp.  5.7
 Other Pseudomonas spp.  4.4
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frequently administered antimicrobials were the cephalosporins, used in 44% of all antibiotic 
treated patients, both for prophylaxis (particularly cefuroxime and cefazolin) and for treat-
ment (particularly ceftazidime and cefotaxim). Table 5 shows the prescription policy of the 
scored antimicrobials. Only few patients were receiving treatment with antifungal drugs 
(6.6%), or antiviral drugs (1.1%). Also the (routinely) use of selective decontamination of the 
digestive tract (SDD) was rare (overall, 6.3% of ICUs used SDD in the week preceding the 
study, 5.6% used SDD on the study day). The majority of ICUs in Europe never use SDD.
Pattern of antibiotic resistance
Data were scored about the patterns of microbial resistance to the diff erent types of antibiot-
ics, of the three most frequently reported isolates in the ICU-acquired infections: P. aerugi-
nosa, S. aureus and coagulase-negative staphylococci. Of the cultured P. aeruginosa isolates 
65% were resistant to one or more antibiotics. Most common was resistance of P. aeruginosa 
to gentamicin (in 46% of resistant isolates), followed by resistance to ureidopenicillin (37%), 
ceftazidime (28%), ciprofl oxacin (26%), and imipenem (21%). Overall, 86% of the S. aureus 
isolates were resistant to one or more antibiotics. Of these, 60% of strains of S. aureus were 
resistant to methicillin (MRSA). The most commonly recorded sites of MRSA infection were 
in the respiratory tract: pneumonia (52%), and lower respiratory tract infections (22%). In 
total 73% of the CNS isolates were resistant to one or more antibiotics. The data reported a 
high resistance rate of CNS to methicillin (70% of resistant isolates), cefotaxime (69%), and 
gentamicin (66%). Resistance of CNS to teicoplanin (9%), and vancomycin (4%) was relatively 
uncommon, but unfortunately does exist.
The problem of resistant pathogens is becoming worse every day, particularly in the ICU, 
everywhere throughout in Europe. Once we thought antibiotics to be the answer to infec-
tions, now we know they are not. The successes of the past, accomplished with the advent 
Table 5. Antibiotics prescribed on the study day (% of total antibiotic use)
Antibiotic Frequency overall (%) Use for prophylaxis (%) Use for treatment (%)
Cephalosporins 43.6 22.1 21.6
Aminoglycosides 23.9  5.4 18.6
Quinolones 11.9  1.6 10.4
Penicillin 10.3  4.8  5.5
Macrolides  4.4  0.8  3.6
Broad-spectrum penicillins 24.3  8.1 16.2
Imipenem  8.1  0.8  7.3
Glycopeptides 11.6  1.2 10.3
Metronidazole 17.1  7.8  9.2
Aztreonam  2.0  0.4  1.6
Other 10.3  2.6  7.7
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of (new) antibiotics, selectively eliminating of what were considered to be pathogenic mi-
croorganisms, have proved to be an illusion. On the contrary, the emergence of extremely 
virulent and resistant microbial strains is certainly the result of (mis)use of these antibiotics 
itself (45,46).
For example, the rapidity with which methicillin-resistant S. aureus developed in Europe after 
the introduction of methicillin (and cephalosporins, as cross-resistance between penicillins 
and fi st generation cephalosporins is a common if not ever present feature). The subsequent 
spread of MRSA throughout Europe have created enormous problems with consequences 
for therapeutics and ICU-management. According to the results of the EPIIC study, 60% of 
strains of S. aureus were resistant to methicillin. We evaluated, using the EPIIC-data, the risk 
of accquisition of an infection with MRSA and the risk of death, compared with patients who 
developed methicillin-sensitive S. aureus (MSSA) infection (47). The most important risk fac-
tor was the length of stay in the ICU: the longer the stay, the higher was the risk of an MRSA 
rather than an MSSA infection (with an odds ratio of 4.07 for a stay longer than three weeks). 
MRSA infection reduced the chance of survival, particularly when it was found in lower respi-
ratory tract infections: the risk of mortality was three times higher in patients with MRSA than 
in those with a MSSA infection.
The key risk factors for ICU-acquired infection
Statistical analysis quantifi ed the possible relationship between investigated risk factors and 
nosocomial infection. After univariate analysis 14 variables were identifi ed as signifi cant risk 
factors: organ failure of any type on admission, emergency surgery (but not elective), trauma, 
respiratory problems and mechanical ventilation, various invasive interventions (central ve-
nous, pulmonary artery and urinary catheterization, intubation, tracheostomy), stress ulcer 
prophylaxis, an APACHE II score of more than 6, and prolonged length of ICU stay. The most 
important risk factor was the length of ICU stay (up to 29.04.92, in days): compared with a 
length of stay of less than 1 day (odds ratio=1), an ICU-stay of 3-4 days increased the risk of 
infection nine times. Those patients who had been in the ICU for 3 weeks or more, were at 
76 times the risk of the one day patient. The size of the ICU was also a risk factor: patients on 
greater units were signifi cantly more at risk than those on smaller units. Interestingly, cancer, 
an age older than 70 years, and elective surgery apparently decreased the odds ratio for infec-
tion. Also the type of ICU (medical, surgical, or mixed) and the length of stay in hospital before 
admission to the ICU, did not signifi cantly aff ect the risk for infection. Analysing risk factors 
for special types of infection, also showed the length of ICU stay to be the most important risk 
factor. Invasive procedures to the respiratory tract (particularly tracheostomy and assisted 
ventilation) increased the risk of pneumonia. These interventions also increased the risk of 
laboratory-confi rmed bloodstream infection, together with a particular risk due to a central 
venous pressure line. In addition multiple logistic regression analysis was done to control for 
the eff ects of confounding variables, using all the described variables signifi cantly associated 
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with infection. Seven variables remained as independent risk factors, shown in Table 6. The 
APACHE II score was no longer a signifi cant, independent risk factor in this analysis.
Awareness of these risk factors should promote their avoidance where possible, or at the 
moment the inevitable interventions are not absolutely necessary any more, one should 
remove them as soon as possible.
Mortality among ICU patients, and the relevance of various risk factors
Data concerning the outcome of the ICU patients (expected, or in the case of death, actual), 
were recorded on discharge from the ICU, up to a follow-up period of 6 weeks after the study 
day.Of those patients 83.2% were discharged from the ICU alive, so the overall mortality 
rate was 16.8%. There was considerable variation in mortality rate by country and by ICU. 
This does not mean that these diff erences in mortality do refl ect diff erences in level of care 
in the ICUs. But rather, these diff erences are more likely due to diff erences in the patient-
population, arising from discrepancies in admission criteria, refl ected in diff erences in the 
severity of illness. The patient admitted for postsurgical control or surveillance has another 
prognosis than the ICU patient with sepsis. Nonetheless, mortality in the EPIIC study was 
higher in those countries with higher ICU-acquired infection rates. A signifi cant correlation 
(R2= 0.68) was noted between the prevalence rate of ICU-acquired infection and the mortal-
ity rate. Again caution must be exercised in drawing any direct conclusions. The statement 
that intensive care patients die of, rather than with, infection is not proven (48). The ques-
tion that arises is whether infection contributes to mortality? The answer remains unclear. 
As stated by Gross and van Antwerpen (49) ‘In two groups, well matched by many criteria, 
Table 6. Independent risk factors associated with ICU-acquired infection
Risk factor Odds ratio 95% Confi dence interval
Length of ICU stay:
  < 1 day  1
  1–2 days  2.54  1.56 - 4.13
  3-4  days  8.99  5.51 - 14.70
  5-6  days 15.01  9.33 - 24.14
  7-13 days 30.75 19.43 - 48.67
  14-20 days 60.40 37.90 - 96.25
  ≥ 21 days 76.06 48.18 - 120.06
Pulmonary artery catheter  1.20  1.01 - 1.43
Central venous pressure line  1.35  1.16 - 1.57
Stress ulcer prophylaxis  1.38  1.20 - 1.60
Urinary catheter  1.41  1.19 - 1.69
Mechanical ventilation  1.75  1.51 - 2.03
Trauma on admission  2.07  1.75 - 2.44
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diff erences in prognosis on admission probably accounted for the major diff erences in sur-
vival. Nosocomial infections may aff ect outcome in those whose condition is not terminal on 
admission’. Notwithstanding that diff erences in mortality rate cannot be directly attributed 
to diff erences in infection rates or diff erences in microbial resistance, univariate analysis of 
the EPIIC data confi rmed that ICU-acquired infections are among the most important inde-
pendent risk factors associated with increased mortality. According to the univariate analysis 
the following risk factors increased the odds of death: various ICU-acquired infection types 
(wound infection, laboratory-confi rmed bloodstream infection, sepsis, pneumonia and lower 
respiratory tract infection, urinary tract infection, skin and soft tissue infection), an age older 
than 60 years, organ failure of any type on admission, cancer, diabetes, prolonged stay in the 
ICU and increasing APACHE II score. The greatest risk was associated with a high APACHE II 
score (which indeed refl ects the risk of death), and with clinical sepsis. After using multiple 
logistic regression analysis, eight risk factors remained as independently associated with an 
increased risk of mortality (Table 7).
THE EPIIC RESULTS: EUROPEAN LANDSCAPE
There were marked variations in the results of the EPIIC data between the diff erent European 
countries. Overall, there was a wide range in prevalence rates of ICU-acquired infections, from 
10% in Switzerland to 32% in Italy. There tended to be a trend toward higher infection rates 
and higher overall ICU mortality rates in Southern Europe. Table 8 shows the prevalence of 
ICU-acquired infection and the ICU mortality rate for each country taking part in the EPIIC 
study.It is more likely that these diff erences are based on diff erences in patient selection on 
admission, and in intensive care practice, rather than any real diff erences in quality and abso-
Table 7. Independent risk factors associated with mortality
Risk factor Odds ratio* 95% Confi dence interval
Age
60—69 years  1.7 1.07 - 2.71
≥ 70 years  2.08 1.31 - 3.31
Organ failure on admission  1.68 1.45 - 19.5
APACHE II score ≥ 31 15.55 9.3 - 26.0
ICU stay ≥ 21 days  2.52 1.99 - 3.18
Carcinoma  1.48 1.23 - 1.79
Pneumonia  1.91 1.6 - 2.29
Clinical sepsis  3.5 1.71 - 7.18
Laboratory-confi rmed bloodstream infection  1.73 1.25 - 2.41
*OR’s: adjusted for age
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lute standards of care. For example, there were substantial diff erences between the countries 
in size of the ICU. Most ICUs were of intermediate size, having 6-10 beds. France and Spain 
had the largest ICUs, with 43% and 42% respectively having ≥ 11 beds. In contrast, in the UK 
only 5% of ICUs were of this size, while 48% were small ICUs, having up to 5 beds. As men-
tioned previously, the size of the unit is an infection risk factor it self, with signifi cantly more 
infections scored in the units of 11 or more beds. There were also wide variations between 
countries in the ICU resources. Overall, 43% of the ICUs had a microbiologist joining the 
team, while Denmark, the Netherlands (both 83%) and the UK (73%) had much more often 
a microbiologist in the team. Discrepancies in patient selection are refl ected in diff erences 
in the APACHE II scores of the patients on admission to the ICU. The average score overall in 
Europe was 12.7. There was a more severely ill ICU population in Eire, France, Greece, Italy, 
Portugal, Spain and the UK, with more than 15% of patients having an APACHE II score >20. 
In Norway, Sweden, Germany and Switzerland only <10% fell into this category, while >50% 
had an APACHE II score of 10 or less. Including in the admission criteria also patients just 
for post-surgical control or surveillance, decreases the average APACHE II score, and most 
likely decreases the average total length of stay, both with the same impact on the preva-
Figure 3. Frequency of resistant P. aeruginosa, of MRSA, and of resistant CNS, by country.
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lence of ICU infections. As part of diff erences in intensive care practice, there were marked 
variations between countries with respect to the use of procedural or therapeutic interven-
tions. Overall, the use was often highest in the UK. With respect to antibiotics most countries 
tended to administer single antibiotic agents for treatment. The exceptions were Eire, France, 
Greece, Spain and the UK where more than half of the patients with antibiotics were receiv-
ing multiple agents. The most considerable diff erence in the use of antibiotics was noted 
in the prevalence of SDD. Overall, the majority of ICUs in Europe never use SDD, the scored 
prevalence for Europe totaly was 6%, while ≥ 40% of units in Austria, the Netherlands and 
Luxembourg use SDD routinely in a selected patientpopulation.
There turned out to be an enormous intercountry variation in the prevalence of resistant 
P. aeruginosa, of MRSA, and of resistant coagulase-negative staphylococci. Figure 3 shows 
the frequency of resistance by European countries (taking into account the limitations of a 
one-day point prevalence survey, and of the sometimes low numbers of patients when ana-
lysing this item, making a surprisingly 0% sometimes possible). Apparently several countries 
have been able to prevent resistance problems in their ICU, by inevitable control measures 
and screening programs, by using antimicrobial agents only judiciously, and by reinforcing 
hygienic measures where necessary (47).
Table 8. Prevalence of ICU-acquired infection, and mortality rate, by participating country
Country No. of
ICUs
No. of
patients
Prevalence of ICU
infection (%)
ICU mortality
Rate (%)
Austria  75  420 20.0 15.3
Belgium  72  669 17.2 14.9
Denmark  12   81  7.4 11.3
Eire  15   91 18.7 11.8
Finland  20  132 15.9 11.9
France 264 2359 24.2 18.7
Germany 268 2010 17.3 14.9
Greece  37  200 30.5 28.5
Italy 110  617 31.6 20.3
Luxembourg   5   29 17.2 13.0
The Netherlands  78  472 15.7 13.8
Norway  23  150 12.7  8.9
Portugal  19  120 23.3 23.9
Spain 137 1233 27.0 19.4
Sweden  39  286  7.7  8.8
Switzerland  49  329  9.7  8.4
United Kingdom 194  840 15.9 19.9
Total 1417 10038 20.6 16.8
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SUMMARY
According to the results of the EPIIC study the scope and magnitude of nosocomial ICU 
infections in Europe is overwhelming. The highlights of the results were the prevalence of 
pneumonia and other lower respiratory tract infections, the importance of the Enterobacte-
riaceae (as a class), S. aureus and P. aeruginosa as the key pathogens, and the high prevalence 
of microbial resistance of these pathogens to the various antibiotics. Overall, there was a 
surprisingly growing signifi cance of gram-positive pathogens, and fungi. The key risk factors 
associated with ICU-acquired infections were in particular a prolonged length of stay on the 
ICU, and various invasive interventions. Mortality rates were high, with a signifi cant correla-
tion between the prevalence rate of ICU-acquired infection and the mortality rate (in particu-
lar pneumonia, laboratory-confi rmed bloodstream infection and sepsis were independent 
risk factors, associated with an increased risk of death).
Europe needs well-implemented infection control policies, to reduce these preventable 
infections. Data from the EPIIC study are just a starting point and motivating factor to achieve 
this. Up to this moment there is in Europe no formalised and ongoing surveillance system 
(such as the NNIS in the USA), needed to establish, stimulate, up date, continuously improve 
the quality, and evaluate the eff ectiveness of such control programs. The ultimate aim for the 
future is more European collaborative eff orts in infection control. Recently European bound-
aries are opened for traffi  c and tourism, consequently also for micro-organisms, making the 
task to control resistant pathogens increasingly diffi  cult.
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Scope and magnitude of nosocomial ICU 
infections; Dutch perspective – a risk analysis
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ABSTRACT
Objective: Evaluation of the point prevalence of nosocomial infections, acquired in the in-
tensive care unit (ICU) and determination of risk factors for ICU patients.
Design: Descriptive study.
Setting: 78 Dutch ICUs.
Methods: Collecting data by detailed questionnaires for each patient admitted to one of the 
participating ICUs, on one specifi ed day (a one-day point prevalence survey: April 29th 1992), 
and after a follow-up period of 6 weeks.
Results: Included in the study were 472 ICU patients; 176 (37%) suff ered from an infection 
of which 74 (16%) was ICU-acquired. The most important risk factors were: the duration of 
an ICU stay (relative risk (RR) 4.23 (95% confi dence interval: 3.32-5.40), 99.37 (22.26-434.50) 
and 146.79 (32.83-656.30) for ICU stays of 3-4 days, 1-2 and more than 3 weeks respectively, 
compared to a stay of 0-2 days), correlated with severity of disease (organ failure) and more 
medical interventions (mechanical ventilation, urinary catheter). The risk of acquiring a 
nosocomial ICU infection was lower after elective surgery than after ICU admission without 
previous surgery; after emergency surgery the ICU infection risk was higher.During follow-up 
63 (14%) patients died. Patients suff ering from an ICU infection had a higher mortality 
risk; the strongest prognostic factor to determine the mortality risk was the APACHE II-Score 
(RR: 13 (3.89-42.69) with a score between 16-26 and RR > 100 (7.67-1377.93) with a score 
> 31).
Conclusion: ICU-acquired infections are a serious problem. Programmes for infection pre-
vention and strategies in infection control need to be adjusted.
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INTRODUCTION
World wide, it has become obvious that the problem of nosocomial infections is increas-
ing. The impact of these nosocomial infections on morbidity, mortality and hospital costs is 
growing (1-7), despite improvements made within the antisepsis policies, where develop-
ment of active and passive immune therapy and the further development of antibiotics were 
important. While we have succeeded to control and treat the infections outside the hospital, 
nosocomial infections inside the hospital are still increasing. It appears that, contrary to ear-
lier belief that the use of antibiotics was the answer to prevention of these infections, the use 
of antibiotics will cause colonisation with pathogenic micro-organisms. The “sine qua non” 
theory (without pathogenic micro-organisms there is no infection), which regarded for long 
as being the basis of the eff ort to control micro-organisms and infections, turned out to be 
fi ction. Because of the abuse of antibiotics during the last decades to eliminate pathogenic 
micro-organisms, more virulent and resistant micro-organisms have emerged.
The growing problem of nosocomial infections is not only due to the growing incidence 
of resistant micro-organisms. Other factors contributing to this problem include the growing 
number of patients with (iatrogenic) immune suppression and disturbed endogenous fl ora, 
a more frequent use of medical interventions, a longer hospital or intensive care unit (ICU) 
stay and a higher average age of the patients. Intrinsic risk factors (lower host resistance) 
together with extrinsic ones (interventions, more virulent and resistant micro-organisms) 
make the ICU patient most vulnerable to nosocomial infections. Meakins stated: ‘Infection is 
their Achilles heel’(8).
Because there was a lack of knowledge on the prevalence of risk factors for nosocomial in-
fections in European ICUs, a new study was conducted: “the European Prevalence of Infection 
in Intensive Care” (EPIIC) Study. This article describes the Dutch results of the EPIIC Study.
PATIENTS AND METHODS
The EPIIC Study, which involved 17 West European countries, collected data on the preva-
lence of ICU infections on one specifi ed day: April 29th 1992 (a one-day point prevalence 
survey). All ICUs were invited to take part in the study, except for neonatal and paediatric ICUs 
and coronary care units. All patients (older than 10 years) admitted to one of the participating 
ICUs, were included in the study.
Prevalence
Infections were defi ned according to the CDC-criteria (9). ICU-acquired infections were 
defi ned as infections clinically manifest or under treatment at the moment of evaluation 
(April 29th 1992), but not clinically manifest or incubating at the moment of admission of the 
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patient to the ICU. Hospital-acquired infections were defi ned as infections clinically manifest 
or incubating at the moment of admission to the ICU and apparently related to the preceding 
hospital stay. Externally-acquired infections were defi ned as infections clinically manifest or 
incubating at the moment of admission to the hospital or ICU and not related to another 
preceding hospital stay.
Risk factors
Besides the prevalence of ICU infections, the infl uence of various infection risk factors was 
evaluated, in order to identify possible risk groups. For each patient, data were collected by 
detailed questionnaires, regarding the presence of ICU infections, the bacteriological results 
and the prescribed antibiotics. In addition, patient data possibly infl uencing the infection 
risk were collected, such as age, sex, reason of admission to the ICU and total length of ICU 
stay. Clinical status at admission was defi ned by means of the ‘Glasgow Coma Score’ and the 
‘Acute Physiology and Chronic Health Evaluation’ (APACHE) II-Score. The APACHE II-Score was 
retrospectively determined, calculated with physiologic data scored during the fi rst 24 hours 
of the ICU stay (10,11). Additional chronic diseases were scored, such as cancer, diabetes and 
AIDS. Iatrogenic risk factors, if present, in the week preceding the study day were scored, such 
as: surgery, invasive interventions, the use of corticosteroids, chemotherapy or other immune 
modulating therapies, radiotherapy, or the use of sedatives or antacids. In addition, interven-
tions in relation to infection prevention strategies were scored, such as the prophylactic use 
of antibiotics and selective gut decontamination. Besides, the most important demographic 
data of each participating ICU, were scored. Finally, data were scored after a follow-up period 
of six weeks, on the mortality rate and/or discharge from the ICU.
Statistical analysis
The analysed eff ect of the scored ICU infection risk factors was translated into odds ratios, 
determined by means of logistic regression models. These odds ratios are like relative risks 
(RR), in relation to the zero level of this risk factor. In the mean time the infl uence of possible 
other infection risk factors is standardised. An RR of one shows no relation between the risk 
factor and the risk to acquire an infection. Analysing the eff ect of mortality risk factors, the 
RRs were standardised for age.
RESULTS
More than half of the ICUs (78/150) in the Netherlands participated in the study, and 472 pa-
tients were included (table 1). On the study date, 176 (37%) of the Dutch ICU patients suff ered 
from one or more infections, of which 16% was ICU-acquired, 73% was hospital-acquired and 
11% was acquired outside the hospital.
42
C
ha
p
te
r 3
Table 1. Demographics of 472 Dutch ICU-patients (on 29th April 1992)
Characteristic feature Description Number of patients (%) *
Sex male 300 (64)
female 172 (36)
Reason for admission respiratory insuffi  ciency  92 (44)
cardiovascular insuffi  ciency  64 (30)
neurologic insuffi  ciency  29 (14)
postoperative care 267 (57)
≥ 1 previous operation**** in total 306 (65)
elective ** 221 (47)
emergency ** 110 (23)
Type of surgery abdominal ** 117 (25)
cardiopulmonal  76 (16)
vascular  50 (11)
Length of ICU stay < 1 day 118 (25)
1-5 days 188 (40)
>5 days 165 (35)
Underlying condition chronic organ failure 253 (54)
cancer  75 (19)
diabetes mellitus  37  (9)
Invasive techniques peripheral infusion 424 (90)
central venous catheter 229 (50)
arterial catheter 286 (62)
urinary catheter 380 (81)
pulmonary artery catheter 100 (22)
wound drain 205 (44)
thorax drain  81 (18)
nasotracheal tube  47 (11)
orotracheal tube 223 (48)
tracheostomy  40  (9)
Medication parenteral nutrition  95 (21)
corticosteroids  84 (18)
chemotherapy   6  (1)
other immunosuppresives  11  (2)
sedatives 216 (47)
antacids *** 232 (49)
SDD  68 (15)
antibiotics in last 48 hours 165 (35)
* Some patients had more than one characteristic.
** Of the patients with multiple operations (n=297), the fi rst operation was in 211 patients (71%) an elective one and in 86 (29%) 
emergency surgery. The second operation (n=61) was elective in 14 patients (23%) and emergency in 47 (77%). Of the second operations 29 
(48%) were abdominal, of the third operations (n=20) 14 (70%) were abdominal.
*** Type of stress-ulcer prophylaxis: 48 patients (10%) used antacids, 131 patients (28%) H2-antagonists, 49 (11%) sucralfate and 29 patients 
(6%) omeprazole.
**** During last month
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There were twice as many male patients as female patients on the Dutch ICUs; 172 females 
versus 300 males. Most of the patients (87%) were older than 40 years; 35% were aged above 
70 years. Only 7% of the patients were admitted primarily to the ICU, without a preceding 
hospital stay, 57% of the patients were admitted to the ICU for postoperative care. Almost 
30% of the patients stayed for 1-2 days in the hospital, before admission to the ICU; 47% of 
the patients had a preceding hospital stay of more than one week. At admission to the ICU, 
8% of the patients were (multi)trauma patients, 54% had one or more chronic organ dysfunc-
tions, 19% were cancer patients and 9% were diabetics. One patient was HIV-seropositive.
Risk factors
Table 2 shows the risk factors with the concomitant RRs and the 95% confi dence interval 
(95% CI). The relative ICU infection risk was signifi cantly lower after elective surgery than 
after ICU admission without surgery: 0.50. In comparison with an ICU stay of 0-2 days, a stay 
of 3-4 days had a RR of 4.23. An ICU stay of 1-2 weeks had a RR of 99.37, a stay of more than 3 
weeks had a RR of 146.79 (fi gure 1). The RR for trauma patients was 3.69, the RR for patients 
with organ dysfunction was 5.03.
The APACHE II score was correlated with the ICU-infection risk; a higher score was cor-
related with a higher infection risk. In comparison with a score between 0-5, a score between 
16-20 had a RR of 9.36 and a score between 26-30 had a RR of 13.90.
Medical interventions with statistically signifi cant RRs were: a central venous catheter, a 
urinary catheter, mechanical ventilation and a tracheostomy (table 2). The use of antacids 
had a RR of 3.92.
Figure 1. Relative Risk of an ICU-acquired infection, in 472 patients. Left ordinate: percentage of patients by length of stay. Right ordinate: 
relative risk of infection by length of stay, compared to the risk of infection with an ICU stay of 0-2 days.
44
C
ha
p
te
r 3
After a follow-up period of 6 weeks, the ICU mortality was 14%. Various mortality risk fac-
tors were analysed, all standardised for age. Compared to an ICU stay of 0-2 days, a stay of 5-6 
days was correlated with a RR for mortality of 3.37 (95% CI: 1.06-10.73), and a stay of more 
than 3 weeks had a RR for mortality of 7.12 (3.06-16.54). The most important mortality risk 
Table 2. Relative Risks of potential riskfactors of ICU-infection in 472 patients
Riskfactor Relative Risk (95% CI) Compared to
Age
 20-40 years 0.50 (0.10-2.50) 10-20 years
 > 60 years 1.25 (0.33-4.62) 10-20 years
Hospital stay before ICU admission
 1-2 days 0.66 (0.32-1.35) Direct ICU admission
 > 3 weeks 1.27 (0.52-3.07) Direct ICU admission
ICU stay
 3-4 days 4.23 (3.32-5.40) ICU stay of 0-2 days
 1-2 weeks 99.37 (22.2-434.5) ICU stay of 0-2 days
 > 3 weeks 146.79 (32.8-656.3) ICU stay of 0-2 days
ICU
 Medical ICU 4.17 (1.62-10.72) Mixed ICU
 Surgical ICU 1.69 (0.79-3.62) Mixed ICU
Surgery
 Elective 0.50 (0.26-0.96) No surgery
 Emergency 1.56 (0.80-3.04) No surgery
 Trauma 3.69 (1.66-8.17) No trauma
APACHE II score
 16-20 9.36 (2.64-33.14) APACHE II score 0-5
 26-30 13.90 (2.58-75.05) APACHE II score 0-5
Infusion
 Peripheral 1.34 (0.55-3.27) No peripheral infusion
 Central venous catheter 2.95 (1.73-5.05) No central venous catheter
 Pulmonary artery catheter 1.47 (0.83-2.60) No pulmonary artery catheter
Ventilation
 Endotracheal tube 5.06 (2.33-10.99) No endotracheal tube
 Tracheostomy 17.59 (6.85-45.20) No tracheostomy
Any organ insuffi  ciency 5.03 (2.68-9.45) No organ insuffi  ciency
Respiratory insuffi  ciency 1.48 (0.67-2.89) No respiratory restriction
Cancer 0.51 (0.22-1.15) No cancer
Diabetes mellitus 1.28 (0.54-3.04) No diabetes mellitus
Antacids 3.92 (2.23-6.92) No antacids
Urinary catheter 10.52 (2.53-43.72) No urinary catheter
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factor was a higher APACHE II score: a score between 16-26 had a RR of 12.88 (3.89-42.69), a 
score of more than 31 had a RR > 100 (7.67-1377.93).
Demographics of the ICUs
Finally, data were scored about structure and existing policies of the participating ICUs. Of all 
the participating ICUs 34% were in University Medical Centers. When subdivided according 
to type of ICU, 8% were surgical ICUs, 4% were medical ICUs, 78% were combined ICUs and 
10% was of other types of specialisation. In comparison to the combined ICU, the medical 
ICU had a relative infection risk of 4.17 (statistically signifi cant), the surgical ICU had a RR 
of 1.7 (not statistically signifi cant) (see table 2). ICUs with more than four ventilators had a 
RR of 2.65 (0.95-7.42) for all patients admitted to this ICU, compared to ICUs with none or a 
maximum of one ventilator.
DISCUSSION
“The Netherlands belongs to the fi ve cleanest countries of Western Europe, together with 
Scandinavia and Switzerland”. This was the conclusion of a national conference in Amsterdam 
(March the 12th 1993), dealing with the national and international results of the EPIIC Study 
(12).
Nevertheless, this conclusion has its limitations, due to the methods and methodology of 
the survey. Because of these limitations it is better not to overemphasise the results.
The basis of the EPIIC Study is a prevalence survey, during a limited time period of 24 hours 
(point prevalence survey). Therefore, the data scored in this survey, give only information 
about the percentages of infection on one specifi c day of study. One needs to be cautious 
to extrapolate these data. Obviously, this type of point prevalence survey diff ers from other 
types of prevalence surveys, in which prevalence of data in risk groups are scored during a 
longer period of time. It also diff ers from an incidence survey, in which only the new patients 
are scored during a fi xed period of time. The choice for a point prevalence survey infl uences 
the results. For example, when the incidence of two infections is the same, the point preva-
lence of the longer lasting infection will be higher than the point prevalence of the infection 
of a shorter duration.
In the Netherlands 78 of the 150 ICUs participated in the study. Of the 78 ICUs, 34% were 
in University Medical Centers. This percentage is not representative for all ICUs in the Nether-
lands, consequently the studied patient group is not representative for all ICUs.
This article only deals with the Dutch results of the EPIIC study, taking into account that the 
Dutch ICUs are comparable qua structure, policy and patients.
It is not possible to standardise the data for all intrinsic and extrinsic ICU infection risk fac-
tors. Consequently, it is not possible to analyse for truly independent risk factors. For example, 
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the reason for admission to the ICU diff ers from hospital to hospital; causing a selection bias 
which infl uences the prognosis (13). The Dutch ICU diff ers from the ICUs in foreign countries: 
the Dutch ICU also has a short postoperative care function, a fact with inevitable a favourable 
eff ect to the infection percentages.
The inability to analyse the real independent risk factors was partially solved by calculating 
the relative risks (odds ratios); in relation to a zero level of the analysed risk factor, fi xing other 
risk factors.
Had the APACHE III Scoring system been part of the methodology of the EPIIC Study, the 
shortcomings in comparing diff erent hospitals could have been overcome (14,15). However, 
the APACHE III, recently developed to deal with the shortcomings of the APACHE II, was not 
ready to be used at the time the EPIIC protocol was formulated.
Despite the fact that “the Netherlands belongs to the fi ve cleanest countries of Western 
Europe”, the results in our own country are disturbing. Whether the infection percentages 
will increase or decrease will only be known by repeating this kind of prevalence surveys in 
the future (16).
Which patient is at risk? The most important risk factor to acquire an ICU infection was a 
longer ICU stay. Compared to a stay of 0-2 days, an ICU stay of 1 week had a relative infection 
risk of 100. After a stay of 3 weeks, this relative infection risk was 147. A stay in the hospital of 
more than 3 weeks, preceding the admission to the ICU, had no infl uence to the infection risk. 
The reason for this diff erence is the ICU patient himself, with a reduced immune resistance 
and multiple exposed entry points, due to invasive devices. In this point of view the ICU 
stay is like an epiphenomenon, functioning like a positive feed-back mechanism (a so called 
‘amplifying loop’): the worse the clinical status of the patient, the longer the ICU period and 
the longer this ICU stay, the more invasive techniques and a more disturbed immune system 
of the patient. In conclusion: a longer ICU stay gives a higher risk of infection. This amplifying 
loop infl uences every analysed risk factor of a patient with a longer ICU stay.
Among the invasive techniques, intubation and mechanical ventilation were associated 
with the highest risk of acquiring a respiratory tract infection. An even higher infection risk 
was correlated with a tracheostomy, probably because this device is only used after a longer 
ICU stay. Patients with a urinary catheter had a relative risk of 10 to acquire an urinary tract 
infection. Intervenous infusions, central venous catheters, arterial catheters etc., were all as-
sociated with a higher ICU infection risk. It is debatable if all these invasive techniques are 
really necessary, and if these techniques are necessary one needs to wonder if there is not 
too much routine in this without frequent reassessment. A policy to eliminate, on a daily 
basis, as many as possible of these potential exposed entry ports, will be the best infection 
prevention.
Prophylactic medicines, such as sedatives, corticosteroids and antacids, were frequently 
prescribed. It is better to outweigh the pros and cons in every individual patient of profylactic 
medicine. Such as the possible increased risk of a pulmonary infection when using prophy-
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lactic antacids (17,18). And furthermore, cost and benefi ts should play a role in the issue of 
profylactic medicines.
Emergency surgery was associated with a higher ICU infection risk (not statistically sig-
nifi cant), while elective surgery was associated with a signifi cant lower infection risk. This 
diff erence could be explained both by a diff erence in the patients preoperative severity of 
disease and by a diff erence in the type of surgery; emergency surgery being more frequently 
of the abdominal type. Of the underlying conditions, organ failure was associated with the 
highest risk of an ICU acquired infection. In addition, polytrauma patients had an enhanced 
infection risk.
The APACHE II-Score was strongly correlated with the ICU infection risk, and even stronger 
with the mortality risk. In this respect, according to this trial the APACHE II-Score was shown 
to be a good prognostic test.
CONCLUSION
In the Netherlands, ICU-acquired infection is a serious problem with a great impact on and a 
real threat for every individual ICU patient. In an attempt to reduce this ICU infection problem, 
a nation wide policy should be implemented dealing with infection prevention and antibiotic 
prescriptions. The indications for prescribing antibiotics should be tailored and eff ectiveness 
should be evaluated. In addition, the indications for and eff ectiveness of invasive diagnostics 
and therapeutics should be evaluated.
The EPIIC-Study tries to contribute to the solution of the nosocomial infection problem, by 
collecting a unique set of data concerning the ICU patients, their conditions and the potential 
ICU infection riskfactors. A key aim of the EPIIC-Study was to draw attention to the problem of 
ICU infections and to raise awareness of the possible risks so that further improvements can 
be made in better infection control in the ICU (19).
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ABSTRACT
Objective: Evaluation of the point prevalence of ICU-acquired infections, the type of infec-
tion, the bacteriological cultures and the antibiotics used.
Design: Point-prevalence study.
Setting: 78 Dutch ICUs, as part of a study in 17 West-European countries.
Methods: Collecting data by detailed questionnaires for each patient admitted to one of the 
participating ICUs, on one specifi ed day (a one-day point prevalence survey: April 29th 1992), 
and during a follow-up period of 6 weeks.
Results: The most frequently seen ICU-acquired infections were: pneumonia and infections 
of the lower respiratory tract (together 63%), followed by urinary tract infections (16%), sep-
sis (16%) and wound infections (11%). The most frequently cultured pathogens were Gram-
negative bacteria (92%), especially Enterobacteriaceae (34%) and Pseudomonas aeruginosa 
(30%), followed by Staphylococcus (37%), Enterococcus (20%) and surprisingly: 10% fungi. The 
antibiotics most frequently prescribed were: cephalosporins (30%), followed by broad-spec-
trum penicillins (17%), metronidazole (17%), and aminoglycosides (13%). No infection with 
Methicillin-Resistant Staphylococcus aureus (MRSA) was found on the day of the point-preva-
lence study in the Netherlands. Gentamicin-resistant coagulase-negative Staphylococcus 
and ciprofl oxacin-resistant P. aeruginosa were found however. In many of the hospitals in the 
Netherlands, microbiologists, infectious disease specialists (84%) and infection control nurses 
(51%) reside in the ICU team. Nearly half of the hospitals use selective decontamination.
Conclusion: ICU-acquired infections are a serious threat to the ICU patient. Resistance re-
mains a serious problem, despite cautious management of antibiotic therapy.
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INTRODUCTION
As described in the previous article, the EPIIC study is an European study of the prevalence of 
infections acquired in Intensive Care Units (ICUs). In that article the answer to the following 
question was obtained: “which patient is at risk and which intrinsic or extrinsic factors are re-
lated to this risk?” In this article we describe the types of infection found in these ICU patients, 
the bacterial characteristics of these infections and the course of antibiotics prescribed. At-
tention was also paid to the prevention of resistant strains of pathogenic micro-organisms 
in the ICU ward.
PATIENTS AND METHODS
For the chosen method of this point prevalence study we would like to refer to the previ-
ous article (1). The data extracted from the questionnaires fi lled out for each individual ICU-
patient were analyzed regarding the type of infection, the localization of the infection, the 
outcome of the bacterial cultures, and the prescribed antibiotics for either prophylactic or 
therapeutic intervention.
Infections (if present) could be evaluated in each patient related questionnaire. Each type 
of infection related to localization was coded according to the “CDC defi nitions for nosocomi-
cal infections” (2) The defi nitions of ICU-acquired infections, hospital acquired infections and 
infections acquired outside the hospital are described in previous article (1). T h e 
available results of the bacteriological cultures of the diagnosed ICU-acquired infections 
on the point-prevalence day of the study (April 29th, 1992) were analyzed and divided into 
the following groups, according to the causal pathogenic micro-organisms: Gram-positive, 
Gram-negative and anaerobe bacteria, viruses, fungi and protozoa.
The delayed culture results, for up to 1 week following the point-prevalence study day, 
were analysed too. There was also an analysis of the resistant pathogens, such as methicillin-, 
or oxacillin-resistent Staphylococcus aureus (MRSA) and resistant coagulase-negative staphy-
lococcus and Pseudomonas aeruginosa.
RESULTS
78 of the 150 ICUs in the Netherlands participated in this study. A total amount of 472 pa-
tients were evaluated.
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Infection Policy on the ICUs
In 84% (n=66) of the participating ICUs there was a microbiologist and (or) infectious dis-
ease specialist in the team. 51% (40) of the ICUs had an infection control nurse. In 51% (40) 
of the ICUs is a written antibiotic protocol present and in 81% (63) of the ICUs there is a 
written protocol regarding infection prevention. Surveillance culturing for bacteriological 
monitoring occured in 65% (51) of the ICUs. In nearly half of the ICUs (53%; n = 41) selective 
decontamination of the digestive tract was never used. In 46% (36) of the ICUs selective de-
contamination was used on indication and 1% (1) of the ICUs used selective decontamination 
for all admitted ICU patients.
Patient statistics
The discovered ICU-acquired infections and their pathogens are shown in table 1 and 2. The 
most frequently diagnosed infection was pneumonia, caused by Enterobacteriaceae (34%), 
P. aeruginosa (30%) and other Gram-negatives (28%). Table 3 shows the causal micro-organ-
isms per type of infection. Table 4 shows the mostly used antibiotics. 308 Patients (65%) were 
on an antibiotic treatment on the study day. Of these patients, a total of 173 patients (37%) 
were on prophylactic antibiotics and 135 (29%) patients were on therapeutic antibiotics. In 
58% (178) of the patients antibiotics were given as a mono-therapeutic course, and in 42% 
Table 1. The most frequently diagnosed ICU-acquired infections in 472 patients at 78 Dutch ICU’s (April 29, 1992)
Type of infection Number of infected patients (%)
Pneumonia 32 (43)
Lower respiratory tract infection 15 (20)
Urinary tract infection 12 (16)
Sepsis  2  (3)
Positive blood culture 10 (13)
Wound infection  8 (11)
Table 2. The most frequently diagnosed pathogens of ICU-acquired infections in 472 patients at 78 Dutch ICU’s (April 29, 1992)
Pathogens Number of infections (%)*
Enterobacteriaceae 22 (34)
Pseudomonas aeruginosa 19 (30)
Other Gram-negative micro-organisms 18 (28)
Entrococcus 13 (20)
Coagulase- negative staphylococcus 13 (20)
Staphylococcus aureus 11 (17)
Fungi  7 (10)
*Mixed infections not separately listed which causes the sum to be over 100%
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(130) of the patients antibiotic combination therapy was given. A total of 5 patients were part 
of a clinical trial in experimental medication therapy on the study day.
Although less pneumonias and lower respiratory tract infections were diagnosed in pa-
tients subjected to selective decontamination (25 and 8% in patients with selective decon-
tamination, as opposed to 43 and 20% in patients without selective decontamination), more 
cases of sepsis and (or) positive blood cultures (33% instead of 16%) were diagnosed. The 
Table 3. Causal pathogens of the most frequently diagnosed infections in 472 patients at 78 Dutch ICU’s (April 29, 1992)*
Prevalence (%)
Micro-organism Pneumonia LRTI UTI Sepsis Wound
Pseudomonas aeruginosa 29 29 33  – 63
Staphylococcus aureus 25  –  – 10 25
Enterobacteriaceae 18  –  –  – 38
Escherichia coli 14  – 25  –  –
Haemophilus infl uenzea 11 14  – 10  –
Fungi  7  – 25 20  –
Serratia  – 21  –  –  –
Other Gram-negative micro-organisms  – 21  –  – 25
Other staphylococcus  –  –  – 60  –
Entercoccus  –  –  – 10 50
Providencia  –  –  – 10  1
LRTI = lower respiratory tract infections; UTI = Urinary tract infections
* Not separately listed which causes the sum to be over 100%
Table 4. Groups of most used antibiotics (therapeutically and prophylactic) in 472 patients at 78 Dutch ICU’s (April 29, 1992)*
Antibiotic group Treated patients (%)
Therapeutic Prophylactic Total (n = 472)
Cefalosporins 11 19 30
Aminoglycosides  7  6 13
Quinolones  3  2  5
Penicillins  3  5  8
Macrolides  1  1  2
Broad-spectrum penicillins 10  7 17
Imipenem  2  –  2
Glycopetides  2  –  2
Metronidazol  7  9 16
Antimycotix  3  4  7
Antiviral  0.5  0.5  1
*Combined therapy not separately listed
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bacteriological cultures of patients subjected to selective decontamination showed, as al-
ready anticipated, less Enterobacteriaceae and other aerobe Gram-negative micro-organisms 
(8 and 8% in patients with selective decontamination as opposed to 34 and 28% in patients 
without selective decontamination). However, there was a higher occurrence of Staphylococ-
cus species in these cultures (58% instead of 37%). No MRSA infections were found in the 
Netherlands on the study day. In other European countries, MRSA was found (table 5).
In nearly half of the infections caused by coagulase-negative staphylococcus, where a re-
sistance pattern was established, strains were seen with resistance for one or more antibiotic; 
all were resistant for gentamicin, and some were also resistant for cefotaxim and methicillin. 
In the infections caused by P. aeruginosa, with known resistance pattern, the bacteria was in 
half of the cases resistant for one or more antibiotic; all strains were resistant for ciprofl oxacin 
and some of them were resistant for gentamicin (table 6).
After 6 weeks, 14% (63) of the patients had died on the ICU. Several risk factors for mortality 
were present: when standardized for age, patients with a pneumonia had a relative mortality 
risk (RR) 2.5 times higher (95% confi dence interval: 1.01-5.87) than patients without pneu-
monia; patients with a wound infection had an RR of 3.25 (0.6-17.7) as opposed to patients 
without wound infection; and patients with sepsis had an RR of 5.0 (0.30-81.07) as opposed 
to patients without sepsis.
Table 5. Methicilline-resistant Staphylococcus aureus (MRSA) at ICUs in a number of European Countries (April 29, 1992)
Country Number of Staphylococcus aureus MRSA (in %)
Belgium  12 66.7
Germany  78 37.2
Finland   2 50.0
France 153 78.4
Greece  13 77
Ireland   3  0
Italy  63 81
Luxembourg  15 13.3
Netherlands  10  0
Austria  17 52.94
Portugal  50 66.7
Spain  61 54.1
United Kingdom  15 13.3
Sweden   2  0
Switzerland   7 14.3
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The infections most frequently acquired on the ICU were pneumonia and lower respira-
tory tract infections, although it was not possible to sharply outline the borderline between 
colonization and actual respiratory tract infection. The explanation for the high number of 
respiratory infections seemed to be the large number of intubations; intubated patients had 
a higher risk of infection, and this risk of infection was even higher in patients with a trache-
ostomy (1). The frequent use of antacids also seemed to contribute to this high percentage 
of respiratory infections, considering the high percentage of intestinal pathogens as causal 
micro-organism of the pneumonia (50% Enterobacteriaceae, of which the Enterobacter and 
the Escherichia coli were mostly cultured) and of the lower respiratory tract infection (53%, 
mostly Serratia). Pneumonia is a serious complication, which increases morbidity and mortal-
ity in ICU patients. Patients with pneumonia had a mortality risk which was 2.5 times higher. 
On the ICU, one needs to be more cautious especially with patients with altered respiratory 
function. The patient with COPD needs good preoperative care as a preventive measure.
Except respiratory infections, urinary tract infections (UTI) were very common. The risk fac-
tor here seemed to be the urinary catheter. It is necessary to mention that two-thirds of these 
UTIs were nonsymptomatic bacteriuria. It is possible that a great part of these urine cultures 
were performed as routine.
The percentage of fungi infections was remarkable, this is probably more proof of the im-
mune compromised status of the ICU patient.
Table 6. Pattern of resistancy of coagulase-negative Staphylococcus and of Pseudomonas aeruginosa of 472 patients at 78 Dutch ICU’s (April 29, 
1992) listed as absolute number of strains of bacteria
Antibiotics Resistant sensitive Missing data
Coagulase-negative Staphylococcus
Methicillins 4 7 12
Cefotaxim 4 6 13
Gentamicin 6 6 11
Vancomicin 1 9 13
Teicoplanin 0 0 23
Total 6 7 10
P. aeruginosa
Gentamicin 3 11 6
Imipenem 0 7 13
Ceftazidim 0 14 6
Ciprofl oxacin 7 5 8
Ureido-penicillin 0 13 7
Totals 7 7 6
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It seemed that great care is taken in the Netherlands in the choice and use of antibiot-
ics; broad-spectrum antibiotics like imipenem, glycopeptides (vancomycin), aztreonam and 
new types of antibiotics were scarcely used (probably to prevent resistance and because of 
fi nancial cost). This seems to be eff ective: the Netherlands had only few problems with resis-
tance. On the day of the EPIIC-study, no MRSA infection was found in the Netherlands. When 
MRSA is found in the Netherlands, the source can be tracked down to patients who imported 
this infection from foreign hospitals. Most Dutch hospitals have strict policies and protocols 
regarding MRSA: these patients are in isolated care, which is a costly and time consuming 
way of treatment and it is (especially for patients and their families)a psychological burden. 
Nevertheless, this treatment seems to have good results.
A remarkable high resistance of P. aeruginosa for the antibiotic ciprofl oxacin was regis-
tered in the Netherlands (table 6). It is not possible to determine whether this resistance is 
caused by cross resistance with norfl oxacin (an antibiotic which is used in large amounts in 
the poultry-industry, because of the high occurrence of Pseudomonas infections) or by the 
use of a diff erent method of bacteriologic culturing. The high percentages of ciprofl oxacin 
resistance and coagulase-negative staphylococcus resistance for gentamicin are relatively 
little relevant, due to the very small numbers obtained.
In contrast to other countries, the Netherlands has a very high percentage of ICUs with a 
microbiologist, an infectious disease specialist and an infection control nurse on staff  in the 
ICU team. The result of the eff orts of these teams is seen in the written procotols regarding 
use of antibiotics and infection prevention. Frequent (sometimes on a daily basis) culturing 
for the purpose of surveillance and bacteriological monitoring is part of infection prevention 
in 65% of the ICUs. One needs to wonder if these standard surveillance cultures are either 
useful or abundant diagnostics. For example, one has to wonder if therapy is or should be ini-
tiated when a urinary tract infection is diagnosed while the patient is not presenting clinical 
symptoms. In our opinion it is profi cient to take cultures at time of admission to the ICU for 
the purpose of obtaining an overview and start reference, so that specifi c antiobiotic treat-
ment can be initiated when infection occurs, instead of administering unnecessary broad-
spectrum antibiotics.
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CHAPTER 5
The surgical ICU patient: a patient at risk
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INTRODUCTION
Infections are common but serious complications of the treatment of critically ill patients. 
The scope of these ICU infections is overwhelming, with a substantial increase in morbidity, 
mortality and as a consequence in the overall hospital charges and economic costs (1-4). 
Moreover, these ICU infections may limit the potential advances to be made in critical care 
medicine.
ICU patients become more prone to develop nosocomial infections as their severity of ill-
ness, the complexity of underlying diseases and exposure to life-saving invasive devices and 
procedures that breach their host defences, increase(5-8).
It seems to be that the surgical ICU patient is even more prone to nosocomial ICU infec-
tions than non-surgical patients. Indeed, surgical departments have a higher rate of nosoco-
mial infections than medical or pediatric departments. The nature of the infections and the 
spectrum of causative organisms depends on very diverse factors, e.g. type of patient, type of 
surgical intervention, age of the patient, application of antibiotics (especially peri-operative 
antibiotic prophylaxis), and training and compliance of the hospital staff .
The focal surgical wound infections are not the only documented infections in surgical 
ICU patients. In fact, they play a minor part in the frequency of the infection sites in these 
patients. Ventilator associated pneumonia and respiratory tract infections are the most fre-
quently reported ICU-acquired infections, also in surgical patients (9-11).
Surgical site infection
Outside the ICU, surgical wound infections are the most common nosocomial infections 
among surgical patients. While usually localised to the incision site, surgical wound infections 
can also extend into adjacent deeper structures; thus the term surgical wound infection has 
now been replaced with the more suitable name, surgical site infection (SSI), with a sub-clas-
sifi cation of superfi cial SSI, occuring in the primary incision down to the fascial layer, and 
deep SSI, located under the fascia. An organ or space SSI may involve any part of the anatomy 
–other than the incision- that was opened or manipulated during the operative procedure. 
The Centres for Disease Control and Prevention (CDC) has developed standardised criteria for 
defi ning surgical site infections, i.e.: ‘infections related to the operative procedure that occur 
at or near the surgical incision within 30 days of an operative procedure’(12).
In the United States SSI accounts for approximately 40 percent of all nosocomial infec-
tions. Same results are documented from surveys in Europe (13-15). Rates of SSI vary widely 
depending upon the patient population, size of hospital, experience of the surgeon, meth-
ods used for surveillance and the type of procedure. For example: several studies noted an 
increased risk of SSI in patients with cancer who had to undergo surgical procedures (16), 
and non teaching hospitals have generally lower rates of SSI compared to teaching hospitals 
(17). The highest rates of SSI occur after abdominal surgery: small bowel surgery (5.3-10.6%), 
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colon surgery (4.3-10.5%), gastric surgery (2.8-12.3%), liver/pancreas surgery (2.8-10.2%), 
exploratory laparotomy (1.0-6.9%) and appendectomy (1.3-3.1%) (18).
Most SSI are acquired at the time of surgery; the most common source is believed to be 
direct inoculation of endogenous- or skin fl ora (19). There are also exogenous sources of 
infection with fl ora from the operating room environment or personnel (20-24).
The species of micro-organisms isolated from SSI have not changed markedly during the 
last decade (25), but the percentage of antibiotic-resistant pathogens has increased (eg 
methicillin-resistant S.aureus MRSA, methicillin-resistant S.epidermidis MRSE and vancomy-
cin-resistant enterococci VRE) (26-29). In addition, fungi -particularly Candida albicans- have 
markedly increased (30,31). This trend toward resistant organisms and Candida spp. probably 
is due to the widespread use of prophylactic and empiric broad spectrum antibiotics, in-
creased severity of illness, and greater number of immuno-compromised patients undergo-
ing surgical procedures. (32).
SSI are associated with substantial morbidity and mortality. Post-operative length of hos-
pital stay increases by 7-10 days, hospital charges increases by 2,000-4,500 US dollars, and 
death is directly related to 75% of patients with a SSI who die in the postoperative period 
(33,34). While organ SSI accounts for only one-third of all SSI, they are associated with 93% of 
death related to SSI. Organ or space SSI are also vastly more costly than incisional SSI (35). SSI 
caused by multidrug-resistant pathogens are often associated with an even higher morbidity 
and mortality, due to inadequate or delayed antibiotic treatment (36-38).
Various classifi cation schemes have been developed to predict the overall risk of a SSI, but 
most of them turned out to be a poor predictor (39). The most used risk score at this moment 
is from the NNIS. The NNIS surgical patient risk index score was developed in 1990. The risk 
index score stratifi ed patients undergoing surgery into four risk index groups by assigning 
each of the following factors a value of one point, if present:
– An American Society of Anesthesiologists (ASA) preoperative assessment score of 3, 4, 
or 5.
– A surgical wound classifi ed as either contaminated or dirty.
– An operation lasting over T hours, where T depends upon the operative procedure being 
performed.
The rates of surgical site infections for the diff erent strata were 1.5 for risk index 1 (zero points), 
2.9 for index 2 (one point), 6.8 for index 3 (two points) and 13 for index 4 (three points) (40).
Reanalysis conducted by the CDC in the light of the NNIS risk index score, found that the 
ASA score was more predictive than age or number of underlying diagnoses and that the 
determined length of the operative procedure (T) was more predictive than an arbitrary 
two-hour cut-off  point (40).The NNIS surgical patient risk index score is a predictive model 
and also provides a system to make valid comparisons of surgical site infection rates among 
surgeons, across time, among hospitals, around the world.
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Diff erence between the USA and Europe
There is a remarkable diff erence in the knowledge of the magnitude of the infection problem 
in surgical patients between the USA and Europe. In the USA, information about the rates of 
nosocomial infection, the epidemiology, ethiological organisms and risk factors are relatively 
easy to retrieve due to the development of various national formalised and ongoing surveil-
lance systems. In the 1960s, the Centres for Disease Control (CDC) began in Georgia, recom-
mending that hospitals conduct surveillance over the occurrence of nosocomial infections 
to obtain epidemiological evidence on which to base rational control measures (41,42). In 
January 1974, CDC initiated the SENIC Project (Study on the Effi  cacy of Nosocomial Infec-
tion Control) to determine whether and, if so, to what extent, this control program approach 
was eff ective in reducing nosocomial infection risk (43,44). Of more recent date the National 
Nosocomial Infection Surveillance (NNIS) study was generated by 80 medical centres in the 
USA from 1980-1992 (45), growing to 300 centres in 2002 (46).
In Europe, no such formalised systems exist, and there had been no large international 
study to determine the nosocomial infection rates throughout the continent, up to 1992. 
Before, only a few studies have been undertaken in individual countries (47-49), without the 
possibility to extrapolate the data from these studies to an overall European ICU setting.
There was room for improvement in the control of nosocomial infections in European ICU’s. 
Small improvements could have a major impact on morbidity and mortality. Easy access to a 
suitable epidemiological database could be a starting point to provide information concern-
ing the rates of infection. Besides, this could make it possible to determine the patterns of 
bacterial populations and their susceptibility or resistance to particular antibiotics. Appropri-
ate (empirical) antimicrobial regimens could be devised, patients who are most at risk of 
developing a nosocomial infection could be identifi ed, the likely outcome of the infections 
could be gauged and eff ective infection control policies could be instituted. Ongoing surveil-
lance and collection of data should then be employed to audit the eff ectiveness of such poli-
cies and to identify secular trends to update and tailor the prevention interventions. Indeed, 
there was room for improvement in the management of nosocomial infections in Europe.
PATIENTS AND METHODS
The aims of the study
It was against this background that in 1992 the European Prevalence of Infection in Intensive 
Care (EPIIC) Study was undertaken, to deal with the relative lack of information concerning 
nosocomial ICU infections, providing a new perspective on the scale of the problem in Europe. 
The EPIIC Study was a one-day study of infections in ICU’s across Europe. It was designed to 
establish the point prevalence of nosocomial and other infections in intensive care units. Be-
sides, it was designed to establish the microbiology, and thus determining those pathogens 
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considered to be causal of these infections, including their patterns of antimicrobial suscep-
tibility (or resistance) to particular antibiotics. In addition, the relative importance of infec-
tion risk factors was established. Specifi c data were collected on the incidence of problem 
pathogens such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. 
To evaluate the impact of risk factors on infection rates and resistance, the following patient 
parameters were recorded: clinical status on admission; presence of iatrogenic risk factors 
such as iv lines; the pattern of antimicrobial prescribing; and the use of specifi c interventions 
such as selective decontamination of the digestive tract. Basic demographic details were col-
lected on each participating unit. The overall key aim of the EPIIC Study was to raise aware-
ness in Europe of the problem of nosocomial infection in the ICU, and to stimulate discussion, 
hopefully leading to better prevention, appropriate therapy and improving infection control 
programs.
The protocol of the study
This point prevalence study was conducted on a 24-hour period, 29 April 1992. In total 1417 
ICU’s from 17 European countries were eligible to take part in the study. Data of 10038 pa-
tients were collected by questionnaire, for later analysis. Nosocomial infections in ICU were 
classifi ed according to standard defi nitions of the Centres for disease Control, CDC (50). As-
sessment of the patient’s status on admission was made on the basis of his/her APACHE II 
Score (Acute Physiology and Chronic Health Evaluation) (51,52). A logistic regression analysis 
was done to estimate the eff ects of possible risk factors, measured as odds ratios (OR, com-
paring relative risks), together with their 95% confi dence intervals (CI). In addition multiple 
logistic regression analysis was done to assess which independent factors aff ected the over-
all risks of infection and death, and to investigate the relationship between these diff erent 
risk factors. The complete methods have been described elsewhere (53). The most important 
drawback of the study to be mentioned is the diffi  culty of identifying pathogens, which may 
have only refl ected possible contamination or colonisation instead of representing the cause 
of the infection.
RESULTS
Over 50% of the 10038 ICU patients had undergone surgery in the month prior to the EPIIC 
Study. Abdominal surgery was the most frequently performed type of surgery, followed by 
cardiothoracic surgery and head and neck surgery. Of these surgical patients, 21.3% devel-
oped an acquired ICU infection.
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THE SURGICAL PATIENT POPULATION AND A RISK ANALYSIS OF POTENTIAL 
INFECTION RISK FACTORS
Patient sex
Almost two-thirds of the surgical patients were male. The infection risk for males was statistic 
signifi cantly higher than for females (table 1).
Patient age
More than half of the surgical ICU patients were aged 60 years or more. The infection risk 
declined when the age increased (table 1 and fi gure 1).
Underlying conditions; clinical status on admission
Not every underlying condition in this group of surgical ICU patients proved to be an infec-
tion risk factor. For example, the surgical patient with cancer had a lower infection risk (OR 
0.72), and also diabetes mellitus was of no infl uence on the infection risk (OR 1.04). Statisti-
cally signifi cant risk factors were: trauma (OR 3.31), organ failure (OR 2.74) and respiratory 
problems (OR 1.42). See fi gure 2.
Underlying disease severity; APACHE II Score
The statistics of the APACHE II scores on admission showed that together with an increasing 
APACHE II score the odds ratios for infection risk increased up to a plateau-phase at APACHE 
scores between 20-30. Higher APACHE scores were associated with a declining odds ratio 
(fi gure 3).
Type of surgery
More than half of the ICU patients had undergone elective surgery, one-third needed 
emergency surgery. The associated infection risk for the emergency surgery was doubled, 
compared to the elective surgery (OR 2.31). The infection risk was highest for the patient 
with multiple operations (OR 3.12). Both diff erences were statistically signifi cant (table 1 and 
fi gure 4). The prevalence of elective and emergency surgery by each age group is showed in 
table 2.
Length of unit stay
60% Of the surgical ICU patients had been admitted to the ICU for more than one week 
(table 1). The risk of acquiring a nosocomial infection in an ICU increased with the length of 
ICU stay. The odds ratio for infection increased with the length of unit stay, without reaching 
a plateau-phase (fi gure 5). After an ICU stay of one day the risk of acquiring an infection was 
already 5 times higher, compared to a stay of less than 24 hours. After an ICU stay of one week 
the infection risk increased 100 times, after 2 weeks it increased 200 times.
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Procedural interventions; invasive procedures
The surgical study population in the EPIIC Study experienced a high number of interventions 
in the week prior to the survey up to the study day (fi gure 6). Invasive procedures associ-
ated with a statistically signifi cant infection risk were a tracheostomy (OR 4.58), stress ulcer 
prophylaxis (OR 3.21), assisted ventilation (OR 2.53) and a cvp-line (OR 2.15).
THE KEY INFECTION TYPES
The fi ve most frequently reported ICU-acquired infections are shown in table 3. More than 
half of the ICU-acquired infections of these surgical ICU patients were located in the respira-
tory tract. The prevalence of the surgical wound infections take only the fourth place.
Table 1. Infection risk factors of surgical ICU patients
Infection Risk Factor Prevalence (%) Infection Risk (%)
Sex Males 61.7 23.7
Females 38.3 17.4
Age (years) 10-19 2.6 26.2
20-39 14.2 28.6
40-59 26.2 22.6
60-69 26.9 19.8
> 69 30.1 17.5
Type of surgery Elective 54.9 14.6
Emergency 35.9 28.2
Both 9.1 34.6
Length of unit stay 0-7 40.8 2.1
(days) 8-14 19.1 14.2
15-21 12.1 29.5
>21 28.1 45.7
Table 2. Prevalence of age by type of surgery of surgical ICU patients
Prevalence (%)
Age (years) Elective surgery Emergency surgery Both types of surgery
10-19 28.5 59.2 12.3
20-39 37.1 51.8 11.1
40-59 58.0 32.9  9.1
60-69 64.1 26.8  9.1
> 69 54.8 37.2  8.0
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THE KEY PATHOGENS
Mentioned in table 3 are only groups of pathogens. The most frequently reported isolates 
were the gram negative bacteria (Pseudomonas aeruginosa, E. Coli). Secondly, close to the 
gram negative bacteria, one sees the gram positive bacteria (Staphylococcus aureus, S. epider-
midis, Enterococci), and thirdly, the fungi are to be noticed.
Table 3. Prevalence of type of infection and type of pathogen in surgical ICU patients
Prevalence (%)
Type of Infection Pneumonia 39.5
Lower respiratory tract 12.2
Blood stream 11.0
Wound infection  8.7
Urinary tract 7.3
Type of Pathogen Gram-negative bacteria 47.1
Gram-positive bacteria 40.9
Fungi 10.8
Anaerobes 1.1
Viruses 0.1
MORTALITY IN THE SURGICAL ICU
Information concerning the outcome of patients was collected 6 weeks after the study day. 
In that period, 85% of surgical ICU patients were discharged alive, thus leaving a mortality 
rate of 15% in the total group (table 4). The mortality in the group of surgical ICU patients 
without an acquired infection was 12% and the mortality in the group of patients with an 
ICU acquired infection was 26%, this is a statistically signifi cant diff erence. Table 5 shows fi ve 
pathogens associated with mortality higher than the average rate of 26% in infected surgical 
ICU patients. The pathogens associated with the highest rate of mortality were the fungi.
DISCUSSION
In search for infection risk factors in the surgical ICU patient population some factors high-
lighted the special situation of the surgical- versus non-surgical ICU patients.
Surprisingly, the infection risk declined when the age of surgical patients increased. An 
explanation could be the fact that the associated infection risk for emergency surgery was 
doubled as compared to elective surgery. This result explains the declining infection odds 
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ratio with increasing age; the prevalence of emergency surgery was highest in younger pa-
tients, the prevalence of elective surgery was highest in the older patients (table 2).
The APACHE II score on admission of the surgical patient to the ICU showed an interesting 
phenomenon: with an increasing APACHE II score the odds ratio for infection risk increased 
up to a plateau phase. APACHE scores higher than 30 were associated with a declining odds 
ratio. Apparently these very severely ill patients died, before they could acquire a nosocomial 
infection.
It is a well-known phenomenon that the risk of acquiring a nosocomial infection in an ICU 
increases with the length of ICU stay. Analysis of the risk factors in the EPIIC study showed 
the length of ICU stay to be the most important risk factor, with odds ratios up to 200 when 
staying longer than 3 weeks. The problem in the analysis of the ICU stay is the complexity of 
this multifactorial risk factor, also known as the ‘epiphenomenon’ of the ICU stay: the longer 
the stay, the more invasive procedures and diagnostic interventions, the greater the risk of an 
ICU-acquired infection, the longer the ICU stay (a spiral eff ect).
Notwithstanding that diff erences in mortality cannot be directly attributed to diff erences 
in infection rates, statistical analysis performed on the EPIIC study database confi rmed that 
ICU-acquired infections are associated with increased mortality. The diff erence between 12% 
mortality in the group of surgical ICU patients without an infection, and 26% in the group of 
surgical ICU patients with an ICU-acquired infection is highly signifi cant (p<0.0001).
Fungi occupied the third place in the prevalence of key pathogens. The highest associated 
mortality rate (31.1%) of all pathogens was also due to the fungi. This highlights the growing 
importance of the fungal pathogens in ICU-acquired infections. Based on the results of other 
studies (54,55), same as the EPIIC study, fungi are called the ‘emerging pathogens’.
Table 4. Mortality in surgical ICU patients
Surgical ICU patient Mortality (%)
Total study group 15
Non-infected surgical ICU patient 12
Infected surgical ICU patient 26
Table 5. Mortality in the surgical ICU patient by type of pathogen
Type of pathogen Mortality (%)
Fungi 31.1
Staphylococcus spp. 29.5
Enterococci 29.3
Pseudomonas aeruginosa 28.4
Escherichia coli 27.0
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CONCLUSION
The most important infection risk factors for surgical ICU patients to be warned for: 1) be-
ware of emergency - and multiple operations. Together with these types of surgery, trauma 
is a signifi cant risk factor. 2) beware of a longer ICU stay, which increases the odds ratio for 
infection dramatically. Undoubtedly, this is (also) due to an increasing number of invasive 
procedures, a prolonged need for assisted ventilation (sometimes in combination with a 
tracheostomy), more procedural diagnostic interventions and multiple operations. 3) be-
ware of pneumonia and lower respiratory tract infections. Precautions, pre-, per- and post-
operative are necessary to attack this type of infection in the surgical patient. 4) Beware of 
gram-positive bacteria. The gram-negative bacteria are not any longer the most important 
and most virulent pathogens in nosocomial ICU infections. Gram-positive bacteria, such as 
the coagulase-negative staphylococci, are not only insignifi cant contaminants anymore. 5) 
beware of fungi. Fungi have deranged from colonising a-pathogens, playing a subordinate 
role, to emerging virulent pathogens.
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ABSTRACT
Objective: To evaluate the risk of patients in intensive care units (ICU) of becoming infected 
with methicillin-resistant Staphylococcus aureus (MRSA) and to assess the mortality during 
a six week follow-up period, compared with patients who developed methicillin-sensitive S 
aureus (MSSA) infection.
Design: Point prevalence survey.
Setting: 1417 ICU in 17 Western European countries.
Subjects: 10038 patients in ICU who were part in the EPIIC (European Prevalence of Infection 
in Intensive Care) Study.
Main outcome measures: Prevalence of MRSA and MSSA ICU-acquired infections, risk fac-
tors, and mortality.
Results: On the study day 21% of patients had ICU-acquired infections. The most commonly 
reported pathogen was Staphylococcus aureus (30%). Overall, 60% of strains of S aureus were 
resistant to methicillin (with a wide intercountry variation). The most commonly reported 
MRSA infections were pneumonia and lower respiratory tract infections. The most important 
risk factor for MRSA was the length of stay in the ICU. MRSA infection reduced the chance 
of survival, particularly when it was found in lower respiratory tract infections: the risk of 
mortality was three times higher in patients with MRSA than in those with MSSA.
Conclusion: Patients in ICU are at high risk of becoming infected with MRSA. The longer the 
stay, the higher the risk. Patients with MRSA infections are less likely to survive than those 
with MSSA.
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INTRODUCTION
Pathogens responsible for infections acquired in the intensive care unit (ICU) have changed 
during the past decades. In the 1960s and 1970s Gram-negative pathogens were predomi-
nantly responsible (enterobacteriaceae and Pseudomonas aeruginosa) while in the 1990s 
Gram- positive micro-organisms have become increasingly prominent including Staphylo-
coccus aureus, coagulase-negative staphylococci, and enterococci (the last two of which have 
long been considered to be non-pathogenic).
The susceptibility pattern of these pathogens has also changed. At present, the main infec-
tive threat in ICU is the increase in micro-organisms that are resistant to many antibiotics, in 
particular methicillin-resistant S aureus (MRSA), Staphylococcus epidermidis, and enterococci, 
both of which are also becoming increasingly resistant to penicillins. Towards the year 2000 
the medical profession will face the challenge of infections against which none of the current 
antimicrobial agents are eff ective; many clinicians are not aware of this impending crisis (25). 
No antibiotic resistance marker has distinguished a species more than methicillin resistance 
has for S aureus. The rapidity with which methicillin resistance developed in Europe after the 
introduction of methicillin and the subsequent spread of this organism throughout the world 
has created enormous therapeutic and management problems resulting in heated argu-
ments, confusing and confl icting recommendations, control measures, and many consensus 
reports (2,24).
The place in which patients are at the greatest risk of acquiring resistant organisms is the 
ICU, and we evaluated the impact of MRSA on such patients. Do patients infected with MRSA 
have a diff erent prognosis from those with methicillin-sensitive S aureus (MSSA)? What are 
the risks of patients in ICU becoming colonised and infected with MRSA? What is the mortal-
ity in patients with MRSA compared with those with MSSA?
PATIENTS AND METHODS
Data were used from the largest pan-European point prevalence study, the European Preva-
lence of Infection in Intensive Care (EPIIC) Study, which was conducted on April 29, 1992. 
On the study day, information was collected for later analyses on 10038 patients in 1417 
adult, non-coronary care ICU in 17 Western European countries. Data were collected by ques-
tionnaire. This one day study was designed to establish the prevalence and microbiology of 
nosocomial infections in ICU (classifi ed according to standard defi nitions of the Centers for 
Disease Control, CDC) (9), and to establish the relative importance of risk factors for these 
infections. In addition, data were collected on the clinical state of patients on admission to 
the ICU and on their outcome during a six week follow-up period. The complete methods and 
a general survey of the results have been described elsewhere (35).
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Statistical analysis: A logistic regression analysis was done to estimate the eff ects of pos-
sible risk factors for ICU-acquired infections, measured as odds ratios (comparing relative 
risks), together with their 95% confi dence intervals (CI). In addition multiple logistic regres-
sion analysis was done to assess which independent factors aff ected the overall risks of infec-
tion and death, and to investigate the relationship between these diff erent risk factors.
RESULTS
Overall EPIIC study (35)
On the study day a total of 4501 patients (from the group of 10038) had one or more infec-
tions (45%), almost half of which (21%) were ICU-acquired. There were pronounced variations 
in the rate of ICU-acquired infection, ranging from 7% for patients in Denmark and 8% in 
Sweden, to 31% for those in Greece and 32% in Italy (Table 1).
S aureus was the ‘key pathogen’ most frequently isolated (30%).Only the enterobacteria-
ceae were reported more often (34%), but as a class. The most commonly reported bacterial 
isolates acquired in the ICU infections are shown in Table 2. Where antibiotic resistance was 
reported, 60% of strains of S aureus were resistant to methicillin (MRSA). There was wide in-
tercountry variation, with the highest proportion of MRSA occuring in Italy and France, while 
many northern countries had none (Table 1).
The most commonly recorded ICU-acquired infections with MRSA compared with MSSA 
are shown in Table 3. For both bacteria the most commonly reported infections were in the 
respiratory tract: pneumonia 52% and 61% respectively, and lower respiratory tract infec-
tions 22% and 17% respectively.
The antibiotics given for these infections are shown in Table 4. The most commonly used 
were the glycopeptides (36%), followed by aminoglycosides (25%) and cephalosporins 
(23%).
MRSA risk factors
Diff erent risk factors evaluated for MRSA ICU-acquired infections were compared with those 
for MSSA (Tables 5 and 6), and the odds ratios calculated. An increasing APACHE II score (cal-
culated on admission to the ICU) was signifi cantly related to an increasing incidence of both 
MRSA and MSSA infections, in contrast with an APACHE II score of more than 21-25 where 
there was a gradually reduction in the incidence of both infections, decreasing to only 0.4% 
with an APACHE II score of more than 35 (Table 5).
Another risk factor evaluated was the length of stay in the ICU. The longer the stay, the 
higher was the risk of an MRSA rather than an MSSA infection (Table 5), with an odds ratio of 
4.07 for a stay longer than three weeks on the ICU (95% CI 2.02 to 8.21, p<0.001).
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Risk factors next evaluated were the type of ICU and the antibiotic policy on the ICU (Table 
6). There were no signifi cant diff erences depending on the type of ICU (medical, surgical, 
specialist, or mixed unit) or the antibiotic policy.
Table 1. Number of patients in ICU by country, percentage incidence of ICU-acquired infection, incidence of MRSA as a percentage of total 
isolates of S aureus, and percentage mortality
Country No. of patients
in ICU
% of ICU–acquired 
infections (n=2064)
MRSA as % of S. 
Aureus (n=528)
% mortality 
(n=1560)
Austria   420 20 53 15
Belgium   669 17 67 15
Denmark    81  7  0 11
Finland   132 16 50 12
France  2359 24 78 19
Germany  2010 17 37 15
Greece   200 31 77 29
Ireland    91 19  0 12
Italy   617 32 81 20
Luxemburg    29 17  0 13
Netherlands   472 16  0 14
Norway   150 13  0  9
Portugal   120 23 67 24
Spain  1233 27 54 19
Sweden   286  8  0  9
Switzerland   329 10 14  8
UK   840 16 13 20
Total 10038 21 60 17
Table 2. Number (%) of reported isolates in ICU-acquired infections
Isolate  No (%)
S aureus 528 (30) 
Ps aeruginosa 504 (29) 
Coagulase negative staphylococci 335 (19) 
Fungi 300 (17) 
Escherichia coli 223 (13) 
Enterococci 205 (12) 
Acinetobacter spp. 164  (9) 
Klebsiella spp. 142  (8) 
Streptococci (other than pneumococci) 124  (7) 
Enterobacter spp. 115  (7) 
Proteus spp. 100  (6) 
Other Pseudomonas spp.  77  (4) 
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Mortality
The mortality before discharge from the ICU up to six weeks after the study day for the total 
study population was 17%. The variation in mortality by country was considerable, ranging 
from 8% for Switzerland and 9% for Sweden to 29% for Greece (Table 1). The overall mortality 
for patients infected with MSSA and MRSA were 25% and 32% respectively. The odds ratio for 
MRSA, compared with MSSA according to survival was 0.70 (p=0.09). The mortality for ICU-
acquired MRSA infections compared with that for MSSA infections according to the various 
infection sites are shown in Table 7, only for those in the lower respiratory tract was there a 
signifi cant diff erence in mortality.
Table 3. Reported types of ICU-acquired infection by MRSA and MSSA
Type of infection MRSA MSSA
Pneumonia 112 (52) 144 (61)
Lower respiratory tract  48 (22)  40 (17)
Bacteraemia  30 (14)  23 (10)
Wound  17 (8)  19 (8)
Urinary tract   7 (3)  12 (5)
Clinical Sepsis   1 (0.5)   0
Infections classifi ed according to CDC defi nitions (9).
Figures are expressed as number (%).
Table 4. Number of strains of MRSA and MSSA (n=528) treated by particular antibiotics and percentage of MRSA and MSSA as a proportion of 
total isolates in each type of antibiotic
Antibiotic No. of isolates (%)
Glycopeptide 189 (36)
Aminoglycoside 132 (25)
Cephalosporin 119 (23)
Quinolone 91 (17)
Broad-spectrum penicillin 83 (16)
Imipenem 68 (13)
Penicillin 43 (8)
Metronidazole 40 (8)
Aztreonam 22 (4)
Macrolide 11 (2)
Other 90 (17)
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DISCUSSION
Virulence of MRSA
Many studies have tried to show that strains of MRSA are more virulent than those of MSSA 
(10,11,19,32). However, none of them showed that MRSA is clinically more virulent than other 
strains of S aureus. There were no signifi cant diff erences in the types of infections produced, or 
in the mortality (1,2,24). On the contrary there were some studies that suggested that many 
Table 5. Percentage prevalence of MRSA and MSSA ICU-acquired infection and odds ratio of risk of developing MRSA infection compared to 
MSSA, depending on APACHE II score and length of stay in ICU
MRSA MSSA Odds ratio 95% CI p-value
APACHE II Score
0-5 9.5 3.3 1.00
6-10 14.4 20.1 0.26 0.11 to 0.62 <0.001
11-15 24.7 26.4 0.34 0.14 to 0.78 0.01
16-20 29.2 26.7 0.39 0.17 to 0.89 0.03
21-25 14.8 15.4 0.34 0.14 to 0.84 0.02
26-30 4.9 6.2 0.28 0.09 to 0.80 0.02
31-35 2.1 1.5 0.65 0.13 to 3.31 0.61
 >35 0.4 0.4 0.39 0.02 to 6.95 0.52
 STAY in ICU (days)
0-14 5.6 18.4 1.00
15-20 11.1 13.9 2.65 1.12 to 6.26 0.03
> 20 83.3 67.7 4.07 2.02 to 8.21 <0.001
Table 6. Percentage prevalence of MRSA ICU-acquired infection and odds ratio of risk of developing MRSA infection depending on type of ICU 
and antibiotic policy
MRSA Odds ratio 95% CI p-value
Type of ICU
Mixed
(medical/surgical, surgical/trauma, or 
medical/surgical/coronary)
55.5 1.00
Medical 74.1 0.92 0.58 to 1.48 0.73
Surgical 69.8 1.42 0.96 to 2.11 0.08
Specialist (respiratory, trauma, burns, 
neurosurgical)
59.5 1.45 0.95 to 2.22 0.09
Antibiotic policy
Other 67.8 1.00
Formal (written) 52.3 0.73 0.51 to 1.06 0.10
Informal 58.9 0.78 0.57 to 1.08 0.13
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strains of MRSA are neither highly contagious nor have determinants of virulence (5,6,15,16). 
Most laboratory studies however, found that strains of MRSA have properties of virulence 
similar to those of MSSA (6,7,8,14, 28,33). There was also no diff erence in the number of death 
in animal studies (12,28). So far there is no clinical or laboratory evidence that MRSA is more 
virulent than other strains of S aureus.
However, there is a diff erence in the virulence of MRSA between patients in acute hospitals 
and in outpatients. Community-acquired MRSA infections occur sporadically and are of no 
particular clinical importance. MRSA carriers (colonised persons) will not easily become in-
fected in the outpatient setting. They become at risk at the time of (re)admission to hospital. 
From an infection control perspective, the home care setting is thus ideal for the patient colo-
nised with MRSA (24). Even in groups of residents colonised with MRSA in American nursing 
homes and in long term care units associated with Veterans Administration hospitals (where 
the prevalence of MRSA colonisation is often high), only 5%-15% subsequently developed 
MRSA infections (2,3,23). However, among patients colonised with MRSA in acute hospitals, 
30%-60% will eventually develop an MRSA infection (2,27,36). The risk factors associated with 
the acquisition of an MRSA infection in hospitals are the same that make a patient at high risk 
from and more vulnerable to the consequences of this infection. Host factors are probably 
Table 7. Percentage mortality according to site in MRSA and MSSA ICU-acquired infections and odds ratio of survival from the MRSA infections 
compared to MSSA (death =OR 1)
Site Mortality (%) Odds ratio 95% CI p-value
EPIIC overall 16.8
MRSA 32.4 0.7 0.47 to 1.06 0.09
MSSA 25.0
Wound infection
MRSA 26.7 0.59 0.11 to 3.20 0.54
MSSA 17.6
Bloodstream
MRSA 26.9 0.68 0.17 to 2.74 0.59
MSSA 20.0
Pneumonia
MRSA 33.3 0.82 0.46 to 1.45 0.50
MSSA 29.1
Urinary tract
MRSA 14.3 3.0 0.24 to 37.58 0.39
MSSA 33.3
Lower respiratory tract
MRSA 45.7 0.35 0.13 to 0.94 0.04
MSSA 22.9
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the most important determinants of progression of infection. In patients in the need off  an 
ICU admission, therefore MRSA can cause considerable morbidity and mortality.
MRSA risk factors
Patients in ICU have an increased susceptibility to nosocomial ICU-acquired infections 
(4,31). Special risk factors make them temporarily immunocompromised: the normal host 
defence mechanisms are often disrupted by multiple invasive devices, impaired by the un-
derlying disease, and reduced by medical interventions and medication. Other risk factors 
include prolonged stay in hospital and in the ICU, the use of (combination) broad-spectrum 
antimicrobial drugs, the prevalence of multiply resistant micro-organisms, and sometimes 
overcrowding. Overall, intrinsic risk factors together with extrinsic ones make the ICU patient 
extremely vulnerable to nosocomial infections. As stated by Meakins et al “Infection is their 
Achilles heel”(20).
These are the same risk factors that make a patient more susceptible to S aureus infec-
tions. S aureus is a pathogenic micro-organism, but in normal conditions it is of low virulence 
(26). Some strains of S aureus are more virulent (13,18,34) but this increase in their virulence 
needs an altered host resistance. A normal functioning immunological (phagocytic) defence 
mechanism prevents an infection with S aureus. For example: selective digestive decontami-
nation alters the normal immunological defence mechanisms, by causing overgrowth of a 
selection of Gram positive organisms, with the MRSA-strains being of particular importance. 
Its use should therefore be restricted, particularly in a MRSA-endemic environment.
In search for special risk factors in the ICU that cause patients to become infected with MRSA 
instead of MSSA, we found that the most important signifi cant diff erence was the length of 
stay in the ICU. The odds ratio for ICU-acquired MRSA infection increased dramatically with 
the length of stay, increasing more than 2.5 times with a stay of longer than two weeks, and 
increasing more than four times after three weeks, as also reported by Law and Gill (17). This 
and our study have in common an increasing incidence of nosocomial MRSA infections after 
starting with only MSSA infections.
This probably is refl ected in the APACHE II score, when it is over 30 patients die too soon to 
become infected with MRSA. These severely ill patients die as a consequence of their underly-
ing disease, whereas the less severely ill patients become exposed to a large number of risk 
factors that encourage them to develop an ICU-acquired infection.
There is an important correlation between antibiotic consumption and antibiotic resistance. 
Development of resistance to an antibiotic is usually the consequence of previously high 
consumption of this antibiotic (21,29). To prevent this kind of antibiotic misuse, an antibiotic 
policy for prophylaxis and treatment guarded by a microbiologist or infectious disease spe-
cialist is needed. We found however that a written as opposed to the “other” antibiotic policy 
could reduce the odds ratio of MRSA by only one in four (not a signifi cant diff erence). Did 
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the antibiotics used for S aureus infection in our study have a role in the high prevalence of 
MRSA? Methicillin resistance is caused not only by the common use of penicillinase-resistant 
beta-lactams, but also by the use of cephalosporins, as cross-resistance between penicillins 
and fi rst generation cephalosporins is a common if not ever present feature. Further, methicil-
lin resistance in staphylococci is often linked with resistance to other antibiotics, particularly 
aminoglycosides, possibly also selecting for methicillin resistance (22). The most commonly 
used antibiotics for S aureus infections (MSSA and MRSA) in our study were the glycopeptides 
(36%), followed by the aminoglycosides (25%) and cephalosporins (23%, Table 4). Maybe this 
selection by the clinical use of antibiotics was made because of the high prevalence of MRSA, 
increasing the chance that the frequent use of glycopeptides in MRSA infections will also 
induce the development of vancomycin-resistant MRSA (and others, such as methicillin-re-
sistant S epidermidis and enterococci).
Another possible risk factor for methicillin resistance is the type of intensive care unit. Mou-
ton et al (22) sought the relationship between methicillin resistance in coagulase- negative 
staphylococci and the type of clinical department, and found that all types of surgical wards 
(thoracic surgery, surgical ICU, neurosurgery) scored highest. We could not corroborate these 
fi ndings, as we found an odds ratio of MRSA infection for the surgical and specialist ICU 1.5 
times higher than for the medical and mixed ICU, a diff erence that was not signifi cant.
Mortality
Mortality in the EPIIC study was higher in those countries with higher ICU-acquired infec-
tion rates and these were higher again in those countries with higher MRSA ICU-acquired 
infection rates. Mortality was higher in those patients infected with MRSA (32%) compared 
with MSSA (25%), and in those patients infected with MSSA compared with the total num-
ber of patients studied in EPIIC (17%). Notwithstanding that diff erences in mortality cannot 
be directly attributed to diff erences in infection rates or diff erences in microbial resistance, 
univariate analysis of the EPIIC data confi rmed that ICU-acquired infections are among the 
most important independent risk factors associated with increased mortality. In the six week 
follow-up period, the greatest risk for all kinds of ICU-acquired infections was associated 
with clinical sepsis. The greatest mortality risk for the MSSA infections was associated with 
pneumonia, and for the MRSA infections with lower respiratory tract infections. The chance 
of survival with a MRSA instead of MSSA lower respiratory tract infection was reduced almost 
three times. We must conclude that an ICU-acquired infection reduces the chance of survival 
(4) and MRSA has a greater impact on mortality than MSSA.
MRSA control measures
There turned out to be an enormous intercountry variation in the prevalence of MRSA, with a 
diff erence of 0-81%. Apparently several countries have been able to prevent MRSA problems 
in (and outside) their ICU, by strict control measures.
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The emergence of MRSA and other resistant micro-organisms is certainly the result of 
misuse of antibiotics, not only in but also outside hospital. Training students, residents, and 
specialists to use antimicrobial agents only judiciously and to reinforce hygienic measures 
where necessary remains the mainstay in the prevention of MRSA problems. As well as overall 
restrictions in the use of antibiotics, the special need for the instigation of rigorous MRSA 
control measures in hospitals persists. In the endemic setting there is a strong need for sur-
veillance of high risk patients to prevent epidemics (2,24, 30,37). All patients at risk of MRSA 
should be screened before admission to hospital and put in isolation until they are free of 
MRSA. In case of an outbreak of MRSA (ICU or epidemic) it is absolutely necessary to use hy-
gienic measures such as barrier precautions, strict isolation, cohorting, decolonisation treat-
ment of carriers and antibiotic treatment of patients (2,24). Also MRSA-positive personnel 
should be given decolonisation treatment and should stay away from the hospital until they 
are free of MRSA. The costs of a MRSA outbreak (in terms of added morbidity, psychological 
morbidity, mortality, hospital days and hospital charges) are overwhelming. To prevent such 
an epidemic is better, easier and cheaper. The scope and intensity of prevention, surveillance, 
and control programmes designed to limit this nosocomial transmission of MRSA should be 
tailored to local conditions. The high risk patient in ICU makes the ICU a place in which local 
control of MRSA is particularly urgent.
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CANDIDA “THE EMERGING PATHOGENS”
Candida species are called “emerging pathogens”, because over the past decades their status 
has changed from colonising a-pathogens, to virulent pathogens causing serious infections. 
At fi rst, Candida was thought to be an insignifi cant, transient contaminant rather than a sig-
nifi cant pathogen (1,2) with the exception for neutropenic patients. This was called the era 
of the concept of “benign candidaemia”, in the 1970’s. However, this hypothesis has become 
outdated and Candida nowadays is accepted to be a serious nosocomial pathogen in non-
neutropenic critically ill patients in the Intensive Care Unit (ICU) (3-10). The greatest increase 
in rate of Candida infections occurs in surgical services, especially in patients recovering from 
abdominal surgery (6,11-21).
The increase in nosocomial invasive candidiasis parallels the advance made in the support-
ive care towards survival of critically ill patients who would previously have died of severe 
illness. Aggressive invasive diagnostics, multiple therapies and a plethora of invasive devices 
in combination with a temporarily compromised immunity render the ICU patient popula-
tion uniquely susceptible to nosocomial (fungal) infections (22-31). Overall, intrinsic risk fac-
tors together with extrinsic factors make the ICU patient extremely vulnerable to nosocomial 
infections. As stated by Meakins et al. “Infection is their Achilles heel” (32).
Probably, one of the most important risk factors for development of invasive fungal infec-
tions in these debilitated patients is the enormous increase in (in) appropriate use of broad-
spectrum antibiotics (33-38). A carefully considered, restrictive antibiotic policy for infectious 
diseases in the ICU is a common and proper practice of medicine in patient care (39). However, 
ill-considered use of antibiotics can lead to a spiralling empiricism of antibiotic therapy, with 
a major impact on the increase of life-threatening fungal infections (40).
CANDIDIASIS, THE PROBLEMS
Parallel to the growing incidence of fungal infections, the clinical signifi cance of these noso-
comial ICU infections is increasing. The increased incidence of fungal infections has resulted 
in new clinical syndromes with systemic or invasive disease, the expression of which depends 
largely upon the immune status of the host. At present, clinicians have not succeeded in 
controlling this growing problem, because the infection itself presents some apparently 
insurmountable problems.
First, there is no symptom or complex of symptoms specifi c for invasive candidiasis. The 
clinical presentation of invasive candidiasis in critically ill ICU patients is very variable and 
non-specifi c with pyrexia and/or persistent leukocytosis during antibiotic treatment. The 
patient may develop a septic shock syndrome or remain hemodynamically stable. A unilat-
eral endophthalmitis may develop. There is a high correlation between the occurrence of 
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eye-lesions and disseminated infection, with reported endophthalmitis incidences of 15-
37% in patients with systemic infection (41,42). In an attempt to defi ne invasive candidiasis 
in surgical patients, Geldner proposed in 2000 a defi nition composed of 5 items: 1. clinical 
signs of infection after surgery 2. absence of bacterial pathogens and/or failure to respond 
to systemic antibiotics 3. cultivation of Candida spp. from normally sterile sites 4. response 
to antimycotic therapy and 5. diagnostic serum antibody test (43). In clinical practice this is a 
rather laborious defi nition.
Secondly, management of serious and life-threatening invasive candidiasis remains severely 
hampered by the lack of reliable diagnostic methods; there is no (rapid) “gold standard” test 
available (9,44-47). For example, failure to detect fungemia by bloodculture is a well-known 
phenomenon. The need for a rapid and accurate multi-species- or even strain-level identifi ca-
tion of signifi cant yeast isolates is imperative for prompt institution of appropriate antifungal 
therapy. Besides the lack of a diagnostic test, the interpretation of the results of mycological 
cultures is diffi  cult, because most of these facultative pathogenic fungi are part of the physi-
ological fl ora (48-51).
Thirdly, at present, there is no miraculous antifungal therapy available yet (52-56). No an-
timycotic drug, eff ective to all types of Candida species exists, without limitations due to 
toxic side eff ects. It seems that successful treatment and patient recovery depend on the 
underlying condition and immune state of the patient. Despite administration of appropriate 
antifungal agents, these Candida species tend to persist, probably refl ecting severe modu-
lations of the immune system of the host with multiple-system organ failure, rather than 
anti-fungal therapy failure.
MORBIDITY AND MORTALITY
The morbidity and mortality associated with these invasive Candida infections is striking, with 
the median ICU-stay increased by as much as 30 days (57,58) and death rates of 30% to 80% 
(14,34,59-63). The same extremely high death rates are reported for abdominal candidiasis, 
and patients often die of complications of the infection in spite of surgical intervention and 
administration of (appropriate?) antifungal therapy (12,13,15-17, 20,48, 51, 64-65). Needful to 
mention is that most studies reported the overall crude mortality, and not the excess mortal-
ity directly attributable to candidiasis. When estimated the attributable mortality, rates of 
40% are reported (34,57,66).
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PROPHYLACTIC AND EMPIRIC THERAPY
Because prompt initiation of antifungal therapy is critical for cure but diffi  cult to accomplish, 
prevention of fungal infections may play an important role in the clinical setting. Several 
studies assessed the positive eff ect of early, systemic antifungal therapy on the improved 
outcome of ICU-patients with invasive Candida infections, in terms of a decrease in morbid-
ity and (attributable) mortality (9,13,29,62,67-69). With “early therapy” one should consider 
both early, prophylactic or pre-emptive antifungal therapy for a selected group of high-risk 
patients, just in an attempt to prevent Candida infections (i.e. in the absence of any evidence 
of infection, 21,70-77). One should also consider the start of early, empirical therapy upon 
the fi rst clinical suspicion of a Candida infection, even though the exact species are not yet 
identifi ed (78-80). Both thresholds must be lowered. Targeting patients for antifungal pro-
phylactic therapy entails identifying and quantifying those patients at high risk. Antifungal 
prophylaxis for all critically ill ICU-patients, irrespective of individual risk factors, on a routine 
basis is generally not advised (81), because it has never been validated in controlled trials. 
Furthermore, widespread use of antifungals in the ICU would promote development of the 
inevitable resistance to azoles and selection of non-Candida albicans species. In this regard, 
fl uconazole is no exception to the rule that the prophylactic use of any anti-infective agent 
might result in increased resistance to this drug.
Because of toxic side eff ects of amphotericin B (82), the fi rst choice of prophylactic or em-
piric antifungal therapy is fl uconazole (9,68,83-87). Two of the heralded problems in using 
fl uconazole as prophylaxis are the existence of fl uconazole resistant non-albicans Candida 
species (88-91), and the possible emergence of de novo fl uconazole resistance through selec-
tive pressure of prolonged azole use. This prolonged use causes a possible selection of less 
susceptible non-albicans Candida species or a shift to fl uconazole resistant Candida albicans 
(66, 84, 88, 92-100). This last hypothesis has been supported by reports of fungal infections, 
which developed in patients with hematologic malignancy (101-104) and in HIV patients (105, 
106) with long courses of prophylaxis. The impact on the possible emergence of resistance of 
short-term courses fl uconazole prophylaxis (2-3 weeks) has not been reported so far.
IDENTIFYING HIGH RISK PATIENT GROUPS
Prophylaxis is restricted to a prospectively defi ned easily identifi able subgroup at high risk 
of candidiasis. Rigorous selection of high-risk patient groups is crucial to optimise the risk-
benefi t ratio of preventive prophylactic or empiric antifungal strategies. Various criteria have 
been proposed to identify patients at risk of candidiasis,but some are not selective enough 
and others are time consuming and expensive (107). The aim of prophylaxis is to maximize 
chances of reducing morbidity and mortality while minimizing exposure of low-risk patients 
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to adverse events, and minimizing the risk of the emergence of de novo or non-albicans Can-
dida strains.
In chapter 8 an analysis is given concerning the results of a retrospective cohort study dur-
ing the period of 2000–2003 in the surgical Intensive Care Unit of the Erasmus MC, University 
Medical Center Rotterdam. This is a study to evaluate the risk of Candida species isolation in 
surgical ICU patients with peritonitis, and to determine independent risk factors or probably 
to select high-risk patient groups. Defi ning those groups could guide the selection of pa-
tients for prophylactic or empiric therapy. In addition morbidity and mortality were assessed 
for the groups with and without Candida isolation in peritonitis specimen.
RAPID IDENTIFICATION METHODS
Rapid species-(or even strain-) level identifi cation of the signifi cant isolates is thus impera-
tive for prompt initiation of appropriate antifungal therapy, since susceptibility data for the 
isolated strain may not immediately be available (108) To switch as soon as possible, from the 
fl uconazole prophylaxis to the appropriate antifungal therapy, a rapid identifi cation of the 
causal Candida species is of paramount importance. Also the adequacy of the initial, empiri-
cal treatment has proven to attenuate morbidity and mortality. Changes in therapy based on 
culture results, that are too late initiated, did not aff ect outcome when the initial regimen was 
inappropriate (109-111).
Thus, the need for a rapid and accurate multi-species level identifi cation of signifi cant yeast 
isolates is imperative for prompt institution of appropriate antifungal therapy. Our current 
techniques are, at best, blunt instruments with limited sensitivity. A convincing tool for the 
diagnosis of invasive candidiasis has yet to emerge (112).
In chapter 9 an analysis is given concerning the results of a prospective study, comparing 
the relatively time-consuming conventional microbiological identifi cation of Candida species 
and rapid identifi cation by Raman Spectroscopy. This is a study to evaluate the feasibility and 
accuracy of the Raman spectroscopic method for rapid identifi cation of clinically relevant 
Candida species in peritoneal specimen of peritonitis patients in the surgical ICU. The Raman 
Spectroscopy off ers probably a rapid identifi cation, with results after one overnight culture, 
which is at least 3 days earlier than the conventional identifi cation.
A risk analysis of potential Candida patients, in combination with a rapid identifi cation of 
Candida species if present, gives the clinician the opportunity to switch as soon as possible 
from early started prophylactic or empiric antifungal therapy to the appropriate therapeuti-
cal antimycotics.
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ABSTRACT
Objective: Over the past decades the incidence of nosocomial fungal infections has risen 
signifi cantly, with the greatest increase occurring in surgical services. We therefore analysed 
the risk of Candida species isolation from peritoneal fl uid in surgical Intensive Care Unit (ICU) 
patients with a peritonitis, and determined independent risk factors
Method: A retrospective cohort study was performed. One hundred and seventeen patients 
with a peritonitis (bacterial n = 69, Candida or mixed Candida/bacterial n = 48) hospitalized 
in a surgical ICU during the period of 2000 up to 2003 were included.
Results: Statistically signifi cant risk factors of Candida isolation were pancreatitis (p=0.0073), 
APACHE II score >30 (p=0.0019), antibiotics used before the day of onset of the peritonitis 
(p=0.040), and perforation in the lower digestive tract (in a protective fashion, p=0.0342). 
In contrast to the mortality (p=0.842), the morbidity (defi ned as length of stay in the ICU) 
in the Candida group was signifi cantly higher than in the bacterial group (27 versus 8 days, 
p=0.001). In contrast to other nosocomial infections, Candida isolation most frequently oc-
curred during the beginning of the ICU stay.
Conclusion: Critically ill peritonitis patients with a high APACHE score are at risk for isolation 
of Candida species from peritoneal fl uid, with a special emphasis on patients with pancreati-
tis. Empirical antimycotics would be recommended in these cases.
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INTRODUCTION
After the persisting challenge of the growing incidence of multi-resistant bacterial infections, 
nowadays a new impending crisis out of the world of microbiology threatens the medical pro-
fession: the nosocomial fungal infections. Over the past decades the incidence of nosocomial 
fungal infections (usually Candida species) has risen signifi cantly, with the greatest increase 
occurring in surgical services, especially in patients recovering from (recurrent) abdominal 
surgery (1,2). In 1981 Guerin stated “Peritonitis due to Candida is both rare and severe” (3). 
Two decennia later it is not rare anymore, and is certainly severe, with an associated mortality 
rate of 50-70% (4-7).
The growing incidence of these fungal infections is due to multiple factors, all refl ecting 
the advances made in the critical care of patients who would previously have died of organ 
failure (2,8,9).
The increased incidence of fungal infections has resulted in new clinical syndromes with 
systemic or invasive disease, the expression of which depends upon the immune status of 
the host. It seems that successful treatment and patient recovery depend on the underlying 
condition and immune state of the patient. Despite administration of appropriate antifungal 
agents, these Candida species tend to persist, probably refl ecting severe suppression of the 
immune system of the host with multiple-system organ failure, rather than anti-fungal thera-
py failure (10).As yet, clinicians have not been successful in tailoring this growing problem.
Because prompt initiation of antifungal therapy is critical for cure but diffi  cult to accom-
plish, prevention of fungal infections may play an important role in the clinical setting. Several 
studies have already provided evidence for a positive eff ect of prophylaxis or early empiric 
antifungal therapy on the outcome of ICU-patients with invasive Candida infections (11-14).
Rigorous selection of high-risk patient groups is crucial to optimize the risk-benefi t ratio of 
preventive antifungal strategies. The aim of prophylaxis is to maximize chances of reducing 
morbidity and mortality while minimizing exposure of low-risk patients to adverse events. 
Various criteria have been proposed to identify patients at risk of candidiasis (15-17). To the 
best of our knowledge, risk factors for developing fungal peritonitis have not previously been 
analysed, except for one study, conducted from 1994-1999, which excluded some of the po-
tential risk groups (18).
Our current aim is to determine independent risk factors of Candida isolation in peritoneal 
fl uid of all surgical intensive care unit (ICU) patients with a peritonitis, in order to identify 
high risk subgroups in surgical peritonitis patients, with implications probably relevant for 
targeting antifungal prophylaxis on the surgical ICU.
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PATIENTS AND METHODS
Inclusion and exclusion criteria
A retrospective study was performed, including all patients with a diagnosis of peritonitis on 
admission to the surgical ICU, or who acquired a peritonitis during their ICU stay, between 
2000-2003. All consecutive peritonitis patients were prospectively included in a database. 
Peritonitis was diagnosed on the basis of both clinical symptoms and a positive bacterial 
culture taken from peritoneal fl uid or from an intra-abdominal abscess, collected during 
a laparotomy. A peritonitis was considered to be a Candida peritonitis when one or more 
peritoneal cultures were positive for Candida spp. Patients referred from other ICU’s were ex-
cluded, as well as patients with a hospital- or community-acquired peritonitis, culture proven 
before admission to the ICU.
Data collection
All patient charts were reviewed retrospectively by use of a digital ICU data system and data 
were collected by detailed questionnaires. Besides the incidence of Candida spp isolation in 
peritonitis patients, the infl uence of various infection risk factors was evaluated in order to 
identify possible risk groups. Factors included age, sex, antibiotic use and use of selective 
digestive decontamination. The time between the admission to the ICU and the onset of 
peritonitis was calculated, as well the number of days between the onset of peritonitis and 
isolation of Candida spp. The APACHE II score (Acute Physiology and Chronic Health Evalua-
tion II score, 19) was recorded at admission to the ICU. The primary disease and the primary 
site of infection responsible for peritonitis were recorded, especially livertransplantation, 
pancreatitis, a laparostomy, and spontaneous perforation or enteral anastomosis breakdown 
at the diff erent anatomical sites in the upper- and lower gastrointestinal tract. All the possible 
risk factors were scored for each ICU day separately, except for age and sex (constant factors) 
and the APACHE II score (which was calculated only during the fi rst 24 hours). Antibiotics 
were scored for each type separately. Only days of therapeutic dose (DDD) were scored, and 
counted in a cumulative fashion.
In addition, the type of isolated Candida species was recorded, together with the possible 
use of antimycotics.
Finally, morbidity was scored (for the group without mortality) as the total length of ICU 
stay. The mortality during the ICU stay was scored, together with the cause of death; was the 
mortality attributable to the peritonitis?
Statistical Analysis
Patients with a pure bacterial peritonitis (the cohort group) were compared to those who 
developed a mixed bacterial/ or pure Candida peritonitis. Statistical analysis started at the 
onset of peritonitis as t=0. Statistical analysis fi nished at the fi rst day of a positive peritoneal 
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Candida culture (for the Candida group) or continued until death or discharge from the ICU 
(for the peritonitis group without Candida).
Univariate analysis of possible risk factors for Candida isolation, taking into account the 
number of days of peritonitis during ICU-stay, was performed with the Kaplan-Meier method 
and the log-rank test. Factors which might change during the ICU stay (all but age, sex and 
the APACHE II-score) were analysed using Cox regression with time-dependent variables. The 
median number of days of antibiotic use at day 0 was analysed between those with and 
without a Candida peritonitis at day 0.
Multivariate analysis of potential independent risk factors for Candida isolation was per-
formed using Cox logistic regression.
RESULTS
Included in the study were 117 peritonitis patients admitted to a surgical ICU. Of these 117 
patients, in total 1844 ICU days were scored, of which 1319 ICU days were statistically an-
alysed (starting at the fi rst day of peritonitis). This resulted in a database of 136,456 items. Of 
these 117 patients 48 (41%) acquired a Candida peritonitis. In most cases this was a mixed 
bacterial / Candida infection, only 6 patients (13%) presented with a pure Candida peritonitis. 
The main characteristics of the studied patient population are presented in Table 1.
In Table 2 the reason of admission to the ICU is presented, together with the probable 
mechanism of the peritonitis. The highest frequency in this study population was the group 
admitted to the ICU because of a liver transplantation.
Table 3 shows the results of the risk analysis of various expected predictive factors of Can-
dida isolation in peritoneal fl uid of peritonitis patients. Patients with a Candida peritonitis 
presented more frequently with a pancreatitis (p=0.0073), had a higher APACHE score (≥31: 
p=0.0019) and more frequently received antibiotic therapy before the onset of peritonitis 
(4.7 versus 3.5 days, p=0.040). There was no signifi cant diff erence between the two groups in 
the antibiotic use during the ICU stay overall (p=0.131). The relationship between the total 
cumulative days of antibiotic use and the days of peritonitis for the groups with and without 
Candida are illustrated in Figure 1. This fi gure also shows the result that the highest frequency 
of Candida isolation occurred during the beginning of the ICU stay. There was a tendency 
towards signifi cance in favour of the Candida group and upper digestive tract origin of peri-
tonitis (p=0.061), whereas a lower digestive tract origin of peritonitis was statistically sig-
nifi cant in a protective fashion (p=0.0342). Kaplan-Meier curves of three of these risk factors 
for Candida isolation are shown in Figure 2. In the multivariate Cox-regression analysis this 
‘protection’ of lower digestive tract origin was not statistically signifi cant anymore, whereas 
pancreatitis (p=0.012) and an APACHE score ≥ 31 (p=0.002) remained as independent signifi -
cant risk factors for Candida isolation.
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The type of Candida species isolated in peritoneal specimen of the 48 patients with a Can-
dida peritonitis is shown in Table 4. Most frequently isolated was Candida albicans (83%). In 
5 patients (10%) there was a mixed infection, with a combination of Candida albicans and a 
non-albicans Candida species.
The diff erence in morbidity between both groups was defi ned as diff erence in total length 
of ICU stay, from the day of onset of the peritonitis up to the day of discharge from the ICU. 
Only patients without mortality were included. The median length of ICU stay for the peri-
tonitis group without Candida was 8 days, whereas the ICU stay for patients with a Candida 
peritonitis was 27 days (p=0.001).
Mortality, attributable to the peritonitis, was only scored during ICU stay. Mortality in the 
total group was 35%, whereas mortality in the Candida group was 44%. A Candida peritonitis 
was associated with a 7% higher mortality than the mortality in the group without Candida 
(p=0.842).
Table 1. Characteristics of the patient population with peritonitis
Peritonitis Group without Candida:
n = 69 (%)
Peritonitis Group with Candida:
n = 48 (%)
Age (years*) 56.3 ± 15 55.8 ± 15
Sex
Male
Female
48
21
(70%)
(30%)
28
20
(58%)
(42%)
Perforation
upper digestive tract
lower digestive tract
28
22
(41%)
(32%)
26
5
(54%)
(10%)
Pancreatitis  1 (1%) 6 (13%)
Liver transplantation 15 (22%) 10 (21%)
Laparostomy 18 (26%) 9 (19%)
APACHE II Score
≤ 20
21-30
≥ 31
24
42
 3
(35%)
(61%)
 (4%)
15
24
 8
(31%)
(50%)
(17%)
SDD  3  (4%)  3  (6%)
ICU stay before onset of peritionitis 
(days)
1
2-6
> 6
18
33
18
(26%)
(48%)
(26%)
13
20
15
(27%)
(42%)
(31%)
* = mean ± SD; SD = standard deviation; APACHE II Score = Acute Physiology and Chronic Health Evaluation; SDD = Selective Digestive 
Decontamination; T 0 = onset of peritonitis
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DISCUSSION
To improve the outcome of invasive Candida infections, preventive antifungal strategies are 
crucial. Early prophylactic antifungal therapy for a selected group of easily identifi able high-
risk patients is considered to be necessary, in an attempt to prevent Candida infections (i.e. 
in the absence of any evidence of infection, 14, 20, 21). One should also consider the start of 
early empirical therapy upon the fi rst clinical suspicion of a Candida peritonitis, even though 
the exact species have not yet been identifi ed (22). Both thresholds must be lowered. Anti-
fungal prophylaxis for all critical ill ICU patients on a routine basis, irrespective of individual 
risk factors, is generally not advised (23). Targeting patients for antifungal prophylaxis entails 
identifying and quantifying those patients at high risk.
First choice of prophylactic or empiric antifungal is fl uconazole (24-26). This preference 
is not because of the antimycotic spectrum of fl uconazole itself, but because of the toxic 
side eff ects of amphotericin B. Two of the heralded problems in using fl uconazole as prophy-
laxis are the existence of fl uconazole resistant non-albicans Candida species and the possible 
emergence of de novo fl uconazole resistant Candida albicans, or a possible selection of less 
susceptible non-albicans Candida species through selective pressure of a liberal and pro-
longed azole use (27-30). This is why a rigorous selection of defi ned high-risk patient groups 
is even more crucial to optimize the risk-benefi t ratio of antifungal prophylactic strategies.
Table 2. Indication of admission to the ICU and cause of peritonitis
Indication of ICU admission n = Cause of peritonitis* n =
Upper digestive tract
Oesophagus operation 9 Complications of oesophagus resection 6
Pancreatic operation (Whipple) 10 Complications of Pancreatic operation 9
Pancreatitis 5 Pancreatitis 9
Liver transplantation 25 Complications of liver transplantation 23
Hepatobiliary operation 6 Biliary tract 13
Lower digestive tract
Intestinal resection 13 Leakage of anastomosis 6
Perforation digestive tract 9 Perforation of digestive tract 27
Gunshot intra-abdominal 6
Ileus 4 Ischaemia digestive tract 14
Crohn 2 Intra-abdominal abcesses 6
Urological operation 4 Urological tract 6
Gynaecological operation 3
Vascular operation
Ruptured aneurysm 5
Multi trauma 9
Other 7 Other 9
* ≥1 cause of peritonitis in each patient is possible.
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Some limitations of this study need to be addressed. First, retrospective assessment of risk 
factors to defi ne high-risk patient groups is subject to criticism and may limit the conclu-
sions and recommendations to be made. However, all consecutive peritonitis patients were 
prospectively included in a specifi c database. Because digital data of every ICU patient were 
available, there were almost no missing data as a potential bias in this retrospective analysis. 
After the univariate analysis we performed a multi-variate analysis in search for indepen-
dent risk factors. Secondly, only 6 patients (13%) had a pure Candida peritonitis, whereas 
the remainder of the 87% of Candida patients had a polymicrobial mixed Candida/bacterial 
peritonitis. However, this corresponds to the low rate of pure Candida peritonitis reported in 
literature.
Table 3. Risk analysis of predictive factors of Candida isolation in peritonitis
Risk factor Univariate Analysis
Upper dig. tract origin p = 0.061
Lower dig. tract origin p = 0.0342 *
Pancreatitis p = 0.0073
Livertransplantation p = 0.2735
Laparostomy p = 0.848
Antibiotics used at onset of peritonitis (t = 0)
Antibiotics used after onset of peritonitis (t = 0)
p = 0.040
p = 0.793 
APACHE ≥ 31 p = 0.0019
ICU stay (days) before onset of peritonitis (t = 0) p = 0.5719
* a negative statistic signifi cance
Figure 1. Graphic of days of peritonitis by days of antibiotic use for both groups with and without Candida
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We identifi ed, with multivariate Cox-regression analysis, two factors independently as-
sociated with Candida isolation from peritoneal fl uid. First, pancreatitis turned out to be an 
independent risk factor (p=0.012). Several studies concerning acute necrotizing pancreatitis 
provide evidence for the increasing clinical signifi cance of Candida infection (31-33). This may 
be due to increased recognition through improved laboratory techniques or to more aggres-
sive diagnosis by percutaneous aspiration. Maybe the most crucial fact is the application of 
broad-spectrum antibiotics for prophylaxis of pancreatic infection, in an attempt to prevent 
 
Figure 2. Kaplan-Meier curves of the risk factors A: pancreatitis (p = 0.0073), B: APACHE II-Score ≥ 31 (p = 0.0019) and C: lower digestive tract 
origin (p = 0.0342*), predicting/protecting for Candida isolation in peritonitis patients.
Table 4. Type of Candida species isolated in Candida peritonitis
Type of candida species n =
Candida albicans 40
Candida glabrata  2
Candida tropicalis  1
Candida albicans + Candida glabrata  3
Candida albicans + Candida tropicalis  1
Candida albicans + Candida parapsilosis  1
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a septic course. This can favour opportunistic infection of Candida species by modulation of 
the endogenous fl ora. Because of the lack of randomized, prospective trials, standardized 
recommendations for use of antifungal prophylaxis in acute pancreatitis would be premature. 
The answer to the problem of opportunistic infections due to antibiotic prophylaxis could be 
selective decontamination of the digestive tract (SDD). In 1995 Luiten published the data of 
a controlled, prospective clinical trial of SDD for the treatment of severe acute pancreatitis, 
and found a signifi cantly reduced morbidity and mortality by SDD, without an increase in 
opportunistic infections (34). Some other experimental (35,36) and clinical (37,38) trials with 
SDD did follow this trial, but a widespread use in clinical setting failed to occur. Whether 
antifungal agents should be added to the prophylactic antibiotic regimens for patients with 
necrotizing pancreatitis remains questionable.
An APACHE II Score ≥ 31 was the second independent predictive factor of Candida isola-
tion (p=0.002). As expected this score was associated with severity in peritonitis patients, 
and with mortality (p=0.0010). We divided the range of calculated APACHE scores in three 
groups for statistical risk analysis. Initially, the plan was to remove the highest APACHE scores, 
because in several trials (39) these very severely ill patients died, before they could acquire a 
nosocomial infection. However, the results showed for Candida infections that this group is 
the highest risk group.
In contrast to the described risk of broad spectrum antibiotics used for prophylaxis in pan-
creatitis patients, antimicrobial therapy overall in the peritonitis group of this study was not a 
signifi cant risk factor for Candida isolation (p=0.793). One explanation could be the fact that 
statistical analysis started at the onset of peritonitis (t=0), whereas from that day on, all 117 
studied peritonitis patients received antibiotics. Another fact to be considered is the time to 
Candida isolation in peritoneal fl uid, which is for nearly half of the patients immediate from 
the onset of peritonitis (46% at t=0) or during the fi rst days of peritonitis (77% within the fi rst 
week). This is in contrast to other nosocomial ICU infections and is not consistent with the 
‘epiphenomenon of ICU stay’. Because of this fi nding we also analysed the previous antibiotic 
use from the admission to the ICU to the onset of peritonitis. At the fi rst day of peritonitis 
there is a statistically signifi cant diff erence in received antibiotics between the 22 patients 
with already a Candida in the peritonitis (a mean of 4.73 days of previous antibiotics) and the 
95 patients without a Candida (3.54 days of previous antibiotics, p=0.040).
There was a tendency towards signifi cance in favour of the Candida group and upper 
digestive tract origin of peritonitis (p=0.061), whereas the lower digestive tract origin of 
peritonitis was statistically signifi cant in a protective fashion (p=0.0342). In the multivariate 
analysis this was no longer signifi cant (p=0.084). Some studies suggested that perforated 
gastro duodenal ulcers are the most frequent cause of upper digestive tract origin of Candida 
isolation (18,40,41). Interestingly, in this study a pancreatic-biliary origin of peritonitis (both 
bilio-digestive anastomosis breakdown and pancreatitis) was frequently more responsible for 
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Candida isolation than perforated ulcers. The mechanism of the protection by lower digestive 
tract origin to Candida isolation is probably an overload of bacteria.
Although the liver transplant recipients formed the greatest group of peritonitis patients 
admitted to the ICU, liver transplantation was not a signifi cant risk factor for Candida perito-
nitis (p=0.2735). This was the only group with immunosuppresive therapy. Nosocomial infec-
tions overall are a constant threat for liver transplant recipients. Therefore, in some centers 
it is common to use antibiotic prophylaxis, which proved to be a signifi cant risk factor for 
invasive candidiasis in these patients (42). A recent study to evaluate risk factors for invasive 
candidiasis in liver transplant recipients mentioned antibiotic prophylaxis, retransplantation 
and posttransplant dialysis to be independent risk factors (43). In our hospital up to 2000 
we used SDD as prophylaxis in every liver transplant recipient. Because of serious side ef-
fects with gram-positive bacterial infections the protocol was changed in use of SDD only in 
case of retransplantation or repeat surgery. Five out of 6 patients mentioned in Table 1 with 
SDD were liver transplant recipients. Surprisingly, SDD was seen both in the group with and 
without Candida.
A laparostomy was not a signifi cant riskfactor for Candida isolation (p=0.848). Refl ecting 
that a Candida infection is an endogenous infection and not a exogenous infection, like most 
nosocomial infections. This is probably one of the explanations why Candida infections are 
acquired in the beginning of ICU stay, in contrast with other nosocomial infections.
The morbidity (in terms of ICU stay) was signifi cantly longer for the Candida group (27 
versus 8 days, p=0.001), whereas – in contrast with several other studies (4-7,32,33.44) – the 
mortality in this study was not signifi cantly higher (7%, p=0.842). Probably, the pathogenicity 
of Candida peritonitis is not solely related to the infection itself, and may be more a refl ection 
than a cause of adverse outcome.
CONCLUSION
According to the results of this trial, critically ill surgical peritonitis patients with a high 
APACHE score are at risk for isolation of Candida species, with a special emphasis on patients 
with a pancreatitis and patients with antibiotic use before the onset of the peritonitis. These 
results tend to the recommendation to combine the therapeutic antibiotics with antimycotic 
prophylaxis in these cases, immediate from the onset of ICU stay. However, the results of this 
retrospective trial have to be controlled in a prospective trial, in order to defi ne the real high 
risk groups who will benefi t from antimycotic prophylaxis or pre-emptive therapy.
Probably the most remarkable result of this study is the fact that a Candida peritonitis 
doesn’t comply with ‘the epiphenomenon of ICU stay’, i.e. the longer the stay in the ICU the 
higher the risk of acquiring a nosocomial infection. According to this trial the risk of Candida 
species isolation is not increasing during the ICU stay, almost half of the Candida infections 
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occurred at the day of onset of the peritonitis (46%), or during the fi rst week of ICU stay (in 
total 77%). This is another argument to start antifungal prophylaxis early in the course of ICU 
stay, or empirical therapy early in the course of the disease.
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CHAPTER 9
Rapid identifi cation of Candida species in 
peritonitis patients by Raman spectroscopy

Rapid identifi cation of Candida species in peritonitis patients by Raman spectroscopy 119
ABSTRACT
Objective: This prospective study evaluated Raman spectroscopy for the identifi cation of 
clinically relevant Candida species in peritonitis patients.
Methods: A Raman database was developed by measuring spectra from a set of 93 refer-
ence strains comprising 10 diff erent Candida species. Clinical samples were obtained from 
the surgical department and intensive care unit of a tertiary university hospital. In total, 88 
peritoneal specimens of 45 patients with a primary, secondary or tertiary peritonitis were 
included, of which 31 cultures were positive for Candida. Specimens were cultured initially 
on a selective Sabouraud medium that contained gentamicin to suppress bacterial growth. 
For conventional identifi cation, a chromogenic medium was used for presumptive identifi -
cation, followed by use of the Vitek 2 system for defi nitive identifi cation (requiring a total 
turn-around time of 48-96 hr). Raman measurements were taken on overnight cultures from 
Sabouraud-gentamicin medium. We compared the feasibility, accuracy and turn-around time 
of this Raman technique, with the conventional identifi cation as reference method.
Results: Using multivariate statistical analyses, a prediction accuracy of 90% was obtained 
for Raman spectroscopy, which appears to off er an accurate and rapid (12 to 24hr) alternative 
for the identifi cation of Candida species in peritonitis patients.
Conclusion: The reduced turn-around time is of great clinical importance for the treatment 
of critically ill patients with invasive candidiasis in intensive care units.
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INTRODUCTION
Candida species are often referred to as “emerging pathogens”. First Candida was thought 
to be an insignifi cant, transient contaminant. However this hypothesis has been abandoned 
and Candida is nowadays a serious nosocomial pathogen in non-neutropenic critically ill pa-
tients on the Intensive Care Unit (ICU) (1-3). Over the past decades the incidence of Candida 
infections has risen signifi cantly. The greatest increase in rate of Candida infections occurs in 
surgical services, especially in patients recovering from abdominal surgery (1,4-7).
The morbidity and mortality associated with these invasive Candida infections is striking; 
the median ICU-stay increased by as much as 30 days (8,9) and death rates of 30% to 80% are 
reported (10-13).
Several studies assessed the positive eff ect of early, systemic antifungal therapy on the 
improved outcome of ICU-patients with invasive Candida infections, in terms of a decrease in 
morbidity and (attributable) mortality (3,4,11,14-17).
Because of toxic side eff ects of amphotericin B, fl uconazole is often fi rst choice of pro-
phylactic or empiric antifungal (3,18,19). Two of the heralded problems in using fl uconazole 
as prophylaxis are the existence of fl uconazole-resistant non-albicans Candida species (20), 
and the possible emergence of de novo fl uconazole resistance through selective pressure of 
prolonged azole use. This prolonged use causes a possible selection of less susceptible non-
albicans Candida spp. or a shift to fl uconazole-resistant Candida albicans (21).
Rapid species-or even strain- level identifi cation of the signifi cant isolates is thus impera-
tive for prompt institution of appropriate antifungal therapy, since susceptibility data for 
the isolated strain may not immediately be available. To switch as soon as possible to the 
appropriate antifungal therapy, a rapid identifi cation of the causal Candida species is of 
paramount importance. Also the adequacy of the initial, empirical treatment has proven to 
attenuate morbidity and mortality. (Too) late changes in therapy based on culture results did 
not improve outcome when the initial regimen was inappropriate (22).
In conclusion, the need for a rapid and accurate multi-species level identifi cation of signifi -
cant yeast isolates is imperative for prompt institution of appropriate antifungal therapy. Our 
current techniques are, at best, blunt instruments with limited sensitivity. A convincing tool 
for the rapid diagnosis of invasive candidiasis has yet to emerge (23).
Vibrational spectroscopic techniques (Raman and infrared spectroscopy) yield spectra that 
are molecule specifi c. When applied to complex biological samples such as cells or tissues the 
spectra are a summation of the signal contributions of all molecular species in the organism, 
and therefore refl ect the overall molecular composition of a sample. Such spectra have been 
shown to be highly suitable for rapid identifi cation of both bacteria (24,25) and yeasts (26,27), 
because they are reproducible and distinct for diff erent bacterial and fungal species. Previous 
publications indicate that the technique might provide suffi  cient resolving power, to enable 
the discrimination of microorganisms even at the strain level and contain information about 
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the susceptibility for antibiotics or antimycotics (26,28). Vibrational spectroscopy appears to 
off er many advantages: requiring minimal biomass, a minimum sample handling, and en-
abling direct analysis of samples, rapidity, automation and accuracy. This appears to render 
spectroscopic techniques clearly superior to current routine methods for the identifi cation 
of Candida species.
Recently, we reported from our own Center for Optical Diagnostics and Therapy, a new 
and rapid method for the identifi cation of clinically relevant microorganisms directly on solid 
culture medium based on confocal Raman micro-spectroscopy. Reproducible Raman spectra 
were obtained from microcolonies of 10-100 µm, after an incubation time of only 6 hours 
(29,30).
Our current aim is to evaluate the Raman identifi cation in a prospective, clinical study for 
the identifi cation of Candida species in peritoneal specimens of peritonitis patients, by test-
ing feasibility, accuracy and turn-around time of this technique.
MATERIALS AND METHODS
Database strains
A collection of 93 reference Candida strains, comprising 10 diff erent Candida species was 
used. Strains were either obtained from culture collections or from collections of clinical 
isolates identifi ed to the species level by the conventional identifi cation methods. Strains 
were stored at –80°C in a brain-heart infusion broth (Becton Dickinson, Franklin Lakes, New 
Jersey, USA) containing 10% glycerol until use. Before measurements, strains were cultured 
on Sabouraud–gentamicin medium (Merck, Darmstadt, Germany) for 12 to 24 hours, at 30°C. 
For each database strain 2 independent cultures were used to collect Raman spectra from.
Technical Procedures of confocal Raman microspectroscopy
Raman spectra were acquired as described previously (29,30). Briefl y, with the CaF
2
 substrate 
placed under a microscope (fi tted with an 80x near-infrared objective, MIR Plan 80x/0.75, 
Olympus), Raman spectra were obtained using a System 1000 Raman microspectrometer 
(Renishaw plc, Wotton-under-Edge, UK). From each smear 10 spectra –obtained at randomly 
chosen positions within the smear- were measured, using approx. 100 mW laser light (830 
nm), and a signal collection time of 30 seconds per spectrum.
Statistical Analysis
All spectral analysis were performed as described previously (30). Briefl y, the fi rst derivatives 
of the spectral range from 400 to 1800 cm-1 were used to minimize the infl uence of back-
ground signal due to slight sample fl uorescence. Per sample, the 10 spectra collected from 
each smear were averaged. Then, the amount of data was reduced using principal compo-
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nent analysis (PCA), performed using the PLS toolbox (Eigenvector Research Inc., Manson, 
WA) for the Matlab software (the Mathworks Inc., Natick, MA). These PCA scores were used 
in a hierarchical cluster analysis (SPSS,Chicago, IL) to generate a dendrogram. Based on the 
major clusters found in the dendrogram, 6 linear discriminant models (LDA) were calculated, 
to construct an identifi cation scheme. For LDA only PC scores accounting for more than 1% of 
the variance in the data set were retained. A two-sided t-test was used to individually select 
those PC scores that showed the highest signifi cance in discriminating the diff erent microbial 
groups presented. The number of PC scores that was used as input for an LDA model was 
kept at least two times smaller than the number of spectra in the smallest model group to 
prevent overfi tting in the LDA model. The prediction accuracy of this model was tested us-
ing a ‘leave-one-strain-out’ method: the spectra of all but one strain were used to generate 
the LDA model (30). By repeating this procedure, and leaving the spectrum of each strain 
out in turn, information is obtained on the accuracy and reproducibility of the identifi cation 
scheme, i.e. if there was enough discriminating information in the Raman spectra to identify 
spectra of unknown samples correctly.
Patient sample collection
During 11 trial weeks in 2001 all patients from the surgical ICU or from the general surgical 
ward, with a primary, secondary or tertiary peritonitis were included prospectively. Specimens 
from peritoneal fl uid or from an intra-abdominal absces were obtained during a laparotomy, 
specimens from CAPD-fl uid were obtained directly out of the CAPD-catheter. Upon arrival in 
the microbiology laboratory, each specimen was devided in two: one for the conventional 
microbiological identifi cation (the reference method) and one for the identifi cation by Ra-
man microspectroscopy.
Conventional microbiological identifi cation of patient samples
For the conventional isolation and identifi cation of yeasts, samples were cultured on 
CHROMagar Candida medium (Becton Dickinson, USA). After 2 days of incubation at 30°C 
a presumptive identifi cation was made, based on distinctive coloured colonies. A defi nitive 
identifi cation was obtained using the Vitek 2 system (bioMerieux, Lyon, France), requiring a 
total turn-around time of 48-96 hr.
Raman measurements and identifi cation of patient samples
Patient samples were cultured under identical conditions as the database strains. From the 
overnight culture, if positive for yeasts, a biomass from several well-isolated colonies was 
smeared onto a CaF
2
 substrate. The smears were dried in a desiccator over drying beads for 
at least 25 minutes, prior to Raman measurements. The performed identifi cation scheme was 
applied to these spectra of unknown samples, in order to arrive at a species identifi cation.
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RESULTS
Representative Raman spectra acquired from database Candida strains are shown in Figure 1. 
Closer inspection of the spectra reveals that there are, indeed, spectral diff erences character-
istic of the various species. These spectra were treated by multivariate analysis as described 
in the section on Material and Methods under “Statistical Data Analysis”, to calculate 6 linear 
discriminant models. Figure 2 shows the schematic representation of this sequential identi-
fi cation model. The strength of this model based on the training set was evaluated using the 
‘leave-one-strain-out’ method. The prediction accuracy of this model was 87%. Spectra of pa-
tient specimens to be identifi ed were predicted by using this species identifi cation scheme.
During the study period 88 peritoneal specimens were obtained. 55 Specimens were ob-
tained from 20 ICU patients, 22 specimens were obtained from 17 patients hospitalised on 
general surgical wards and 11 specimens were from 8 patients with a CAPDitis. 31 (35%) 
of these specimens were positive for Candida. 30 (55%) of the specimens from ICU patients 
were positive for Candida, 1 (5%) of the specimens from patients of the general surgical ward 
was positive for Candida, none of the 11 specimens out of a CAPD-catheter was Candida 
positive.
29 of the 31 Candida isolates were available for evaluation; two Candida strains failed to 
grow on further subculture, one in the Raman arm and one in the conventional arm of the 
study.
Results of the conventional microbiological identifi cation of the 29 Candida strains are 
reported in Table 1: 20 specimens were pure Candida cultures, 9 specimens were mixed Can-
dida cultures.
The Raman species identifi cation of these 29 isolates was predicted by presenting their 
spectra to models 1 to 6 of the database sequential identifi cation scheme (Figure 2). Results 
are shown in Table 1. In 3 Candida strains there was a diff erence between the microbiological 
and the Raman identifi cation. One Candida albicans was predicted by the Raman technique 
as a Candida tropicalis, and another as a Candida dubliniensis (Figure 2: model 2). One Candida 
albicans/glabrata mixed culture was misidentifi ed as a Candida tropicalis. From the other 8 
mixed Candida albicans/glabrata cultures we only identifi ed Candida albicans (6) or Can-
dida glabrata (2) by means of Raman spectroscopy. Taking the conventional microbiological 
identifi cation as reference method, the prediction accuracy of the Raman identifi cation was 
90%.
DISCUSSION
During the last decades the incidence of nosocomial invasive candidiasis has risen. Since the 
mid-1990s there is a perceived shift in the etiology of Candida infections resulting in a selec-
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tion of less susceptible Candida species. In the USA SCOPE Survey, looking at nosocomial 
Candida bloodstream infections, it appeared that 50% of Candida isolates were non-albicans 
species (31). Awareness, especially in intensive care practice, of the growing impact of inva-
sive candidiasis is the fi rst step in a rapid identifi cation and diagnosis.
Because of the increasing incidence of less susceptible non-albicans species the need for 
a rapid and accurate identifi cation of clinical signifi cant yeast isolates is even more impera-
tive for the prompt institution of appropriate antifungal therapy. The adequacy of the initial, 
empirical treatment has proven to be of paramount signifi cance on morbidity and mortality 
in critically ill patients with an invasive Candida infection (32).
Clinical microbiologists face an important challenge to select a system for yeast identifi ca-
tion that is rapid and accurate (high specifi city and sensitivity). No current available method 
fully meets these criteria. Conventional identifi cation is based on an extensive series of bio-
chemical assays, following an obligatory culture time to obtain enough biomass of 106-108 
cells (33). This “gold standard” identifi cation is time-consuming, with an unavoidable turn-
around time of 48-96 hr. A large variety of methods have been developed with the aim of 
facilitating rapid same-day yeast identifi cation, but most of these systems are designed to 
discriminate between two common species or to confi rm only a presumptive identifi cation 
(28,34). A second identifi cation system, like the commercial yeast identifi cation panels, is 
often needed for a defi nitive identifi cation (35,36). Consequently, up to four days may go 
by before a defi nitive report reaches the clinician. Besides, the reported accuracies of these 
Figure 1. Representative Raman spectra of 10 Candida species, used for the Candida database in this study. The shaded areas highlight some 
characteristic diff erences between the species. (a.u. = arbitrary units).
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commercial yeast identifi cation systems varies from 60-99% (28,37). So, the need for a rapid 
and accurate multi-species level identifi cation of signifi cant yeast isolates is imperative for 
prompt institution of appropriate antifungal therapy.
Confocal Raman microspectroscopy is highly suitable for the rapid identifi cation of Candida 
species since Raman spectra can be directly obtained from microcolonies on a solid culture 
medium after only 6 hours of culturing. Following the development in our Center for Optical 
Diagnostics and Therapy of a new, rapid method for the identifi cation of clinically relevant 
microorganisms (29), we evaluated this method to test the feasibility of this technique for 
the identifi cation of Candida species (30). In that study we used a set of 42 reference Candida 
strains comprising 5 clinically relevant species and obtained Raman spectra directly from 
microcolonies on a solid culture medium after only 6 hours of culturing. We concluded that 
Raman microspectroscopy also off ers a potentially powerful technique for the rapid identifi -
cation of Candida species, with an obtained high prediction accuracy of 97-100%.
In the present clinical study the prediction accuracy of the Raman identifi cation was 90%. 
One Candida albicans was predicted by the Raman technique as a Candida dubliniensis. Sul-
Figure 2 Schematic representation of the sequential species identifi cation procedure, based on the Candida database LDA model 1 to 6. Spectra 
of trial specimens to be identifi ed are predicted by using model1, followed by subsequent the next projections.
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livan and coworkers characterized a novel species associated with oral candidiasis in human 
immunodefi ciency virus infected individuals (38). This species Candida dubliniensis shares 
many phenotypic properties with Candida albicans. As a result, this uncommon species is 
often identifi ed as Candida albicans in the microbiology laboratory (28). Because of possible 
resistance of Candida dubliniensis to azole antifungal agents, it is of great importance to dif-
ferentiate the two species. Easy-to-perform selective isolation procedures for these closely 
related species do not exist. Marot-Leblond et al (39) described an anti-Candida albicans cell 
wall surface-specifi c monoclonal antibody which might be a candidate for the diff erentiation 
of Candida albicans from Candida dubliniensis. Tintelnot et al (27) from the Robert Koch Insti-
tute, evaluated discriminatory phenotypic markers for Candida dubliniensis and concluded 
that only Fourier transform infrared spectroscopy combined with hierarchical clustering 
proved to be as reliable as genotyping for discriminating the two species. Future Raman 
studies with Candida albicans and Candida dubliniensis strains may reveal the accuracy in 
discriminating these two related species.
From 8 mixed Candida albicans/glabrata cultures we only identifi ed Candida albicans or 
Candida glabrata on the Sabouraud medium, presumably because we did not detect the 
existence of a mixed culture and measured only spectra of one Candida species. The identi-
fi cation of only one instead of both Candida species of a mixed culture was not counted as a 
misidentifi cation. Although this infl uences the prediction accuracy, we believe that the un-
derlying problem is not due to the intrinsic identifi cation capabilities of Raman spectroscopy. 
However, we assign this to the sample preparation protocol, prior to Raman measurements. 
Optimising of this preparation protocol, in order to detect the existence of mixed cultures 
could provide a solution. Because of the absence of any diff erential indicator in the Sabouraud 
medium used, chromogenic isolation media are often used for the recognition and presump-
tive identifi cation of mixed yeast cultures. We have successfully measured Raman spectra 
directly on CHROMagar medium, after only one overnight passage (unpublished data). Fu-
ture studies will be directed to measure Raman spectra directly on CHROMagar medium, 
followed by an incubation of the Candida isolates for another 2 days on the same medium, 
Table 1. Results of the conventional microbiological identifi cation and Raman identifi cation of the Candida strains from 29 trial specimens
Conventional 
identifi cation
Raman identifi cation
Species C.albicans C.glabrata C.inconspicua C.tropicalis C.dubliniensis Total
C.albicans 13 1 1 15
C.albicans/glabrata  6 2 1  9
C.glabrata 2  2
C.inconspicua 2  2
C.tropicalis 1  1
Total 19 4 2 3 1 29
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to facilitate the recognition of an eventually mixed culture. If so, the fi rst identifi cation of one 
species precedes the second identifi cation of another Candida species by another Raman 
measurement. A review of recent literature shows mixed Candida cultures to be uncommon, 
but defenitely not rare. If mentioned in trials, we found mixed Candida culture percentages 
of 9-38% (12,15,40). At this moment chromogenic isolation media are the only tests demon-
strating a better detection rate of yeasts in mixed cultures than traditional media, but still 
with the restriction of only a presumptive identifi cation. A rapid and accurate test for the 
defi nitive identifi cation of these mixed Candida cultures is still lacking.
The last item to be evaluated in this study was the rapidity, compared to the conventional 
identifi cation. Raman spectra were measured from colonies after overnight culturing, smeared 
onto CaF
2
 glass slides. This method diff ers from the sample preparation in our preclinical 
Candida trial, where we obtained spectra of microcolonies after only 6 hours of culturing. In 
the present study we have chosen for the most practical way in a clinical setting. Raman mea-
surements from smears are easier and more rapid to perform, but are not as homogenous 
as microcolonies. In all 29 Candida strains it was feasible to measure representative Raman 
spectra from overnight cultures, resulting in a turn-around time of maximal one day, instead 
of 3-4 days required for the conventional identifi cation.
CONCLUSION
Raman spectroscopy off ers an accurate and rapid alternative for the identifi cation of Candida 
species in ICU-peritonitis patients. Further investigations should be directed to optimise the 
technique for a better detection of mixed Candida cultures and to evaluate the impact of this 
novel identifi cation on clinical practice and patient outcome in a prospective, clinical trial.
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THE POST EPIIC PERIOD IN EUROPE
Was the EPIIC study the start to a new European era in which ongoing European wide surveil-
lance over the occurrence of nosocomial infection determines the appropriate antimicrobial 
regimens? Was 1992 the start of an ongoing European collaboration on data collection to 
audit the eff ectiveness of European infection control programs? The answer is unfortunately 
no. No European SENIC Project, no European NNIS Study followed the major undertaking of 
the EPIIC Study. Ongoing surveillance programs were not implemented throughout Europe. 
No European infection control policies were instituted. No European counterpart to the Cen-
ters for Disease Control and Prevention (CDC), which was started in the 1960’s in Georgia, 
and which recommended that hospitals in the USA conduct surveillance on the occurrence 
of nosocomial infections, was instituted. The goal of the CDC was to obtain epidemiological 
evidence on which to base rational control measures. Four decades later, Europe still has not 
followed this American model.
Again individual studies undertaken in individual countries dominate the European per-
spectives on critical care infectious diseases (1-6), individual studies with a wide variety in 
study design. It is inappropriate to extrapolate the data from these trials for use in a Euro-
pean wide setting. However, the results of all these individual studies emphasise again the 
diff erence in prevalences of nosocomial infections in ICU’s between Southern and Northern 
European countries. The same is stresssed in the diff erence in reduced antibiotic suscepti-
bility among ICU bacterial pathogens. The reason for these existing diff erences is the great 
diff erence in control strategies and formulary programs between countries.
Recently European boundaries have been opened for traffi  c, economics and tourism, 
consequently also for micro-organisms. This makes the task to control pathogens, especially 
resistant pathogens in Europe increasingly diffi  cult.
THE FUTURE CHALLENGES OF INFECTION CONTROL; LOOKING FORWARD
The goal of eradicating nosocomial infection from ICU’s is one that is unlikely to be attainable 
in the future. However, where eradication is impossible, the goal to reduce and control this 
ever growing problem is feasible.
What are the challenges to address in future?
A EUROPEAN SURVEILLANCE NETWORK
The ultimate aim for the near future is a European Surveillance network with more European 
collaborative eff orts in infection control. A European wide network is the only way to mea-
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sure and constantly re-measure the scope and magnitude of the incidence of ICU infections. 
A European-wide network is the only way to measure the organisms causing these nosoco-
mial infections and the antibiotic resistancy patterns of these pathogens. A European- wide 
network is the only way to guide in antibiotic policy and formulary decision making.
A European-wide network is also the only way to generate a database that would make a 
real contribution to the understanding of the nature and frequency of nosocomial infection 
in the ICU. It is important to have as accurate a picture as possible of the scale of the problem 
and the factors that aff ect it. Easy access to a suitable epidemiological database is a good 
starting point. With these data, patients most at risk of developing nosocomial ICU infec-
tions can be identifi ed, to target those patients at risk who will benefi t from antimicrobial or 
antifungal prophylactic strategies.
The outcome of nosocomial ICU infections can be gauged and eff ective infection control 
policies can be instituted. Ongoing collection of data can then be employed to audit the ef-
fectiveness of such policies. For example, the act of systematically collecting, tabulating and 
analysing data on the occurrence of nosocomial infections is known as ‘surveillance’. Another 
method to easily measure the effi  cacy of infection control policies is by repeated prevalence 
surveys.
Evaluation of cost-benefi t of new infection control measures will be crucial because of the 
high economic burden of ICU infections. Financial incentives may ultimately be the most pro-
active catalyst for every European country to ensure the implementation of infection control 
policies to save substantial money for the hospital budget.
It is important that collected data are translated into positive action, to improve infection 
control and management. Therefore, it is of paramount concern to all European countries 
to take an active role in reducing this problem of nosocomial ICU infections. An increased 
collaborative eff ort in infection control will provide the roots for a European perspective on 
nosocomial infections in ICUs, and will begin to establish some solutions to this growing 
problem.
NEW TYPES OF DEVICES
The farmaceutical companies are constantly in search for new devices with antibacterial ef-
fects. Some examples under investigation are urinary catheters impregnated with antimicro-
bial or antiseptic agents which is expected to reduce catheter-associated urinary tract infec-
tion. Silver-hydrogel urinary catheters prevent adherence of bacterial and yeast pathogens to 
the catheter surface. Some trials with these kinds of urinary catheters have shown promise, 
but defi nitive studies have not yet been published.
Innovation in sutures has developed a new antibacterial suture with a zone of inhibition 
that is eff ective against the pathogens that most frequently cause surgical site infections.
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For prevention of ventilator associated pneumonia, endotracheal tubes with continuous 
subglottic suctioning decrease the risk of aspiration of secretions that pool around the endo-
tracheal cuff , which has been shown to prevent ventilator associated pneumonia. Noninva-
sive ventilation is an alternative to intubation and mechanical ventilation, to reduce the risk 
of nosocomial pneumonia.
Undoubtedly, the most eff ective method to prevent a nosocomial infection caused by an 
indwelling device is to avoid unnecessary placement of this device, or to limit the duration of 
use once a device is in place. A policy to withdraw devices as soon as possible will be more 
preventive than the use of high-tech, newly developed, costly devices.
NEW TYPES OF SURGERY
Minimally invasive surgery
Minimally invasive surgical procedures have been increasingly performed by surgeons in 
the last decades. In addition to faster functional recovery and improved cosmetics, a patient 
undergoing laparoscopic surgery may benefi t from lower rates of surgical site infections. Sur-
gical stress derails the functions of both cellular and humoral immunity, resulting in immu-
nosuppression and consequently an increased risk of postoperative infection. Laparoscopic 
surgery may result in less induced surgical trauma than conventional open surgery which is 
translated in a reduced infl ammatory response and minimal immuno-suppression. Several 
comparative studies of cellular immunity after laparoscopic and conventional surgery dem-
onstrated immunologic advantage conferred by laparoscopy (7,8).
A recently described lucky coincidence of laparoscopic surgery is the bacteriostatic eff ect 
of 100% CO
2
 (9). CO
2
 has been combined with cold storage since the 1930’s for the preserva-
tion of food. Animal studies showed the attenuated infl ammatory response to the abdominal 
insuffl  ation with CO
2
 (10). No human studies had been reported, but in this particular case, 
the laparoscopists are in the unusual position in that the trials have been partially conducted 
before the hypothesis has been advanced. At present, it is probably ethically incorrect to go 
back to prospective, randomized trials with other types of insuffl  ation gases, to measure the 
bacteriostatic eff ect in comparison with CO
2.
With regard to minor surgical procedures such as laparoscopic cholecystectomy(11,12) 
and laparoscopic appendectomy (13-15) this immunologic benefi t is most obvious, and sev-
eral randomized studies assessed signifi cant lower rates of surgical site infection after these 
procedures. Also mesh-related infections after hernia repair surgery seems to be consider-
ably lower after endoscopic or laparoscopic procedures (16-17). However, for more complex 
procedures such as laparoscopic surgery for cancer of the esophagus, colorectal cancer sur-
gery (18-19) and for hepato-biliary or pancreatic surgery, these laparoscopic benefi ts are not 
immediately obvious or studied yet.
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It will be necessary to wait for the results of more randomised, clinical trials of a greater 
variety of laparoscopic procedures to provide further data and clarifi cation of these immuno-
logic and nosocomial infection benefi ts of laparoscopic surgery.
Fast-track surgery
Fast-track surgery, also called fast-track rehabilitation, is an interdisciplinary, multimodal con-
cept to accelerate postoperative reconvalescence and reduce general morbidity. Fast-track 
rehabilitation focuses on preoperative patient education, atraumatic and minimal-invasive 
access to the operative fi eld, optimized anesthesia under normovolemia and prevention of 
intraoperative hypoxia and hypothermia, eff ective analgetic therapy without high systemic 
doses of opioids, enforced postoperative patient mobilisation, early postoperative oral feed-
ing, and avoidance of tubes and drains. This set of rules is recorded in a multimodal reha-
bilitation programme. The overall aim is to hasten recovery, to reduce hospital stay, and to 
reduce morbidity and mortality.
One aspect is the restart of oral intake as soon as possible, possibly the evening of the op-
eration day, which is expected to have a favourable eff ect on the intestinal fl ora and thus on 
the possible endogenous postoperative infections (20,21). Fast-track rehabilitation for major 
surgery should be evaluated in randomized, controlled trials, both for open and laparoscopic 
surgery.
Ambulatory same-day or outpatient surgery
In these days of high-pressure health-care systems, hospital fi nancial budgets, and rapid sur-
gical throughput there is an increase in ambulatory same-day or outpatient surgery. A very 
rapid throughput of patients often leads to overcrowding and high bed occupancy rates, a 
situation in which infection control principles are likely to be undermined. Also in ambulatory 
and outpatient care we have to adhere to the principles of infection control.
NEW TYPES OF MEDICINES OR REGIMENS
The farmaceutical companies are constantly in search for new types of antibiotics,new types 
of antimycotics, and a new ‘miracle’ drug. For example, a human genetically recombinant 
antibody against the immunodominant hsp90 antigen of Candida albicans has been devel-
oped, which has demonstrated protective potential in murine models of invasive candidiasis. 
A phase II double-blind, prospective study with this antibody in patients with disseminated 
candidosis is going on.
New types of regimens have been used to decrease the overall utilization of antimicro-
bial agents. These measures should, in turn, decrease selective pressure that can foster the 
emergence of resistant strains. Antibiotic cycling by regularly cycling diff erent antimicrobial 
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classes, is one of the newer methods for antibiotic control (22). The goal is to prevent pro-
longed overutilization of a single antimicrobial class in an attempt to prevent widespread 
class resistance throughout an ICU and to improve the appropriateness of antimicrobial ther-
apy, by limiting the emergence of resistant bacteria. In theory, by rotating diff erent classes of 
antibiotics, overall resistance is kept at a low level, and when a particular class is reintroduced 
(ie, when the cycle is repeated), most pathogens are susceptible. Despite the theoretical 
promise, studies of antibiotic cycling have been diffi  cult to interpret. The independent eff ects 
of antibiotic cycling need to be more thoroughly studied, particularly after agents have been 
reintroduced in an ICU several times (after several cycles), before defi nitive conclusions can 
be drawn regarding the effi  cacy of this strategy.
Selective digestive decontamination (SDD) is an infection-prophylaxis regimen that 
was introduced into intensive care medicine in 1984 (23). SDD is based on the concept of 
colonisation resistance, according to which the indigenous intestinal fl ora has a protective 
eff ect against secondary colonisation with gram-negative aerobic bacteria. The approach 
aims to eradicate colonisation of aerobic potentially pathogenic micro-organisms from the 
oropharynx, stomach, and the gut, while leaving the indigenous anaerobic fl ora largely 
undisturbed. Controversy exists about the eff ect of SDD on mortality, on the emergence of 
infections caused by gram-positive bacteria, and on antibiotic resistance. Several prospec-
tive, randomised, clinical trials showed a decrease in ICU mortality and infection with gram-
negative aerobic bacteria (24,25). However, the eff ects of these methods on resistant fl ora 
and infection rates in ICUs and hospitals as a whole have not been rigorously studied and 
cannot currently be accepted as standard of care.
Immunonutrition has met with various successes in the prevention of nosocomial ICU 
infections. Perioperative immune modulation using specialized enteral (or parenteral) diets 
containing specifi c immunonutrients (formula supplemented with combinations of arginine, 
omega-3 fatty acids, ribonucleic acid, antioxidants, and glutamine) may improve postopera-
tive outcomes in critically ill patients. Several trials showed that immunonutrition reduced 
the number of infectious complications, and improved the function of the immune system 
(26,27). However, there are still many questions regarding the place of immunonutrition in 
clinical practice. There may be patients who will not benefi t or even suff er detrimental eff ects 
from immunonutrition. L-arginine is an important immunonutrient having both benefi cial 
and adverse eff ects. The former eff ect occurs in necrotizing enterocolitis; the latter infl uence 
is seen in septic patients. Immunonutrition merits further study before used in clinical prac-
tice.
Probiotics are living microorganisms that, ingested in adequate amounts, exert benefi cial 
eff ects. Due to the lack of proven effi  cacy and an unidentifi ed mode of action, probiotics were 
dismissed by the traditional medical sector for many years. Today, some probiotics represent 
prophylactic or therapeutic standards in certain indications (28). However, the administration 
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of oral probiotic supplementation (such as Saccharomyces boulardii and Lactobacillus sp.) 
remains controversial, and merits further study.
Aside from the impact of the emergence of various new types of antibiotic and antimycotic 
medicine, the results of several studies reinforced the conviction that an eff ective, restrictive 
antibiotic policy may be one of the most important patient care standards for preventing 
life-threatening infections. A more tailored antibiotic regimen should be implemented, with 
no broad-spectrum antibiotic regimen for everyone anymore, but with an antibiotic regimen 
with the smallest spectrum possible, only for specifi c risk groups.
AWARENESS OF THE PROBLEM
Last, but certainly not least, raising awareness of the problem of nosocomial ICU infections is 
of utmost importance. A key ‘milestone’ of the future challenges to control infection should 
be to raise awareness of the problems of nosocomial infection in the ICU among all ICU per-
sonnel, and to stimulate discussion, research, and consideration of ways to improve infection 
control and management. All these diff erent aspects together will jump-start the progress 
towards better infection control in ICUs.
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SUMMARY AND CONCLUSIONS
Chapter 1
The scope and magnitude of nosocomial Intensive Care Unit (ICU) infections is overwhelm-
ing, with a negative impact on both the added morbidity, mortality, and as a consequence 
on the overall hospital charges and economic costs. Aggressive invasive diagnostics, multiple 
therapies and a plethora of invasive devices in combinati on with a temporarily compromised 
immunity -intrinsic risk together with extrinsic factors- renders the ICU patient population 
uniquely susceptible to nosocomial infections.
The growing incidence of the nosocomial ICU infections will continue to limit the potential 
advances to be made in modern critical care medicine, which has to deal with more complex 
critically ill patients. In chapter 1 the problem of this growing incidence and impact of the 
nosocomial ICU infections is further elucidated, followed by an outline of the thesis.
Chapter 2
There is a remarkable diff erence in the knowledge of the magnitude of the infection problem 
between the USA and Europe. In the United States systematized information concerning 
the rates of nosocomial infections is available due to the development of various national 
formalized systems for ongoing surveillance. In Europe, no such formalized system exists, 
and there has been no large international study to determine the nosocomial infection rates 
throughout the continent, up to 1992. It was against this background that in 1992 the Euro-
pean Prevalence of Infection in Intensive Care (EPIIC) Study was undertaken, - the largest ever 
one-day point prevalence survey, conducted throughout Europe- to deal with the relative 
lack of information concerning nosocomial ICU infections.
Chapter 2 describes the results of the overall study, taking part in 1417 ICU’s in 17 West-
ern European countries, with data from 10,038 ICU patients. According to the results of the 
EPIIC study 45% of the total ICU patient population had one or more infections, almost half 
were ICU- acquired infections (21% of the total). The highlights of the results were the high 
prevalence of pneumonia and other lower respiratory tract infections (a prevalence together 
of 63% of the total infection types), the importance of S. aureus (with a prevalence of 30.1% 
the most frequently isolated pathogen), P. aeruginosa (28.7%), and the Enterobacteriaceae 
(as a class) as the key pathogens, and the high prevalence of microbial resistance of these 
pathogens to the various antibiotics. Most obvious was the resistance to methicillin in 60% 
of strains of S. aureus, with a remarkable diff erence between the various countries in Europe. 
Overall, there was a surprisingly growing signifi cance of gram-positive pathogens, and fungi. 
The key risk factors associated with ICU-acquired infections were in particular a prolonged 
length of stay on the ICU (with a relative risk (RR) of infection of 15.01 after an ICU stay of 1 
week, RR of 30.75 after 2 weeks and RR of 76.06 after 3 weeks), and various invasive interven-
tions. Mortality rates were high (16.8%), with a signifi cant correlation between the prevalence 
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rate of ICU-acquired infection and the mortality rate. In particular pneumonia, laboratory-
confi rmed bloodstream infection and sepsis were independent risk factors, associated with 
an increased risk of death.
Chapter 3
Chapter 3 describes the scope and magnitude of nosocomial ICU infections in the Nether-
lands. Data from 472 patients in 78 ICU’s in the Netherlands are separated from the data of 
the EPIIC Study.
37% Of the ICU patients suff ered from an infection, of which 16% of the total was ICU-
acquired. The most important risk factors were: the duration of an ICU stay (relative risk (RR) 
of 4.23, 99.37 and 146.79 for ICU stays of 3-4 days, 1-2 and more than 3 weeks respectively), 
correlated with severity of disease (organ failure) and more medical interventions (mechani-
cal ventilation, urinary catheter). The risk of acquiring a nosocomial ICU infection was lower 
after elective surgery than after ICU admission without previous surgery; after emergency 
surgery the ICU infection risk was higher. During follow-up 14% of patients died. Patients 
suff ering from an ICU infection had a higher mortality risk; the strongest prognostic factor to 
determine the mortality risk was the APACHE II-Score (RR of 13 with a score between 16-26 
and RR > 100 with a score > 31).
Chapter 4
The risk analysis of infections in Dutch ICU patients is completed with an analysis of the na-
ture of these ICU-acquired infections, as described in chapter 4. Pneumonia and infections of 
the lower respiratory tract had the highest prevalence (together 63%), followed by urinary 
tract infections (16%), sepsis (16%) and wound infections (11%).
The most frequently cultured pathogens were Gram-negative bacteria (92% in total), es-
pecially Enterobacteriaceae (34% as a class) and Pseudomonas aeruginosa (30%), followed by 
Staphylococcus (37%), Enterococcus (20%) and surprisingly: 10% fungi.
The antibiotics most frequently prescribed were: cephalosporins (30%), followed by broad-
spectrum penicillins (17%), metronidazole (17%), and aminoglycosides (13%). No infection 
with Methicillin-Resistant Staphylococcus aureus (MRSA) was found on the day of this study in 
the Netherlands, in contrast to many other European countries. Gentamicin-resistant coagu-
lase-negative Staphylococcus and ciprofl oxacin-resistant P. aeruginosa were found however. 
In many of the hospitals in the Netherlands, microbiologists, infectious disease specialists 
(84%) and infection control nurses (51%) reside in the ICU team.
Chapter 5
Chapter 5 starts with a review of the current literature about the surgical ICU patients and 
surgical site infections (SSI). The most used risk score for SSI’s at this moment (the NNIS surgi-
cal patient risk index score) is described.
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This review is followed by the results of the surgical ICU patients, separated from the data 
of the EPIIC Study. Over 50% of the 10,038 ICU patients had undergone surgery in the month 
prior to the EPIIC Study. Abdominal surgery was the most frequently performed type of sur-
gery, followed by cardiothoracic surgery and head and neck surgery. Of these 5066 surgical 
ICU patients, 21.3% developed an ICU-acquired infection. A risk analysis of the most impor-
tant infection risk factors for surgical ICU patients focused on: emergency - and multiple 
operations (RR of 2.31 and 3.12 respectively). Together with these types of surgery, trauma 
was a signifi cant risk factor (RR of 3.31) The infection risk was highest for the younger patient 
population (age between 20-40 years), and declined when the age increased. A longer ICU 
stay increased the odds ratio for infection dramatically, also due to an increasing number of 
invasive procedures, a prolonged need for assisted ventilation (sometimes in combination 
with a tracheostomy), more procedural diagnostic interventions and multiple operations. 
More than half of the ICU-acquired infections of these surgical ICU patients were located 
in the respiratory tract (prevalence of 51.7%), whereas the prevalence of wound infections 
was 8.7%. Gram-negative bacteria had the highest prevalence (47.1%), followed by the gram-
positive bacteria (40.9%), and fungi (10.8%).
The mortality in the group of surgical patients with an ICU-acquired infection was signifi -
cant higher (26 versus 12%), the pathogens associated with the highest rate of mortality were 
the fungi (31.1%).
Chapter 6
To evaluate the risk of patients in ICU’s of becoming infected with methicillin-resistant 
Staphylococcus aureus (MRSA) and to assess the mortality, compared to patients with a 
methicillin-sensitive S. aureus (MSSA) infection, data were separated from the EPIIC Study 
about prevalence of MRSA and MSSA infections, risk factors and mortality. Overall in Europe, 
60% of strains of S aureus were resistant to methicillin, with a wide intercountry variation; the 
highest proportion of MRSA occured in Italy (81%) and France (78%), while many northern 
countries had none.
For both bacteria the most commonly reported infections were in the respiratory tract: 
pneumonia 52% and 61% for MRSA and MSSA respectively, and lower respiratory tract infec-
tions 22% and 17% respectively. The most important risk factor for MRSA was the length 
of stay in the ICU (with a RR of 4.07 for a stay longer than three weeks), and an increasing 
APACHE II score. MRSA infection reduced the chance of survival, particularly when it was 
found in lower respiratory tract infections: the risk of mortality was three times higher in 
patients with MRSA than in those with MSSA.
Chapter 7
Fungi are called the ‘emerging pathogens’, because over the past decades they deranged 
from colonising a-pathogens, playing a subordinate role, to emerging virulent pathogens.
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The EPIIC results highlighted the growing prevalence of fungi, with a surprisingly high fre-
quency of 17% in the total study group, 10% in the Dutch subgroup and 11% in the surgical 
group.
Chapter 7 reviews the current literature about fungal infections and the epidemiology. 
There are some major problems of candidiasis to be mentioned: fi rst, there is no complex 
of symptoms specifi c for the diagnosis invasive candidiasis. Secondly, there is a lack of reli-
able diagnostic methods; there is no rapid “gold standard” test available. Thirdly, at present, 
there is no ‘wonder weapon’ antifungal therapy available yet. The morbidity and mortality 
associated with these invasive Candida infections is striking, with reported mortality rates of 
40-80%. The positive eff ect is described of early, systemic antifungal prophylaxis or empirical 
therapy on the outcome of ICU patients with candidiasis.
Chapter 8 focuses on the identifi cation of high risk patient groups, to target antifungal 
prophylaxis. Chapter 9 focuses on a new rapid identifi cation method of Candida species.
Chapter 8
Chapter 8 describes a retrospective cohort study to analyse the risk of Candida species isola-
tion from peritoneal fl uid in surgical Intensive Care Unit (ICU) patients with a peritonitis, and 
to determine independent risk factors. During the period of 2000 up to 2003, one hundred 
and seventeen patients with a peritonitis (bacterial n = 69, Candida or mixed Candida/bac-
terial n = 48) hospitalized in a surgical ICU of a tertiary university hospital were included. 
Statistically signifi cant risk factors of Candida isolation were pancreatitis (p=0.0073), APACHE 
II score >30 (p=0.0019), antibiotics used before the day of onset of the peritonitis (p=0.040), 
and perforation in the lower digestive tract (in a protective fashion, p=0.0342). In contrast to 
the mortality (p=0.842), the morbidity (defi ned as length of stay in the ICU) in the Candida 
group was signifi cantly higher than in the bacterial group (27 versus 8 days, p=0.001). In 
contrast to other nosocomial infections, Candida isolation most frequently occurred during 
the beginning of the ICU stay.
According to these results, we concluded that: Critically ill peritonitis patients with a high 
APACHE score are at risk for isolation of Candida species from peritoneal fl uid, with a special 
emphasis on patients with pancreatitis. Empirical antimycotics would be recommended in 
these cases
Chapter 9
Chapter 9 describes a prospective study which evaluated Raman spectroscopy for the iden-
tifi cation of clinically relevant Candida species in peritonitis patients. A Raman database 
was developed by measuring spectra from 93 reference strains belonging to ten diff erent 
Candida species. Clinical samples were obtained from the surgical department and intensive 
care unit of a tertiary university hospital. In total, 88 peritoneal specimens of 45 patients 
with a primary, secondary or tertiary peritonitis were included, of which 31 cultures were 
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positive for Candida. Specimens were cultured initially on a selective Sabouraud medium 
that contained gentamicin to suppress bacterial growth. For conventional identifi cation, a 
chromogenic medium was used for presumptive identifi cation, followed by use of the Vitek 
2 system for defi nitive identifi cation (requiring a total turn-around time of 48-96 hr). Raman 
measurements were taken on overnight cultures from Sabouraud-gentamicin medium. We 
compared the feasibility, accuracy and turn-around time of this Raman technique, with the 
conventional identifi cation as reference method. Using multivariate statistical analyses, a 
prediction accuracy of 90% was obtained for Raman spectroscopy, which appears to off er an 
accurate and rapid (12 to 24hr) alternative for the identifi cation of Candida species in peri-
tonitis patients. The reduced turn-around time could be of great clinical importance for the 
treatment of critically ill patients with invasive candidiasis in intensive care units.
Chapter 10
In chapter 10 the question is addressed whether there is an ongoing European collaboration 
on infection data collection and whether there are European infection control programs.
Challenges of infection control to address in future are discussed, such as: a European 
surveillance network, new types of devices, new types of surgery (minimally invasive surgery, 
fast-track surgery and ambulatory same-day or outpatient surgery), new types of medicines 
or regimens, and last but not least: raising awareness of the problem
IN CONCLUSION THE MOST IMPORTANT RISK FACTORS FOR NOSOCOMIAL 
INFECTIONS IN ICU PATIENTS TO BE WARNED FOR:
• Beware of prolonged length of stay on the ICU, which increases the odds ratio for infec-
tion dramatically. Also the risk for infection with a resistant pathogen, like MRSA, increases 
with the length of ICU stay.
• Beware of pneumonia and lower respiratory tract infections. Precautions, pre-, per- and 
post-operative are necessary to attack this type of infection in the surgical patient.
• Beware of gram-positive bacteria. The gram-negative bacteria are not any longer the 
most important and most virulent pathogens in nosocomial ICU infections. Gram-posi-
tive bacteria, such as the coagulase-negative staphylococci, are not only insignifi cant 
contaminants anymore.
• Beware of fungi. Fungi have deranged from colonising a-pathogens, playing a subordi-
nate role, to emerging virulent pathogens, with high associated morbidity and mortality 
rates.
• Beware of emergency - and multiple operations. As a consequence, trauma is a signifi cant 
risk factor for surgical ICU patients.
• Beware of a high APACHE score on admission to the ICU.
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• Beware of the growing resistance of these pathogens to the various antibiotics. There is a 
correlation between antibiotic consumption and antibiotic resistance; stressing the need 
for programs with restricted antibiotic policies.
• Beware of indwelling devices, invasive procedures and diagnostic interventions, which 
all have proven to be independent risk factors for ICU-acquired infections. A policy to 
withdraw devices as soon as possible is recommended.
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SAMENVATTING EN CONCLUSIES
Hoofdstuk 1
De ziekenhuis verworven infecties op de intensive care (IC) vormen een overweldigend groot 
en complex probleem, met een negatieve invloed op zowel de geassocieerde morbiditeit en 
mortaliteit, als dientengevolge op het ziekenhuis budget en de economische kosten van de 
zorgsector als geheel. Invasieve diagnostiek, agressieve behandelings methoden en een veel-
vuldig gebruik van invasieve catheters, in combinatie met een tijdelijk gecompromiteerde 
immuniteit –intrinsieke en extrinsieke risico factoren- maken dat de IC patient populatie bij 
uitstek gevoelig is voor ziekenhuis verworven infecties.
De groeiende incidentie van IC verworven infecties vormt een potentiele bedreiging voor 
de nog te boeken vooruitgang in de behandeling van de steeds complexere ziektebeelden, 
waar de huidige intensive care geneeskunde mee te maken heeft. Hoofdstuk 1 beschrijft dit 
probleem van de groeiende incidentie en impact van IC verworven infecties, gevolgd door 
een korte uiteenzetting van de doelstellingen van dit proefschrift.
Hoofdstuk 2
Er is een schrijnend verschil tussen Europa en de USA, in de kennis over de reikwijdte van het 
infectie probleem. In de Verenigde Staten worden kwantitatieve en kwalitatieve gegevens 
over de ziekenhuis verworven infecties systematisch gedocumenteerd, door middel van di-
verse nationaal geformaliseerde programma’s voor continue monitoring. In Europa bestaan 
dergelijke programma’s niet, en tot 1992 is er geen grote internationale studie uitgevoerd 
waarmee het probleem van de ziekenhuis verworven infecties voor heel Europa in kaart 
kon worden gebracht. Dit was de reden dat in 1992 de European Prevalence of Infection 
in Intensive Care (EPIIC) Study werd opgezet, de grootste prevalentie studie ooit verricht in 
heel Europa; teneinde deze leemte aan kennis over de ziekenhuis verworven IC infecties te 
corrigeren.
Hoofdstuk 2 beschrijft de resultaten van deze studie, uitgevoerd op 1417 Intensive Care’s in 
17 West-Europese landen, met 10.038 geïncludeerde IC-patienten. Van de totale IC populatie 
had op de studiedag 45% een of meerdere infecties, waarvan bijna de helft IC- verworven 
was (21% van het totaal). De meest opvallende resultaten waren de hoge prevalentie pneu-
monieen en lagere luchtweg infecties (tezamen een prevalentie van 63% van het totaal aan-
tal infectie typen), S. aureus (met een prevalentie van 30.1% de meest frequent geisoleerde 
pathogeen), P. aeruginosa (28.7%), en de Enterobacteriaceae (als groep) als de belangrijkste 
pathogenen, en de hoge prevalentie pathogenen met een resistentie tegen een of meerdere 
antimicrobiele middelen. Meest opmerkelijk was de resistentie voor methicilline in 60% van 
de S. aureus stammen, met een opzienbarend grote variatie in prevalentie tussen de diverse 
Europese landen. In zijn geheel was er een opvallende groei in de prevalentie van gram-posi-
tieve pathogenen en fungi. De belangrijkste risico factoren voor een IC-verworven infectie 
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waren, met name een langduriger IC verblijf (relatief risico (RR) voor infectie was 15.01 na een 
IC verblijf van 1 week, RR: 30.75 na 2 weken, en 76.06 na 3 weken), verder diverse invasieve 
interventies. De mortaliteit was hoog (16.8%), met een signifi cante correlatie tussen de prev-
alentie van IC-verworven infecties en de mortaliteit. Met name pneumonie, bacteriaemie 
en sepsis waren onafhankelijke risico factoren, geassocieerd met een verhoogde kans op 
mortaliteit.
Hoofdstuk 3
Hoofdstuk 3 beschrijft het probleem van de ziekenhuis verworven infecties op de intensive 
care in Nederland. Gegevens hiertoe, van 472 patienten, gelegen op 78 Nederlandse inten-
sive care’s, werden verkregen uit het totaal bestand van de EPIIC studie.
Van de patienten op de Nederlandse IC’s had 37% een infectie, waarvan 16% IC-verworven 
was. De belangrijkste infectie risico factoren waren: de duur van het IC verblijf (RR: 4.23, 99.37 
en 146.79 na een IC verblijf van respectievelijk 3-4 dagen, 1-2 weken en langer dan 3 weken), 
gecorreleerd aan de ernst van het ziektebeeld (orgaan falen) en een groter aantal medische 
interventies (zoals beademing en een blaascatheter). Voor een electief geopereerde patient 
was het risico op een IC-verworven infectie kleiner dan voor een patient zonder vooraf-
gaande operatie; na een spoedoperatie was dit infectie risico juist groter. Gedurende de fol-
low-up overleed 14% van de patienten. Patienten met een IC-verworven infectie hadden een 
hogere mortaliteit; de best prognostische waarde teneinde mortaliteit te voorspellen, had 
de APACHE II-Score (RR voor mortaliteit: 13 voor een APACHE score tussen 16-26, en RR>100 
voor een score>31).
Hoofdstuk 4
De risico analyse naar de IC verworven infecties op de Nederlandse intensive care’s wordt in 
hoofdstuk 4 vervolgd door een analyse betreff ende het type IC-verworven infecties. Pneu-
monie en lagere luchtweg infecties hadden tezamen de grootste prevalentie (63%), gevolgd 
door urineweg infecties (16%), sepsis (16%) en wondinfecties (11%). De meest frequent 
gekweekte pathogenen waren de gram-negatieve bacterien (92% in totaal), met name de 
Enterobacteriaceae (34% als groep) en Pseudomonas aeruginosa (30%), gevolgd door Staphy-
lococcus (37%), Enterococcus (20%) en verrassend: fungi (10%).
De meest voorgeschreven antibiotica waren: de cephalosporinen (30%), breed-spec-
trum penicillinen (17%), metronidazol (17%) en aminoglycosiden (13%). Geen infectie met 
Methicillin-Resistant Staphylococcus aureus (MRSA) werd op deze studiedag in Nederland 
waargenomen; dit in schril contrast tot vele andere Europese landen. Gentamicine-resis-
tente coagulase-negatieve Staphylococcus en ciprofl oxacine-resistente P. aeruginosa werden 
echter wel waargenomen. In de meeste Nederlandse ziekenhuizen maakten microbiologen, 
ziekenhuis hygienisten (84%) en infectie controle verpleegkundigen (51%) deel uit van het 
intensive care team.
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Hoofdstuk 5
Hoofdstuk 5 begint met een review van de huidige literatuur over chirurgische IC patienten 
en chirurgische infecties (surgical site infections SSI). De thans meest gebruikte risico score 
voor chirurgische infecties wordt beschreven: de NNIS surgical patient risk index score.
Vervolgens worden de resultaten van uitsluitend de chirurgische IC patienten uit de 
EPIIC studie behandeld. Meer dan 50% van de in totaal 10.038 IC patienten hadden chirur-
gie ondergaan in de maand voorafgaande aan de EPIIC studie. Abdominale chirurgie werd 
het meest frequent uitgevoerd, gevolgd door thorax- en hoofd/hals chirurgie. Van de 5066 
chirugische IC patienten ontwikkelde 21.3% een IC-verworven infectie. De belangrijkste in-
fectie risico factoren voor deze chirurgie patienten waren spoed- en multipele operaties (RR 
respectievelijk: 2.31 en 3.12); dientengevolge was trauma een signifi cante risico factor (RR: 
3.31). Het infectie risico was het hoogste voor de jongere IC patienten (leeftijd 20-40 jaar), 
en nam af met het stijgen van de leeftijd. Een langer IC verblijf verhoogde het relatieve risico 
voor infectie dramatisch, mede ten gevolge van een stijgend aantal invasieve procedures, 
een langere beademings periode (al dan niet in combinatie met een tracheostoma), meer 
diagnostische interventies en meerdere operaties. Meer dan de helft van de IC-verworven in-
fecties bij de chirurgische patienten was gelocaliseerd in de tractus respiratorius (prevalentie 
51.7%), terwijl het percentage wond infecties 8.7% betrof. Gram-negatieve bacterien hadden 
de hoogste prevalentie (47.1%), gevolgd door de gram-positieven (40.9%) en fungi (10.8%). 
De mortaliteit voor chirurgische patienten met een IC-verworven infectie was signifi cant 
hoger (26 versus 12%), de pathogenen welke geassocieerd waren met de hoogste mortaliteit 
waren de fungi (31.1%).
Hoofdstuk 6
Teneinde het risico voor IC patienten te evalueren op een infectie met methicilline-resistente 
Staphylococcus aureus (MRSA), in plaats van een infectie met methicilline-sensitieve S. aureus 
(MSSA), werden data betreff ende MRSA en MSSA prevalentie, risico factoren en mortaliteit 
verkregen uit het totale EPIIC bestand. In Europa als geheel was 60% van de S. aureus stam-
men resistent voor methicilline, met een grote variatie tussen de diverse Europese landen; 
de hoogste prevalentie MRSA werd gezien in Italie (81%) en Frankrijk (78%), terwijl in vele 
noorderlijke landen geen MRSA werd gezien.
De meest gerapporteerde infecties voor beide bacterien waren pneumonie (prevalentie 
van 52% voor MRSA en 61% voor MSSA) en lagere luchtweg infecties (respectievelijk 22% en 
17%). De belangrijkste risico factoren voor MRSA waren een langer IC-verblijf (RR: 4.07 bij een 
IC duur langer dan 3 weken), en een hogere APACHE-II score. Een MRSA infectie verlaagde 
de kans op overleving, met name indien gelocaliseerd in de lagere luchtwegen: het risico op 
mortaliteit was drie keer hoger voor patienten met een MRSA infectie dan voor diegenen met 
een MSSA infectie.
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Hoofdstuk 7
Fungi worden wel ‘the emerging pathogens’ genoemd, daar ze in de laatste decennia zijn 
veranderd van koloniserende, klinisch onbelangrijke a-pathogenen, in opkomende virulente 
pathogenen. Ook de EPIIC resultaten lieten deze groei van fungi zien, met een verrassend 
hoge infectie prevalentie van 17% fungi in de totale EPIIC groep, 10% in de Nederlandse 
subgroep en 11% in de chirurgische subgroep.
Hoofdstuk 7 geeft een overzicht van de huidige literatuur betreff ende schimmel infec-
ties en de epidemiologie. De belangrijkste problemen van candidiasis worden toegelicht: 
ten eerste, is er geen symptoom complex specifi ek voor de diagnose invasieve candidiasis. 
Ten tweede, ontbreekt het aan bruikbare,snelle diagnostische methoden; er is geen gouden 
standaard test beschikbaar. Ten derde, is er tot op heden geen ‘wonder’ antimycoticum be-
schikbaar, geschikt voor alle typen schimmel infecties. De morbiditeit en mortaliteit geas-
socieerd met invasieve Candida infecties is hoog, met gerapporteerde mortaliteits cijfers van 
40-80%. Het positieve eff ect van vroege, systemische prophylaxe of antimycotische therapie 
op empirische gronden op de uitkomst van IC patienten met candidiasis, wordt beschreven.
Hoofdstuk 8 richt zich op de identifi catie van hoog risico patienten, teneinde subgroepen 
voor prophylaxe te defi nieren. Hoofdstuk 9 richt zich op een nieuwe, snellere identifi catie 
methode van Candida spp.
Hoofdstuk 8
Hoofdstuk 8 beschrijft een retrospectieve, cohort studie naar het risico op isolatie van Candida 
spp. in peritoneaal vloeistof van chirurgische IC patienten met een peritonitis. Tevens werd 
gezocht naar onafhankelijke risico factoren. Van 2000-2003, honderdzeventien patienten met 
een peritonitis (bacterieel: n=69, Candida of mix Candida/bacterieel: n=48) werden geinclu-
deerd, op de intensive care van een tertiair, universiteits ziekenhuis. Statistisch signifi cante 
risico factoren voor Candida isolatie waren: pancreatitis ((p=0.0073), een APACHE II score >30 
(p=0.0019), antibiotica gebruik voor het begin van de peritonitis (p=0.040) en een perforatie 
in de onderste tractus digestivus (in beschermende zin, p=0.0342). In tegenstelling tot de 
mortaliteit (p=0.842), was de morbiditeit (gedefi nieerd als de duur van het IC verblijf ) in de 
Candida groep signifi cant hoger dan in de bacteriele groep (27 versus 8 dagen, p=0.001). In 
tegenstelling tot andere IC-verworven infecties, treedt Candida isolatie voornamelijk in het 
begin van het IC verblijf op.
Naar aanleiding van deze resultaten concludeerden wij dat: ernstig zieke peritonitis pati-
enten met een hoge APACHE score at risk zijn voor isolatie van Candida species in peritoneaal 
vloeistof, met speciale aandacht voor pancreatitis patienten. In deze patienten zouden anti-
mycotica op empirische gronden in een vroeg stadium geadviseerd worden.
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Hoofdstuk 9
In hoofdstuk 9, een prospectieve studie wordt beschreven, welke Raman spectroscopie eval-
ueert voor de identifi catie van klinisch relevante Candida species in peritonitis patienten. Een 
Raman database werd ontwikkeld met behulp van gemeten spectra van 93 referentie stam-
men van tien verschillende Candida spp. Vervolgens werden klinische kweken verzameld via 
de afdeling heelkunde en de intensive care unit, van een tertiair universiteits ziekenhuis. In 
totaal werden 88 peritonitis kweken geincludeerd, van 45 patienten met een primaire, se-
cundaire of tertiaire peritontis, waarvan er 31 positief bleken voor Candida. Kweken werden 
ingezet op een selectief Sabouraud medium, dat gentamicine bevat teneinde bacteriele 
groei te onderdrukken. Conventionele identifi catie startte met een chromogeen medium 
voor de zogeheten presumptive identifi catie, gevolgd door het gebruik van het Vitek 2 
systeem voor de defi nitieve identifi catie (een uiteindelijke vereiste turn-around time van 48-
96 uur). Raman metingen werden verricht op overnacht kweken, eveneens op Sabouraud-
gentamicine medium. De uitvoerbaarheid, de sensitiviteit en turn-around time van deze 
Raman techniek werd geanalyseerd, vergeleken met de conventionele identifi catie methode 
als referentie. Met behulp van multivariaat statistische analyse bleek Raman spectroscopie 
een voorspellende waarde van 90% te hebben, waarmee Raman spectroscopie een accuraat 
en snel (12-24 uur) alternatief vormt voor de identifi catie van Candida species in peritonitis 
patienten. De verkorte turn-around time zou van groot klinisch belang kunnen zijn voor de 
behandeling van kritisch zieke IC patienten met een invasieve candidiasis.
Chapter 10
Hoofdstuk 10 probeert de vraag te beantwoorden, of er een vervolg bestaat op de EPIIC 
studie, met in Europees samenwerkings verband het documenteren van infectie gegevens, 
en het formeren van infectie controle programma’s.
Nieuwe uitdagingen in de infectie controle in het heden dan wel de (nabije) toekomst wor-
den bediscussieerd, zoals: een Europees infectie controle netwerk, nieuwe typen catheters 
of interventies, nieuwe typen chirurgie (minimaal invasieve chirurgie, fast-track chirurgie, en 
poliklinische dagbehandeling), nieuwe typen medicijnen, en een verdere stimulering van de 
brede bewustwording van het infectie probleem.
Concluderend, de belangrijkste risico factoren voor ziekenhuis verworven infecties op de 
intensive care unit zijn:
• Wees gewaarschuwd voor een langere verblijfsduur op de intensive care, hetgeen het 
relatieve risico voor infecties dramatisch verhoogt. Evenzo stijgt het risico op infecties 
met resistente pathogenen, zoals MRSA, met een langer IC verblijf.
• Wees gewaarschuwd voor pneumonieen en lagere luchtweg infecties. Voorzorgsmaatre-
gelen, zowel pre-, per- als post-operatief zijn noodzakelijk teneinde de kans op dit type 
infectie voor de chirurgie patient te verlagen.
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• Wees gewaarschuwd voor gram-positieve bacterien. De gram-negatieve bacterien zijn 
niet langer de meest voorkomende en meest virulente pathogenen van ziekenhuis infec-
ties. Gram-positieve bacterien, zoals de coagulase-negatieve Staphylococcus zijn meer 
dan slechts niet signifi cante contaminanten.
• Wees gewaarschuwd voor fungi. Fungi zijn veranderd van koloniserende, klinisch on-
belangrijke a-pathogenen, in opkomende virulente pathogenen met een hoge geasso-
cieerde morbiditeit en mortaliteit.
• Wees gewaarschuwd voor spoed- en multipele operaties. Zo ook is trauma een signifi -
cante risicofactor voor infecties in chirurgische IC patienten.
• Wees gewaarschuwd voor hoge APACHE scores bij opname op de intensive care.
• Wees gewaarschuwd voor het groeiende resistentie probleem van de IC pathogenen voor 
de diverse antibiotica. Er bestaat een correlatie tussen antibiotica gebruik en resistentie 
vorming tegen ditzelfde antibioticum, hetgeen een strikt antibioticum protocol alleen 
nog maar noodzakelijker maakt.
• Wees gewaarschuwd voor catheters, invasieve procedures en diagnostische interven-
ties, welke ieder afzonderlijk, onafhankelijke risico factoren vormen voor IC-verworven 
infecties. Een beleid waarin iedere catheter zo spoedig mogelijk wordt verwijderd wordt 
gepropageerd.
APPENDICES
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PATIENT INFORMATION
1  Date of birth
2  Sex
3  Date of current admission to hospital (any)
4  Date of admission to your Unit
5  Has the patient undergone major surgery (ie requiring general anaesthesia) on one or 
more occasions since 29.3.92? 
6  If you answered Yes to Question 5, please indicate the date of surgery, the site of surgery 
(see Codes below) and the type of procedure-elective or emergency.
CODES: SITE OF SURGERY
01 abdominal
02 cardiothoracic
03 major head and/or neck surgery
04 vascular
05 gynaecological
06 genito-urinary
07 neurological
08 orthopaedic
09 transplant
10 other
PATIENT STATUS ON ADMISSION TO THE ICU
7 Was the patient admitted for postsurgical control/surveillance?
 If Yes, please go to Question 9.
 If No, please complete Question 8.
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8  If the patient was admitted for any reason other than postsurgical surveillance, please 
indicate up to three organ systems (in most-, next most- and third most important), which 
were the main reason for admission to the ICU, according to the items below:
 • Central nervous system
 • Cardiovascular
 • Respiratory
 • Gastrointestinal
 • Hepatic
 • Renal
 • Genito-urinary
 • Musculoskeletal
 • Haematological
 • Metabolic / endocrine
 • Skin / burns
 • Other
9 Which of the following conditions were present on admission?
 (Please refer to Defi nitions below.)
 • Cardiovasculair failure
 • Respiratory
 • Renal failure
. • Haematological failure
 • Neurological failure
 • Abnormality in liver function
 • Multiple trauma
  with head injury
  without head injury
 • Cancer
 • Diabetes
 • Chronic respiratory insuffi  ciency
 • Impaired respiratory refl ex
 • AIDS/HIV-positive
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DEFINITIONS: ORGAN FAILURE
• Cardiovascular failure
 Presence of one or more of the following:
 a. heart rate < 55/min
 b. mean arterial blood pressure < 50 mmHg
 c. occurrence of venticular tachycardia and/or ventricular fi brillation
 d. serum pH < 7.25 with a PaCO
2
 of <50 mmHg
• Respiratory failure
 Presence of one or more of the following:
 a. respiratory rate<6/min or >49/min
 b. PaCO
2
>50 mmHg
 c. (A-a)DO
2
>350 mmHg
  (A-a)DO
2 
= 713 FiO
2 
-PaCO
2 
-PaO
2
 d. dependent on ventilator on fourth day of organ system failure
• Renal failure
 Presence of one or more of the following:
 a. urine output < 480 ml/24h or < 160 ml/8h
 b. serum BUN >100 mg/100 ml
 c. serum creatinine > 3.5 mg/100 ml (>375μmol/l)
• Haematological failure
 a. WBC<1001/mm3
 b. platelets < 20001/mm3
 c. haematocrit < 21%
• Neurological failure
 When Glasgow Coma Score is <9 (For details of score, see question 11)
• Abnormality in liver function
 Defi ned by:
 a. a raised bilirubin >200μmol/l (>12mg/100ml)
 and/or
 b. alkaline phosphatase/aspartate transaminase > 3 times normal
• Chronic respiratory insuffi  ciency
  Chronic restrictive, obstructive or vascular disease resulting in severe exercise restriction, 
ie unable to climb stairs or to perform household duties; documented chronic hypoxia, 
hypercapnia, secondary polycythaemia, severe pulmonary hypertension (>40mmHg); 
ventilator dependency.
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• Impaired respiratory refl ex
  Airways refl exes may be considered impaired when spontaneous breathing, glottic 
closure and cough refl exes were impaired or absent on admission and/or there was no 
defence reaction to endotracheal intubation or pharyngeal suctioning.
CLINICAL STATUS OF THIS PATIENT ON ADMISSION TO THE ICU
10 Was neurological injury present on admission.
11  If you answered Yes to Question 10, please record the best values for the Glasgow Coma 
Score in each case, in the boxes provided in the following table.
Eyes Open Score Best Verbal Response Score Best Motor Response Score
Spontaneously
On spoken command
To pain
No response
4
3
2
1
Orientated and adequate
Disorientated
Inadequate words
Incomprehensive sounds
No response
If patient is intubated, use
clinical judgement for verbal
response:
Patient appears able to 
converse
Patient’s ability to converse in
question
Patient generally unresponsive
5
4
3
2
1
5
3
1
Obeys spoken command
To painful stimulus:
Localised pain
Flexion withdrawel
Flexion abnormal
Extension
No response
Movement without any control
6
5
4
3
2
1
4
12  The following data will be used to calculate an admission APACHE II Score for this patient. 
This information is important. Please record all variables. For each variable take the 
worst value over the fi rst 24 hours on the ICU, eg the highest tempreature. (NB: If any 
item of information is not available please indicate by writing N/A.)
Acute Physiology Variable
• Temperature-rectal (ºC)
• Mean arterial pressure (mmHg)
=
2 x diastolic BP + systolic BP
3
• Heart rate (beats/minute)
• Respiratory rate (breaths/minute)
  Spontaneous
  Ventilated or CPAP rate
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• Oxygenation: (A-a)DO
2
 or PaO
2
 i) If FiO
2
 >49% record (A-a)DO
2
  kPa
  mmHg
• ii) If FiO
2
 < 50% record PaO
2
 kPa
 mmHg
• Arterial pH
• Serum HCO–
3
 (venous mmol/l or mEq/l). (Not preferred, use if no arterial blood gases)
• Serum sodium (mmol/l or mEq/l)
• Serum potassium (mmol/l or mEq/l)
• Serum creatinine (mmol/l) and (mg/l)
• Haematocrit (%)
• White cell count (total/mm3) (in 1000s)
Chronic Health Points
i)  Does the patient have a history of severe organ system insuffi  ciency prior to this hospital 
admission?
 (Please refer to Defi nitions below)
ii) Was the patient immunocompromised? (Please refer to Defi nitions below).
 If Yes, please indicate cause:
 • immunosuppressive therapy
 • chemotherapy
 • radiotherapy
 • long-term or recent high-dose steroids
 • diseaese-related
iii) Please indicate if the patient is:
 • non-operative or emergency post-operative
 • elective post-operative
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DEFINITIONS: ORGAN SYSTEM INSUFFICIENCY
Organ insuffi  ciency or immunocompromised state must have been evident prior to this hos-
pital admission and conform to the following criteria:
• Liver
  Biopsy-proven cirrhosis and documented portal hypertension, episodes of past upper 
gastrointestinal bleeding attributed to portal hypertension, or prior episodes of hepatic 
failure, encephalopathy, coma.
• Cardiovascular
 New York Heart Association Class IV
• Respiratory
  Chronic restrictive, obstructive or vascular disease resulting in severe exercise restriction, 
ie unable to climb stairs or perform household duties; documented chronic hypoxia, 
hypercapnia, secondary polycythaemia, severe pulmonary hypertension (>40mmHg); 
ventilator dependency.
• Renal
 Receiving chronic dialysis
Immunocompromised
The patient has received therapy that supresses resistance to infection, eg immunosuppres-
sion, chemotherapy, radiation, long-term or recent high-dose steroids; or has a disease that is 
suffi  ciently advanced to suppress resistance to infection, eg leukaemia, lymphoma, AIDS
PATIENT STATUS DURING THE WEEK 23.4.92 TO 29.4.92
13 Has the patient had any of the following therapeutic interventions in the last week?
 • iv catheter
 • CVP line
 • Arterial catheter
 • PA catheter (Swan Ganz)
 • Urinary catheter
 • Chest tube
 • Wound drain
 • Intracranial pressure monitoring
 • Peritoneal dialysis
 • Haemodialysis
 • Atrial and/or ventricular pacing
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 • Nasotracheal intubation
 • Orotracheal intubation
 • Tracheostomy
 • Assisted ventilation
 • Central iv hyperalimentation
 • Peripheral iv hyperalimentation
14 In the last week, has the patient received any of the following:
 • long-term or high-dose steroids?
 • cancer chemotherapy?
 • other immunosuppressive drugs?
 • radiotherapy?
 • sedation?
15 In the last week, has the patient received any of the following anti-ulcer agents?
 • antacids
 • H
2
-antagonists
 • sucralfate
 • omeprazole
 • other
16 In the last week, has the patient received:
 • selective digestive decontamination?
 •  prophylactic antibiotics given for no longer than 48 hours to cover the risk of infec-
tion related to a clinical procedure?
17 Is the patient receiving selective digestive decontamination today 29.4.92?
18 Is the patient receiving antibiotics for prophylaxis today 29.4.92?
19 If Yes, please specify the indication for prophylaxis:
 • presurgical
 • immediate post-operative
 • cover for invasive procedure, eg CVP catheterisation
 • other
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PATIENT STATUS TODAY
20 For each variable please record the worst value from midnight to midnight.
 • Temperature – rectal (°C)
 • Mean arterial pressure (mmHg)
=
2 x diastolic BP + systolic BP
3
 • Heart rate (beats/minute)
 • Arterial pH
 • Urine output (ml/24h)
21  Is the patient currently receiving antibiotics for treatment or prophylaxis of infection 
today?
22  If Yes, which antibiotics are the patient taking? Please also indicate the date on which the 
antibiotic was started and whether it was prescribed for treatment or prophylaxis.
 • Cephalosporin
  cefazolin
  cefuroxime
  ceftriaxone
  ceftazidime
  cefotaxime
  other cephalosporin
 • Aminoglycoside
  gentamicin
  tobramycin
  amikacin
  netilmicin
  other aminoglycoside
 • Quinolone
  ciprofl oxacin
  ofl oxacin
  perfl oxacin
  other quinolone
 • Penicillin
  benzylpenicillin
  fl ucloxacillin
  cloxacillin
  other penicillin
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 • Macrolide
  erythromycin
  other macrolide
 • Broad-spectrum penicillin
  ampicillin or amoxycillin
  amoxycillin/clavulanate
  mezlocillin
  piperacillin
  ticarcillin/clavulanate
  carbenicillin
  other broad-spectrum penicillin
 • Imipenem
 • Glycopeptide
  vancomycin
  teicoplanin
 • Metronidazole
 • Aztreonam
 • Other
23  Please indicate if any of the following are being prescribed for treatment or prophylaxis 
today:
 • Antifungal
  amphotericin
  fl ucytosine
  other
 • Antiviral
  acyclovir
  ganciclovir
  other
24 During this admission, has the patient received:
 • monoclonal antibody against endotoxin?
 • any other drug under clinical trial?
25  Is this patient infected? (Please indicate ‘Yes’ if there is active infection, suspected 
infection or the patient is receiving antibiotics for the TREATMENT OF INFECTION.)
26  Please indicate infection diagnosis (enter up to four infections in order of severity). 
(Please refer to Codes and Defi nitions below)
166
A
p
p
en
di
ce
s
CODES: INFECTION DIAGNOSIS
The following Codes are based on CDC Defi nitions for nosocomial infections. (see below).
A1 Incisional surgical wound infection
A2 Deep surgical wound infection
B1 Laboratory-confi rmed primary bloodstream infection
B2 Clinical sepsis
C1 Pneumonia
D1 Symptomatic urinary tract infection
D2 Asymptomatic bacteriuria
D3 Other infection of the urinary tract
E1 Osteomyelitis
E2 Joint or bursa infection
E3 Vertebral disc space infection
F1 Arterial or venous infection
F2 Endocarditis
F3 Myocarditis or pericarditis
F4 Mediastinitis
G1 Intracranial infection
G2 Meningitis or ventriculitis
G3 Spinal abscess without meningitis
H1 Conjunctivitis
H2 Other eye infections
H3 Otitis externa
H4 Otitis media
H5 Otitis interna
H6 Mastoiditis
H7 Oral cavity infection
H8 Sinusitis
H9 Upper respiratory tract infection
I1 Gastroenteritis
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I2 Hepatitis
I3 Gastrointestinal (GI) tract infection
I4 Intra-abdominal infection
J1 Bronchitis, tracheobronchitis, bronchiolitis, tracheitis without evidence of pneumonia
J2 Other infections of the lower respiratory tract
K1 Endometritis
K2 Episotomy site infection
K3 Vaginal cuff  infection
K4 Other infections of the male or female reproductive tract
L1 Skin infection
L2 Soft-tissue infection
L3 Decubitus ulcer infection
L4 Burn infection
L5 Breast abscess or mastitis
M1 Systemic infection
CDC DEFINITIONS
Surgical Wound Infection
A1 Incisional surgical wound infection. Infection at incision site within 30 days of surgery, 
and involves skin, subcutaneous tissue or muscle above the fascial layer, and any of the fol-
lowing:
 - purulent darinage from incision, or drain located above fascial layer
 - organism isolated from fl uid culture from wound closed primarily
 - surgeon deliberately opens wound, unless wound site culture-negative
 - surgeon’s or physican’s diagnosis
A2 Deep surgical wound infection. Infection at the site of the incision within 30 days of 
surgery (within 1 year if implant is left in situ), and infection appears related to surgery, and 
involves tissues or spaces at or beneath fascial layer, and any of the following:
 - purulent darinage from drain beneath fascial layer
 -  wound spontaneously dehisces or is deliberately opened by surgeon when patient has 
fever (>38°C) and/or localized pain or tenderness unless culture-negative
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 -  an abscess or other sign of infection seen on direct examination, during surgery, or on 
histopathological examination
 - surgeon’s diagnosis
Primary Bloodstream Infection
B1 Laboratory-confi rmed primary bloodstream infection must meet one of the following 
criteria:
1.  Recognised pathogen isolated from blood culture and pathogen is not related to infec-
tion at another site
2. One of the following: fever (>38°C), chills or hypotension and any of the following
 -  common skin contaminant isolated from two blood cultures drawn on separate occa-
sions and not related to infection at another site
 -  common skin contaminant isolated from blood culture from patient with intravascular 
access device and physician institutes appropriate antimicrobial therapy
 - positive antigen blood test and pathogen is not related to infection at another site.
B2 Clinical sepsis must meet one of the following criteria:
fever (>38° C), hypotension (systolic pressure <91 mmHg) or oliguria (.20 ml/h) with no other 
recognised cause and all of the following:
- blood culture not performed or no organisms or antigen detected in blood
- no apparent infection at another site
- physician institites appropriate antimicrobial therapy for sepsis.
Pneumonia
C1 Pneumonia must meet one of the following criteria:
1.  Rales or dullness to percussion on physical examination of the chest and any of the fol-
lowing:
 - new onset of purulent sputum or change in character of sputum
 - organism isolated from blood culture
 - pathogen isolated from transtracheal aspirate, bronchial brushing or biopsy specimen.
2.  Chest radiographic examination shows new or progressive infi ltrate, consolidation, cavi-
tation or pleural eff usion and any of the following:
 - new onset of purulent sputum or change in character of sputum
 - organism isolated from blood culture
 -  isolation of pathogen from specimen obtained by transtracheal aspirate, bronchial 
brushing or biopsy
 - isolation of virus or detection of viral antigen in respiratory secretions
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 -  diagnostic single antibody titre (IgM) or four-fold increase in paired serum samples (IgG) 
for pathogen
 - histopathological evidence of pneumonia.
Urinary Tract Infection
D1 Symptomatic urinary tract infection must meet one of the following criteria:
1.  One of the following: fever (>38° C), urgency, frequency, dysuria or suprapubic tender-
ness and a urine culture of 105 or more colonies/ml urine with no more than two species 
of organism.
2.  Two of the following: fever (>38°C), urgency, frequency, dysuria or suprapubic tenderness 
and any of the following:
 - dipstick test positive for leucocyte esterase and/or nitrate
 -  pyuria (10 or more white blood cells (WBC)/ml3 or 3 or more WBC/high power fi eld of 
unspun urine)
 - organisms seen on Gram stain of unspun urine
 -  two urine cultures with repeated isolation of the same uropathogen with 102 or more 
colonies/ml urine in non-voided specimens
 -  urine culture with 105 or less colonies/ml urine of single uropathogen in patient being 
treated with appropriate antimicrobal therapy
 - physician’s diagnosis
 - physician institutes appropriate antimicrobial therapy.
D2 Asymptomatic bacteriuria must meet either of the following criteria:
1.  An indwelling urinary catheter is present within 7 days before urine culture, and patient 
has no longer fever (<38°C) or urinary symptoms, and has urine culture of 105 or more 
organisms/ml with no more than two species of organisms.
2.  No indwelling urinary catheter present within 7 days before the fi rst of two urine cultures 
with 105 or more organisms/ml urine of the same organism and no more than two species 
and patient has no fever or urinary symptoms.
D3 Other infections of the urinary tract (kidney, ureter bladder, urethra, etc) must meet 
one of the following criteria:
1. Organisms isolated from culture of fl uid (not urine) or tissue from aff ected site.
2.  An abscess or other evidence of infection seen on direct examination, during surgery, or 
by histopathological examination.
3.  Two of the following: fever (>38°C), localised pain, or tenderness at site and any of the 
following:
 - purulent drainage from aff ected site
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 - organism isolated from blood culture
 - radiographic evidence of infection
 - physician’s diagnosis
 - physician institutes appropriate antimicrobial therapy.
27 Is the infection
 • active (ie clinical symptoms are present)?
 • no longer clinically active but under treatment with antibiotics?
 • suspected?
28 Is the infection
 • localised?
 • generalised (signs of sepsis)?
29 On what date was this infection diagnosed (day/month/year)?
30 In your judgement, is this infection (Please refer to Defi nitions below)
 • ICU-acquired?
 • hospital-acquired?
 • community-acquired?
DEFINITIONS OF INFECTION
ICU-acquired
An infection active or under active treatment on 29.4.92 but not clinically manifest or incu-
bating at the time of admission to the ICU
Hospital-acquired
An infection manifest or incubating on admission to the ICU and deemed to be related to the 
preceding hospital admission (same or other hospital)
Community-acquired
An infection manifest or incubating on admission to the hospital or ICU
31 Are bacteriological culture results available for this infection?
32  If Yes, please enter the organisms considered to be causal. Enter up to three. (See Codes 
below)
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CODES; ORGANISMS
Gram-positive
ENT Enterococci
PNE Pneumococci
OST Other Streptococcus spp.
SAN Staphylococcus aureus
SCN Other Staphylococcus spp.
OGP Other Gram-positive
Gram-negative
ENS Enterobacter spp.
CIS  Citrobacter spp.
ECO Escherichia coli
PRM Proteus mirabilis
PRI  Other Proteus spp.
MOS Morganella spp.
PRS Providencia spp.
SES Serratia spp.
ACS Acinetobacter spp.
PSA Pseudomonas aeruginosa
PSS Other Pseunomonas spp.
HEI  Haemophilus infl uenzae
LES  Legionella spp.
BRC Branhamella catarrhalis
KLS Klebsiella spp.
OGN Other Gram-negative
Anaerobes
BAF Bacteroides fragilis
CLS Clostridium spp.
OTB Other anaerobes
Viruses
CMV Cytomegalovirus
HSV Herpesvirus
HIV  Human immunodefi ciency virus
HEP Viral hepatitis
OTV Other virus
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FUN Fungi
PRO Protozoa
33 If Staphylococcus aureus was isolated, was it methicillin-resistant or oxaccillin-resistant?
  If coagulase-negative staphylococci were isolated, were they resistant to any of the fol-
lowing?
 • Methcillin/oxacillin
 • Cefotaxime
 • Gentamicin
 • Vancomycin
 • Teicoplanin
 If Pseudomonas aeruginosa was isolated was it resistant to any of the following?
 • Gentamicin
 • Imepenem
 • Ceftazidime
 • Ciprofl oxacin
 • A ureidopenicillin, eg azlocillin/piperacillin
34  If no organism has been isolated, what pathogen is considered responsible for the infec-
tion?
 • Gram-positive bacteria
 • Gram-negative bacteria
 • Mixed bacterial infection
 • An anaerobe
 • Fungus
 • Virus
 • Protozoa
 • Impossible to say
35 If no pathogens have been identifi ed, are culture results awaited?
36 Have any specimens for culture been taken today 29.4.92?
 If the answer to either question 35 or 36 is YES go to Bacteriological results below.
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PATIENT OUTCOME
Section 1
1 Date of birth (day/month/year)
2 Sex
Section 2
3 Was the patient discharged
 • dead? Date of death (day/month/year)
 • alive? Date of discharge (day/month/year)
For those patients discharged from the unit
4 Please indicate, in your judgement, the prognosis:
 • likely to survive 1 week
 • likely to survive 1 month
 • likely to survive 1-6 months
 • likely to survive more than 6 months
Bacteriological results
Bacteriological results from specimens collected on 29.04.92 or before 29.04.92
but not available on The EPIIC Study day
Please complete this section by 06.05.92
Please enter the bacteriological results for specimens collected for the infections recorded in 
Question 26 to 36. Codes for the specimens are supplied below.
Include date of collection and pathogen (enter up to 3 pathogens see codes question 32).
Codes
X 0 Blood
X 1 iv catheter
X 2 Sputum aspirate
X 3 Tracheal aspirate
X 4 BAL or protected distal specimen
X 5 Urine – voided sample
X 6 Urine – catheter sample
X 7 Skin or wound swab
X 8 Drain fl uid (not nasogastric tube)
X 9 Stool culture
“Sentiment” (wijs Margherita, Marco Borsato)
In de verte spreekt een stem
Die ik herken van vroeger tijden
Nooit veel woorden, laat staan zinnen
Over al jouw rijl en zeilen
En dan voel ik weer die afstand
Van klein meisje tot opleider
Die mij altijd bij zal blijven
Ook al groeit het meisje verder.
In een waas hoor ik die stem weer
Als je eindelijk kreeg te horen
‘het gaat goed zo, ga zo verder,
je gedrag is naar behoren’
En al luisterend naar die woorden
Ging het weerwoord op in wolken
Murw geslagen, niets te vragen
Een verpletterende man.
Kille woorden, oppervlakkig
Maar inmiddels weet ik beter
Een strak masker als fasçade
Wat de afstand safe verzekerd
Maar nu vele jaren verder
Komt de ware aard naar boven
Weinig woorden, laat staan zinnen
Maar een hart dat doet geloven;
Het klein mens hoog op die sokkel
Is meer mens dan Fries gebleken
Met een hart te groot voor woorden
Werd ook jij als mens bekeken
Nog bezorgder dan een vader
Nam hij jou onder zijn hoede
Sust jou kinders in zijn armen
Wie had dat kunnen vermoeden?
Het is net of iemand anders
Achter weinig woorden schuilgaat
Waarmee het beeld uit jonger jaren
Langzaam in luchtledig opgaat
Dat is onze Kieje Bruining
Onze man, voor altijd-eeuwig
Niemand kan daar nog aan tippen
Want hij is gewoon van goud.
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DANKWOORD
Prof.dr. H.A. Bruining, beste Kieje, ik ben jou en Evelien ongeloofl ijk veel dank verschuldigd. 
Dank voor mijn opleiding uberhaupt, maar ook voor dit boekje, voor de vele gastvrije, culi-
naire onthalen in Nederland dan wel Frankrijk, en vooral voor jou oneindige engelen geduld 
met mij (weer een dikke buik, dus boekje weer een jaartje verder); een eigenschap die weinig 
mensen jou zullen toedichten. Ik weet beter. Eens heb ik mijn dank en waardering verwoord 
in de tekst van een lied, hetgeen ik in ons ‘Brownies Girls’ cabaret -ter ere van je emeritaat- 
heb gezongen. De tekst heb ik geschreven in de auto, staand op de parkeerplaats van het 
Leyenburg ziekenhuis, alwaar ik te vroeg was gearriveerd voor een sollicitatie- gesprek. Zoals 
altijd: onder stress presteert men het beste. Beter kan ik het niet zeggen, vandaar een herha-
ling van deze tekst “Sentiment”.
 
De andere leden van mijn promotiecommissie: Prof.dr. H.W. Tilanus, Prof.drs. J.H.P. Wilson, 
Prof.dr. H.A. Verbrugh, Prof.dr. H.J. Bonjer, Dr. H.Ph. Endtz, en Dr.Ir. G.J. Puppels dank ik allen 
voor het beoordelen van het manuscript, voor de interesse in de infectieuze problematiek en 
voor de bereidheid zitting te willen nemen achter de tafel in mijn Commissie.
Prof.dr. H.W. Tilanus, beste Huug, het was een waar genoegen om jou als CHIVO-opleider te 
hebben. Ik ben er trots op dat ik uit jouw ‘symphonie der handen’ de buismaag onderwezen 
heb gekregen. Jouw nimmer stuitende energie, optimisme en humor maken het werk tot een 
feest. Ook ’s nachts om 4 uur kom je nog met een grap op de OK binnen, kijkt naar de toch 
wel essentieel doorgenomen structuur, mompelt hooguit ‘niet zo mooi’, zet alles met grote 
steken weer aan elkaar, en verdwijnt weer met een zwaai. Waren we allemaal maar zo.
Prof.dr. H.J. Bonjer, beste Jaap, dank voor je eeuwige enthousiasme waarmee je iedereen voor 
je weet te winnen, en je nimmer afl atende optimisme; voor alles bestaat een oplossing, zo 
niet, dan toch. Canada is een onbegrensd gedreven mens, chirurg, laparoscopist maar vooral 
ook group-builder rijker. Zij wel.
Dr. H.Ph. Endtz, beste Hubert, dank voor je microbiologische sturing aan van die snijdende 
microbiele leken. Als de chaos daar is weet jij zonder probleem orde in de wereld der microben 
te scheppen door vlijmscherpe correcties in protocollen, dan wel geschriften te plaatsen.
Dr.Ir. G.J. Puppels, beste Gerwin, dank voor je begeleiding aan zo’n a-technische, witte jassen, 
aanvankelijk Raman-barbaar. Je hebt een ongekend nuchtere en snelle kijk op alles, waar-
door ieder probleem inclusief het antwoord binnen 3 seconden in slechts 3 woorden wordt 
samengevat. Heb je soms Bruining als opleider gehad?
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Dr. N.D. Bouvy, beste Nicole, veel hebben we gemeen: onze goede, oude RVSV tijd, de Ika-
ziaanse bakermat, de liefde voor het chirurgenvak die gedeeld moet worden met de liefde 
voor de kleine guppies thuis, het gezamenlijke gepuf op de dikke buiken gym, en de voor-
liefde voor de wat genuanceerdere trocar-chirurgie. Samen zijn we uitgevlogen (wanted, but 
gone) uit Rotterdam: jij naar je miami-vice bunker in de Limburgsche heuvels, ik naar mijn 
hutje in de duinen. Dank voor deze mooie tijden, ik ben er trots op dat jij je tussen de groten 
der aarde in de wereld der laparoscopie begeeft, en ik ben er trots op dat je mijn paranimf 
wilt zijn.
Drs. G.P. Gerritsen, beste Pieter, mijn Tilburgse room-mate en steun en toeverlaat. Beiden heb-
ben we onze roots in Rotterdam liggen, hetgeen toch een soort gelijkgestemde sociale radio-
frequentie geeft. Je bent een ongekend breed (sorry; fi guurlijk, of zeg je dan juist letterlijk?) 
chirurg van de oude stempel, met een honger naar moderne, chirurgische ontwikkelingen 
als van een jonge hond. Het is goed om de Tilburgse horizon steeds verder te verleggen, en 
onze praktijk nog mooier te maken. Dank dat je mij, ook als paranimf, terzijde wilt staan.
Beste Oene van Meer en Pleunie Rood, dank voor al jullie monnikenwerk. Dat het een data-
base met 136.456 gegevens zou worden hebben we gelukkig van te voren niet geweten. Vele 
operatieverslagen, APACHE Score berekeningen en onuitspreekbare Candida namen zijn in 
weekenden en nachten de revue gepasseerd. Maar uiteindelijk mag het resultaat daar zijn.
Dr. W.C.J. Hop, beste Wim, je bent een magistraal goochelaar met cijfers, hetgeen in nettere 
bewoordingen ook ‘statisticus’ heet te wezen. Achteraf als je thuis op je gemak de stapels 
computer uitdraaien met de aanvankelijk volledig onbegrijpelijke tabellen, berekeningen 
en curves gaat bekijken, blijkt het wel mee te vallen met het gegoochel, en blijken er nog 
logische en causale verbanden te bestaan ook. Sorry, maar die causale gedachtengang gaat 
bij jou miraculeus veel sneller. Dank voor al dat gereken.
De Raman groep: Kees, Tom, Peter, Rolf, Senada, Annieke, Bas, Sweder en natuurlijk de grote 
baas Gerwin. Jullie zijn als een soort trein, nee een TGV, waarbij ik een stuk hard heb mogen 
meerijden, om vervolgens duizelend bij het volgende station uit te stappen. Dank voor dit 
en voor de enorme lol; die lachsalvo’s van Rolf hoor ik nu nog over de gang. Kees verdient 
een extra, heeeeel groot bedankje; dat onbegrensde geduld waarmee jij telkenmale de fi lo-
sofi eën achter optiek, spectroscopie en moleculen probeerde uit te leggen aan deze witte jas 
(‘dit is een appel en dit is een ei’). Tenslotte begreep ik het (op appel en ei niveau) nog ook. We 
zouden veel meer als witte jassen en techneuten moeten samen werken, daar zouden nog 
mooie en bruikbare diagnostische ontwikkelingen uit kunnen voortvloeien. 
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Dr. H.F. Veen, beste Herman, dank voor jou chirurgische hoeksteen. Wat was het ook al weer 
die allereerste steen? Ik geloof een schouder botbiopt. Ik, volledig ongeremd door welke 
chirurgische ervaring dan ook, eager op een operatie. Jij, de kersverse opleider die de jongste 
oogappel wel door de ingreep zou sturen, volledig stupefait door zoveel niet te staven voort-
varendheid. We hebben in de jaren erna nog mooie dingen samen gedaan, ik heb veel van je 
geleerd. Je bent een geboren opleider; onder jou toeziend oog lijkt het of iedere ingreep zo 
simpel is als een lipoompje.
Chirurgen en assistenten heelkunde uit Rotterdam, dank voor de geweldige Rotterdam tijd 
die ik met jullie heb mogen beleven. “We” (sorry Tilburg) zijn sociaal en chirurgisch een heel 
bijzondere stad, beter in Nederland heb je niet. Ik zal altijd trots blijven dat ik een zogeheten 
chirurgische Rotterdammer ben. Proost op Rotterdam!
Mijn Tilburgse maten: Stefan Brenninkmeijer, Ron van Doorn, Marnix de Fijter, Pieter Gerritsen, 
Fred Jacobs, Steef Kranendonk, Eddy Leerkotte, Diederick Wouters en Stefan van Zutphen. 
Dank dat jullie mij het voordeel van de twijfel hebben durven geven. Het alles innemende 
chirurgen bestaan combineren met een thuisfront klinkt ongeloofwaardig, doch is dit niet. 
Tilburg is vooruitstrevender gebleken dan de rest van conservatief, angstig, chirurgisch Ne-
derland. We hebben veel plannen met z’n allen voor de toekomst; chirurgisch Tilburg wordt 
steeds fraaier.
Dr. I.G. Schoots, beste Ivo, dank voor je spontaan en genereuze aanbod om de afronding 
van mijn boekje computertechnisch te ondersteunen. Als een door de AMC-wol geverfde 
fi guren&tabellen producerende pdf-engel kwam je uit de Tilburgse hemel vallen.
Beste Angelique Gilles, als Ivo de Tilburgse-computer-engel is, ben jij de Tilburgse-engelse- 
spelling-controller-engel uit diezelfde hemel. Mijn hemel wat een hoeveelheid taal- en spel-
fouten weet jij nog te corrigeren. Dank daarvoor.
Beste Irene van Nuland, dank voor je fabuleuze kaftontwerp, en de sturing van mijn kinders 
daarbij. Het moet een Wolkers achtig tafereel zijn geweest: een tafel vol met rondkruipend, 
in de tuin gevangen ongedierte, hetgeen als ‘infectieus’ tekenmodel voor mijn kinders moest 
dienen. Het is een heus kunstwerk geworden.
Mijn ouders, pa en ma, zonder jullie was ik niet zo ver gekomen. Dat evenwicht tussen 
opvoeding, vrijheid en stimulans tot een opleiding moet ik zelf in de opvoeding van mijn 
kinders nog maar zien te vinden. Mama, dit boekje is voor jou. Voor al jouw liefde, geduld en 
vertrouwen wat je ons hebt meegegeven. Kon je er nog maar bij zijn, en kon je het nog maar 
bewust meemaken. Je zou trots zijn op wat ik geworden ben dankzij jou.
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Lieve, lieve Meike, Wobbe en Dieuwe, jullie zijn m’n alles, het leven is prachtig met jullie. 
Een ding: lees dit boek nooit! Gooi het weg (op de kaft na dan), sorry dat het bestaat, het is 
vreselijk. Het heeft ons een heleboel zeer kostbare speeltijd gekost. Wat lezen we vanavond 
weer op het grote bed: Pluk, Sjakie of Assepoesje?
Last but not least, lieve Harrie. Als men mij vraagt wat het geheim achter mijn (voort)bestaan 
is, zeg ik steevast: Harrie. Ik wil vanuit deze positie dan ook toekomstige chirurgen sollicitatie 
commissies van een ongevraagd advies dienen, indien zij een vrouwelijke kandidate voor 
zich hebben. Behoudens dat de kandidate zelf het chirurgenvak in haar hart moet hebben, 
is minstens zo belangrijk wie zij als wederhelft in die andere ventrikel heeft geborgen. Is 
hij ook een chirurg?: niet aannemen. Twee niet fl exibele mensen in een ouderpaar lopen 
m.i. vast. Is hij een brave burgerman?: niet aannemen. Hij moet op z’n minst zoveel van zijn 
liefde houden, dat hij tot absurde daden in staat is. Zoals alle vergaderingen en afspraken 
aan z’n laars lappen, op het moment dat er thuis een kleine ziek is en moeder moet werken. 
Zoals hele weekenden, wanneer moederlief in het ziekenhuis de productie cijfers nog wat 
bijschaaft, voor alle kindermondjes, billen en bedjes thuis zorgen. Zoals een hulpmoeder 
op schoolreisje willen zijn. IK heb zo’n vent. Daarom ben ik zo trots op jou, daarom ben ik zo 
trots op onze 3 miljoentjes, die een vader hebben die evenveel vader is als ik moeder ben, en 
daarom hou ik zoveel van jou.
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Maaike Ibelings werd op 16 december 1964 te ’s Gravenhage geboren, doch is getogen onder 
de rook van Rotterdam. Aldaar doorliep zij de middelbare school op het Emmaus College, en 
studeerde vervolgens van 1984 tot 1991 geneeskunde aan de Erasmus Universiteit te Rot-
terdam. In 1988-1989 deed zij een veldonderzoek naar ‘Prevalence of anaemia in children’ in 
Tamil Nadu, South India.
Via haar studentlidmaatschap van de Medisch Ethische Commissie van het AZR-Dijkzigt, 
en via een onderzoek naar ‘Congenitale duodenumobstructie en Morbus Down’ bij prof.dr. 
J.C. Molenaar, verkreeg zij in 1991 haar eerste artsenbaan als AGNIO kinderchirurgie in het 
Sophia Kinderziekenhuis te Rotterdam. Een jaar later werd zij aangenomen voor de opleiding 
heelkunde in Rotterdam. Zij ving in 1993 de opleiding aan in het Ikazia ziekenhuis (opleider 
dr. H.F. Veen), om deze in 1996 te vervolgen in het toenmalige Academisch Ziekenhuis Rot-
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toe te treden in het TweeSteden ziekenhuis te Tilburg. Zij is daar – vanaf het verkrijgen van 
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